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Abstract 
 
The recent discovery of an HCV isolate which replicates in cell culture has opened up opportunities 
to study the full viral life cycle in vitro.  This genotype 2a isolate (JFH-1) and its derivatives are the 
only ones known to replicate efficiently in cell culture, and recent work has indicated that viral 
determinants for efficient replication may lie in the non-structural protein coding region of the 
genome.  In this thesis chimaeric JFH-1 virus containing full length NS3, NS3 helicase and NS3 
protease sequences from genotype 1a and 1b were constructed.  The replication efficiencies of 
chimaeric viruses were tested in cell culture, and were shown not to replicate, indicating that vital 
viral determinants for JFH-1 replication exist in NS3.  The JFH-1 model also provides the opportunity 
to study the effect of the full viral life cycle on the host cell.  Microarray analyses were performed to 
identify gene expression changes in Huh7 and Huh7.5 cells that had been infected with JFH-1 for 6, 
12, 18, 24 and 48 hours.  A large number of host genes were found to be regulated during JFH-1 
infection, including those involved in lipid metabolism, oxidative stress, apoptosis and intracellular 
transport.  The microarray data were validated by quantitative PCR analyses of separate infection 
experiments.  A selection of the most highly regulated genes was assessed for their necessity to HCV 
replication by RNA interference studies.  The knockdown by siRNA of genes ABLIM3, SPTLC3 and 
CYP1A1 resulted in significant impairment of HCV replication.  The knockdown by siRNA of gene 
TXNIP (thioredoxin interacting protein) resulted in up to 90% reduction in HCV replication.  This is a 
novel finding which may be of importance to the study of HCV as TXNIP plays roles in oxidative 
stress, lipid metabolism and glucose metabolism, all of which have potential to influence the HCV 
lifecycle.  Magnetic resonance spectroscopy indicated a change in levels of choline metabolites in 
JFH-1 infected cells, which has implications for the aspects of the HCV lifecycle associated with lipid 
membranes and other lipid structures. 
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1.1 HCV Epidemiology 
 
Hepatitis C Virus (HCV) is estimated to have infected 170 million people around the world1,  resulting 
in a serious global health problem.   
 
There are estimated to be 200, 000 people chronically infected with HCV in England2, based on a 
seroprevalence of 0.5% calculated from specimens collected from 1995 to 1996, and chronicity rate 
of 80%.  In the USA an estimated 4.1 million people have anti-HCV antibodies, and 3.2 million have a 
chronic infection3.  HCV is epidemic In Egypt, where according to the recent demographic and health 
survey, 15% of individuals aged 15-59 had anti-HCV antibodies indicating exposure, and 10% had an 
active infection4. 
  
The major route of infection in the UK and around the world is through use of contaminated 
needles.  In the UK, intravenous drug use is the primary cause of infections, accounting for 80% of 
cases.  The remainder of cases are accounted for by previous infection through contaminated blood 
transfusions or other blood products.  Since testing for presence of the virus was introduced, the 
number of new infections by this route has fallen greatly.  However, there are still many people 
living with the disease, having contracted it though one of these routes.  In Ireland, between 1977 
and 1978, 704 women were infected when administered with anti-D immune globulin that was 
contaminated with HCV5.  Similar events have occurred all over the world, for example an outbreak 
in Germany from the same source.  In Egypt, the high prevalence of infection was caused by a 
programme of immunisation against schistosomiasis6.  The goals of the programme required the fast 
delivery of vaccines to a large population, and the medical practices involved resulted in needles 
being shared before they were properly sterilised.   A high level of HCV in the population can also 
make the transfer of HCV by blood transfusion a significant risk7, unless screening is carried out on 
all blood donations.  HCV can also be transmitted through sexual contact and vertically from mother 
to child during childbirth. 
 
The incidence of infection with HCV is declining due to testing of blood products and when proper 
precautions are taken in medical situations involving needles.  However infections will still occur 
among intravenous drug users who share non-sterile needles.   
   
  
Cellular and Viral Determinants for HCV Replication  Andrew Baillie 
 
Imperial College London  17 
 
1.2 HCV Taxonomy 
 
HCV is a member of the family Flaviviridae, which consists of three genera, the Flaviviruses, 
Pestiviruses and Hepaciviruses. Phylogenetic trees indicating the genetic relationships between 
viruses of this family are shown in Figure 18-10.  The Flavivirus genus includes the pathogens of 
humans Yellow Fever virus (YFV) and Dengue virus, as well as West Nile virus (WNV) and Tick-Borne 
Encephalitis virus (TBE), and are transmitted by arthropod vectors.  The Pestivirus genus is 
comprised of animal pathogens such as Bovine Viral Diarrhoea virus (BVDV).  The Hepacivirus genus 
consists of the GB viruses (GBV-A, GBV-B and GBV-C) and Hepatitis C virus (HCV).  Since HCV is likely 
to have evolved before the use of needles for injection, it is not clear how the virus was originally 
transmitted.  The six genotypes of HCV (Figure 1C) appear to have evolved more recently (within the 
last 200 years11) which may coincide with an increase in transmission as the use of needles became 
more common. 
Cellular and Viral Determinants for HCV Replication  Andrew Baillie 
 
Imperial College London  18 
 
 
 
Figure 1: Phylogenetic trees of the Flaviviridae and HCV genotypes.   
A Phylogeny of Flaviviridae based on polymerase sequences8.  Numbers at nodes indicate the 
statistical support of the branching order by bootstrap criteria. The bar at the bottom of the 
phylogram indicates the evolutionary distance, to which the branch lengths are scaled based on 
the estimated divergence.  B Evolutionary tree of available complete open-reading frame 
sequences for each HCV genotype.  The main identified risk groups and the world regions where 
they are found are indicated for each genotype10 
  
A 
B 
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1.3 HCV Disease 
 
The acute phase of HCV infection is largely asymptomatic.  The lack of symptoms is the major reason 
that HCV infections are often not diagnosed until many years after initial exposure.  Some infections 
will spontaneously resolve, leaving HCV RNA undetectable, and anti-HCV antibodies present in the 
patient. However, most cases (around 80%) will progress to chronic infection, characterised by 
continuing disease for more than six months.  The virus persists in the liver and eventually causes 
damage resulting in fibrosis (20% of cases), cirrhosis and hepatocellular carcinoma (4% of cases).  
The incidence of liver failure coupled with the number of cases of HCV, mean that HCV infection is 
one of the major reasons why patients require a liver transplant.   
 
The damage which occurs to the liver impairs the liver functions, resulting in further pathologies of 
disease.  This damage can allow measurement of the progression of disease as, for example, levels of 
the enzyme alanine aminotransferase (ALT) in blood increase with damage to liver cells, although 
histopathology grade is not directly related to ALT levels.   A major cause of fibrosis and liver damage 
during HCV infection is the host inflammatory response to the virus.  An important feature in the 
development of fibrosis is the activation of hepatic stellate cells (HSC), which produce the 
extracellular collagen matrix12.  Natural killer (NK) cells may aid the process by production of 
inflammatory and profibrogenic cytokines13-14.  HSC also express high levels of CD81, to which HCV 
protein E2 can bind, inducing production of a matrix metalloproteinase which degrades the 
extracellular matrix15.  HCV infection is linked to progression to cancer, and it is likely that the effects 
of long term inflammation, cirrhosis, oxidative stress and subsequent DNA damage are partly 
responsible for development of cancer16.  There is also evidence for more direct carcinogenic effects 
of HCV proteins, for example mice expressing core protein have been shown to develop 
hepatocellular carcinoma17-18.   
 
Steatosis is the accumulation of lipid in hepatocytes, and occurs with varying severity in around 50% 
of patients with chronic HCV infection19-20.   Steatosis associated with HCV can be induced directly by 
the virus, or as a result of metabolic factors.  Virally induced steatosis is associated with genotype 3 
HCV infections21-22, and there is a correlation between viral load and severity of steatosis (not 
observed in other genotypes23).  Expression of genotype 3a core protein alone has been shown to 
induce steatosis in transgenic mice17.  HCV core protein has been shown to localise to intracellular 
membranes and lipid droplets in hepatocytes24.  Steatosis induced by genotype 3 HCV has been 
shown to resolve in patients after achieving a sustained virological response to treatment25.  
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Steatosis is more common in patients with HCV than in patients with other viral infections of the 
liver such as HBV, further indicating that HCV replication itself is a cause of fatty liver26-27, and HCV 
has been shown to cause steatosis in the absence of other risk factors such as obesity, alcoholism 
and diabetes20.  Metabolic factors contributing to steatosis can include dysfunctional oxidation of 
fatty acids28, alcohol abuse, and non-alcoholic fatty liver disease (NAFLD) which occurs due to 
obesity, hyperlipidaemia and diabetes29.  Insulin resistance is a major mechanism for development of 
steatosis30-31, and it has been shown that the use of insulin sensitising therapy can improve steatosis 
in patients32.  Chronic HCV infection is associated with insulin resistance33, and several mechanisms 
for HCV induced insulin resistance have been proposed.  Core protein has been shown to cause 
interferon resistance by reducing levels of signalling molecules IRS-1 and IRS-234-35, and by reducing 
association of IRS-1 with its downstream effector phosphoinositide 3-kinase (PI3K)36.  Increases in 
levels of SOCS3 (suppressor of cytokine signalling 3)35 and SOCS737 have also been associated with 
expression of HCV core protein, leading to reduced levels of IRS-1.   An inducer of late proteasome 
activity, PA28γ, has been shown to be required for the development of interferon resistance in mice 
expressing HCV core protein38.  Protein phosphatase 2A (PP2A) has been shown to be upregulated in 
HCV infection and by expression of HCV protein NS5A39.  PP2A can dephosphorylate and therefore 
inactivate Akt, potentially leading to HCV associated interferon resistance40.  HCV biopsies have 
shown reduced levels of peroxisome proliferator activated receptor α (PPARα) and PPARγ.  These 
are modulators of lipid and glucose metabolism41.    PPARα is required for HCV core induced 
steatosis in mice42, and treatment of cells expressing HCV core with a PPARγ agonist resulted in 
improved insulin signalling37.  Oxidative stress in expression of HCV protein (in vitro16 and in mouse 
models16,43) and in HCV infected patients has been associated with steatosis and insulin resistance.  
HCV infection is therefore a risk factor for development of diabetes and steatosis.    
 
Symptoms of HCV infection can also be displayed outside of the liver.   These include fatigue44, minor 
mental problems such as mild depression and minor cognitive inhibition45-46.  Patients may 
experience cryoglobulinemia necrotizing vasculitis of the skin and glomerulonephritis47, for which 
the precise mechanisms of pathology are not known.  Some pathologies observed in HCV infected 
patients may be due to autoimmune diseases.  HCV can induce autoreactive cytotoxic T lymphocytes 
by molecular mimicry, as for example in the case of some cytochrome p450 molecules which have 
regions of amino acid sequence homology with HCV core protein48-49.  
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HCV can be a major burden on the individuals who have the disease, and on the healthcare systems.  
In the USA alone, the estimated annual cost of HCV (1998), including medical care and work loss was 
over US$1 billion50. 
 
 
 
 
1.4 HCV Treatment 
 
There is no vaccine available for prevention of HCV infection.  Primary infection does not prevent a 
secondary infection, so a vaccine based on a killed virus would be unlikely to be effective.  HCV also 
displays variation in the sequence of its envelope proteins, so the antigens presented to the immune 
system are different across HCV subtypes, and can change inside one infected individual51-54.  This 
presents difficulty in designing vaccines, although similar situations have been overcome, for 
example in the case of influenza.    
 
The current treatment for HCV is pegylated interferon alpha plus ribavirin.  Interferon alpha induces 
the host to initiate innate immune responses which may have otherwise been suppressed or not 
activated by the actions of the virus.  Ribavirin is a guanosine analogue, which has anti-viral activity 
against a number of DNA and RNA viruses55-57.  The exact mechanism of its action against HCV is 
unknown but several mechanisms have been proposed.  Ribavirin may directly inhibit the viral 
polymerase as it is taken up as a substrate, or it may cause mutations to occur after it is 
incorporated into the genome and then errors are made in copying the genome, however it is 
unlikely that this is the mechanism of inhibition.  As in the case of yellow fever virus, ribavirin may 
inhibit inosine monophosphate dehydrogenase leading to depletion of GTP58 (this may not be the 
mode of action in chronic HCV).  Ribavirin may enhance production of T-helper cells, interleukin-2 
and interferon gamma (although the L-enantiomer which shares these properties, but not anti-viral 
activity, did not inhibit HCV as ribavirin does)59.  The regimen advised by NICE (National Institute for 
Health and Clinical Excellence) in 2006 for patients with genotype 1 or 4 was 180µg pegylated 
interferon alpha 2a (Roferon, Roche) per week plus 1000-1200mg ribavirin per day for 48 weeks.  
Patients with genotype 2 or 3 were recommended to have 180µg pegylated interferon alpha 2a per 
week plus 800mg ribavirin per day for 24 weeks.  The strict regimen must be adhered to and can 
only be undertaken by willing patients.  Treatment with interferon can also have unpleasant side 
effects, primarily flu-like symptoms, depression and nausea.  The combination of a strict regimen 
and side-effects mean that not all patients are suitable for treatment.  Of the patients who are 
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treated, a sustained virological response (SVR) will be achieved in 40-50% of those with genotype 1 
or 4 and in 80% of those with genotype 2 or 360.  The lack of an effective treatment for genotype 1 
HCV is of concern as this is the most common genotype in Europe and the USA, and genotype 4 is 
the most prevalent in Egypt.  The development of new and effective treatments for HCV is a major 
healthcare priority.   
 
A number of avenues of research are being examined to find possible new treatments for HCV.  
These include small molecule inhibitors of viral protease and polymerase, RNA interference based 
methods, and improvements to the current forms of interferon and ribavirin.  Many drugs are 
currently in the early stages of development and early clinical trials.  Treatments in development 
that are based on modifications of the current regimen include Taribivirin61 (or Viramidine, Valeant 
Pharmaceuticals), and Albumin-IFN-α2b (produced by Human Genome Sciences as under the name 
Zalbin) which is designed to last longer in the body than standard interferon, and is currently in 
phase III trials62-63. 
 
The NS3/4 protease is a popular candidate for targeting with antiviral drugs, and the only specifically 
anti-HCV targeted drugs currently at phase III trials are protease inhibitors.   BILN2061 (also known 
as Ciluprevir, produced by Boehringer-Manheim)64 was shown to give reductions in HCV viral load of 
2-3 log10 copies/ml after two days of treatment during phase I trials
65.  However, histology on rhesus 
monkeys treated with BILN2061 showed cardiotoxicity, stopping the development of the drug.  
BILN2061 is also a powerful inhibitor of HCV replicons in cell culture, and is often used for in vitro 
studies.  Resistance mutations can occur, primarily around the binding site of the drug66.  Efficacy of 
BILN2061 is greater against genotype 1 than genotypes 2 or 3, which corresponds to the greater 
affinity for BILN2061 displayed by the genotype 1 protease67.  Telaprevir (VX-950, Vertex)68 also 
showed positive results in phase I trials, achieving a 4 log10 drop in HCV RNA in those patients 
receiving a 750mg dose69.  Resistance mutations also occur in patients and replicons, but this can be 
partly overcome by combination therapy70.  Telaprevir has also shown the highest response of any 
drug so far in a trial of patients (50% in Prove 3 trial) who failed to respond to standard treatment.  A 
rash is a common side effect, but is rarely severe (less than 10% of cases).   Telaprevir is currently 
undergoing phase III trials.  Boceprevir (also known as SCH503034, Schering-Plough/Merck)71, is also 
currently in phase III trials.  Results of phase II trials on patients who did not respond to standard 
treatment showed a 55% sustained virological response rate after 48 weeks of treatment72. 
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Polymerase enzymes are the other classical targets for anti-virals, and a number of HCV polymerase 
inhibitors are in early development or have been stopped after clinical trials.  NM107 
(Idenix/Novartis) is the nucleoside 2’-C-methylcytidine.  This molecule was found to inhibit the 
replication of bovine viral diarrhoea virus (BVDV) in cell culture.  NM107 has been shown to have 
strong activity against HCV replicons with an EC50 of around 0.5 µM
73. The 3’-O-valinyl ester of 
NM107 was synthesised as a prodrug (NM283 or valopictabine) for better oral bioavailability74, but 
trials with this drug have been stopped.  Drugs targeting other HCV proteins, particularly NS5A and 
NS4B, are also in development and early clinical trials.   An entry inhibitor, ITX506175 (iTherx) is 
currently in phase Ib trials. 
 
Given the difficulty in producing anti-virals targeted to HCV proteins, a number of treatments are in 
development targeting the host factors that HCV requires for replication.  These include the 
cyclophilin inhibitors SCY-63576 (Scynexis) and DEBIO-2577 (Debio) which is currently in phase II trials.  
Better understanding of the host factors involved in HCV replication could lead to identification of 
additional potential targets for therapy. 
 
 
 
 
1.5 HCV Particle Structure 
 
The HCV particle consists of the positive strand RNA genome encapsulated by an icosahedron made 
up of core protein capsomers.  The capsid is surrounded by a lipid bi-layer envelope, in which are 
embedded viral envelope glycoproteins E1 and E2 as heterodimers.  HCV particles produced in cell 
culture have been observed using immune-electron microscopy.  In these studies two sizes of 
particles were observed.  Those measuring 30-35nm in diameter were thought to be viral capsids, 
and those measuring 50-60nm were infectious virions78-80.  In the host, HCV can be associated with 
lipoproteins ApoB and ApoE, low-density lipoproteins (LDL), and very low-density lipoproteins 
(VLDL)81-85.   
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1.6 HCV Genome 
 
 
 
Figure 2: The structure of the HCV genome.   
A Representation of the HCV RNA genome86 with the non-translated regions (NTRs) depicted as 
black lines, and the polyprotein coding region depicted by the blue rectangle.  Individual HCV 
protein coding regions are delineated by their relative sizes.  The structural proteins core (C) and 
envelope glycoproteins E1 and E2 are coded for at the 5’ end of the open reading frame (ORF).  
The non-structural proteins are coded for at the 3’ end of the ORF.  The essential functions of the 
non-structural proteins are as follows: p7 is a viroporin, NS2 is an autoprotease, NS3 is a 
protease and helicase, NS4A is a cofactor for NS3, NS4B is involved in rearrangement of cellular 
membranes, NS5A has multiple functions interacting with cellular components, and NS5B is the 
polymerase.  Further descriptions of the structure and function of individual regions of the HCV 
genome can be found in the text.  B Predicted secondary structure of the 5’ NTR87-88.  C Predicted 
secondary structure of the 3’ NTR87,89-90. 
 
A 
B C 
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HCV has genome of single-stranded positive sense RNA of around 9.6kb in length.  The HCV genomic 
structure (depicted in Figure 2A) consists mostly of an open reading frame that codes for a 
polyprotein of approximately 3000 amino acids which is flanked by non-coding RNA at both ends of 
the genome.   
 
The 5’NTR is about 341 nucleotides long and is highly conserved across HCV genotypes.  It has 
secondary structure (Figure 2B) that plays a role both in replication of RNA and in translation of the 
polyprotein.  The 5’ NTR contains an internal ribosomal entry site (IRES), made up of domain 
structures II, III and IV (Figure 2B).  The IRES can bind the 40S ribosomal subunit without needing the 
other initiation factors usually required for translation of host mRNA (including eIF3, eIF4A, eIF4B 
and eIF4F)91.  An interaction has been identified between micro RNA 122 (miR122) and a short 
region of the 5’ NTR that is required for efficient replication of HCV RNA92.   
 
The 3’NTR is also highly structured and made up of three regions; a variable region, a region rich in U 
and C residues, and a highly conserved domain called the X-tail (Figure 2C).  A long poly-U/C region 
of 50-60 nucleotides is required for efficient replication, and the X-tail is essential for RNA 
replication, having very little tolerance for deletion or mutation93-97.   
 
The majority of the HCV genome is an open reading frame (ORF) coding for translation of a 
polyprotein of about 3000 amino acids in length, which, when processed, yields 10 individual 
proteins.  Another ORF has been identified, expressing the frameshift (F) protein or alternative 
reading frame (ARF) protein, so called as its coding begins one nucleotide out of frame of the major 
ORF.  The function of this protein is currently unknown, but antibodies to it have been identified in 
patient sera, indicating that it is naturally expressed during infection98-100.  Translation of the ORF 
occurs across the endoplasmic reticulum membrane, with the different parts of the polyprotein 
relating to individual proteins expressed on either the ER lumen or cytoplasmic side of the 
membrane, depending on the function of the individual protein (Figure 3). 
  
Cellular and Viral Determinants for HCV Replication  Andrew Baillie 
 
Imperial College London  26 
 
 
 
Figure 3: Structures, membrane association and processing of HCV proteins101. 
Scissors indicate cleavages by the endoplasmic reticulum (ER) signal peptidase, except on the 
cytosolic side where it indicates the processing of the core protein by signal peptide peptidase. 
The cyclic arrow denotes cleavage by the NS2–3 protease. Black arrows indicate processing by 
the NS3–4A protease complex. Known protein structures (as of 2007, when data were 
collated101) are shown as ribbon diagrams. The structures and the membrane bilayer are shown 
at the same scale. Proteins or protein segments of unresolved structures are represented as 
coloured spheres or cylinders. 
 
 
Structural proteins are coded for at the amino terminus of the polyprotein, and non-structural 
proteins at the carboxy terminus of the polyprotein.  There are three major structural proteins; core 
(C) and two envelope proteins (E1 and E2). 
 
Core protein is about 191 amino acids in length and performs the role of capsomer for construction 
of the viral capsid.  It is cleaved from the polyprotein by host signal peptidase102 and further 
processed by host signal peptide peptidase103.  The mature protein forms a dimer104.  The N-terminal 
domain of core comprises about two-thirds of the protein and is hydrophilic103-104.  The C-terminal 
domain of core is hydrophobic and is required for proper folding and localisation of the protein103,105.  
Core protein localises to endoplasmic reticulum and lipid droplets in the cell103,106-108.  Core protein 
has the ability to bind RNA, which is an important feature for the packaging of genomic RNA into the 
capsid109-110.  Expression of core protein in cell culture and animal models has identified a number of 
interactions with host cell proteins.  Expression of core protein has also been shown to regulate the 
expression of host genes including those involved in immunity, apoptosis and proliferation, signalling 
and lipid metabolism111-113 which are further described in subsequent sections.    
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The HCV proteins E1 and E2 are envelope glycoproteins.  E1 and E2 are cleaved from the polyprotein 
by a host signal peptidase106.  E1 and E2 together form a non-covalent heterodimer114.  They localise 
to the ER, with the N-terminal majority of the proteins in the ER lumen (Figure 3).    Both E1 and E2 
are post-translationally modified by addition of N-linked glycans.  E1 is glycosylated at up to 6 amino 
acid positions, and E2 at up to 11 positions115-116.  These glycans play roles in envelope protein 
folding and viral entry115,117-118.  E2 has been shown to bind several host cell factors, including 
CD81119 and scavenger receptor class B type I (SR-BI)120 which have been shown to be involved in 
HCV entry to the cell, as further described in subsequent sections.  Regions of sequence 
heterogeneity, termed hypervariable regions (HVR), were identified in E2121, and these have been 
proposed to be involved in generation of antibody escape mutants, and in modulating receptor 
binding and entry122-124. 
 
A small protein, p7, is expressed in the polyprotein after E2.  This protein is likely to be a viroporin 
responsible for transfer of ions.  Similar proteins in other viruses (e.g. influenza protein M2125) play a 
role in uncoating, but p7 has not yet been shown to be incorporated into the viral particle.  It has 
been shown to form both hexameric and heptameric structures126. 
 
There are five non-structural (NS) proteins expressed by HCV.  NS2 is a protein of about 216 amino 
acids.  NS2 is a cysteine autoprotease which cleaves HCV polyprotein at the boundary between itself 
and NS3 (Figure 3).  NS2 requires the protease domain of NS3 for autoprotease activity127.  The 
active site of NS2 is formed between dimers, with histidine and glutamate residues of the catalytic 
triad provided by one monomer and the cysteine residue provided by the other monomer128.  The 
target sequence of WRLL↓APIT is well conserved across HCV genotypes although mutations are 
tolerated, except to the residues at the cleavage position or those which seriously affect the 
structure129.  NS2 is not essential for the formation of the RNA replication complex, as has been 
demonstrated in subgenomic HCV replicon cell culture models130-131.  An HCV clone containing point 
mutations which inactivated NS2 protease activity was shown to infect chimpanzees but not cause a 
persistent infection95.  As the non-structural proteins cannot function until NS2 has autocleaved 
from the polyprotein, NS2 may play a role in regulating their activity.  NS2 expression has also been 
shown to affect expression from various host promoters including NFκB and TNFα132.  NS2 has also 
been shown to inhibit apoptosis induced by CIDE-B (cell death-inducing DFF45-like effector).133 
   
NS3 is around 630 amino acids in size.  It is cleaved from the polyprotein at the amino terminus by 
the autoprotease activity of NS2-3, and at the carboxy terminus by NS3 protease activity.  NS3 is a 
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multifunctional protein with two major domains.  The amino terminal portion (180 amino acids) is a 
serine protease domain, and the carboxy terminal portion (450 amino acids) of NS3 is a helicase 
domain with NTPase activity.  NS3 protease is a trypsin-like protease134, and as such has a catalytic 
triad formed of the amino acids histidine (NS3 amino acid position 57), aspartate (81) and serine 
(139).  NS3 protease is responsible for cleavage of the polyprotein at the boundaries between all the 
non-structural proteins from NS3 to NS5B (Figure 3)135-140.  The protease recognises a Cys/(Ala/Ser) 
motif at most NS protein boundaries, but at the NS3/NS4A boundary a Thr/Ser sequence is the 
substrate (consensus cleavage sequence: D/EXXXXC/T↓A/SXXX).  This results in slower cleavage at 
the NS3/4A boundary than at the other sites, possibly because the uncleaved NS3/NS4A protein is 
required for assembly of the replicase complex141.  The primary function, identified so far, of the 54 
amino acid long NS4A protein is to act as a cofactor for enhancing NS3 protease activity.  NS3 does 
have protease activity alone and will cleave, for example, the NS5A/NS5B boundary.  However, NS4A 
enhances NS3 protease activity, and is required for cleavage of the polyprotein at the remaining 
three boundaries between non-structural proteins142-146.  HCV NS3 is also known to have protease 
activity against host proteins.  This is of particular importance for the evasion of host innate immune 
responses to infection.  NS3 is able to cleave TRIF147, a mediator of TLR-3 signalling.  TLR3 detects the 
presence of double stranded RNA and through the recruitment of TRIF and subsequent activation of 
NF-κB and IKK induces an interferon response148.   NS3 can also cleave MAVS149-151, a mediator of 
RIG-I and Mda5 signalling, both of which are involved in the initiation of innate immune systems in 
response to sensing of double stranded RNA.  RIG-I has also been shown respond to 5’ triphosphate 
on single stranded RNA molecules152-153.  RIG-I, through MAVS and subsequently IRF signalling can 
induce an interferon response.   The inactivation by cleavage of the mediator proteins TRIF and 
MAVS allows HCV to avoid detection through these signal pathways.  The carboxy terminal domain 
of NS3 is a helicase with NTPase activity.  The helicase domain binds RNA and has NTPase activity.  
NS3 is in the general class of DExD/H box helicases.  The eight commonly conserved motifs of 
DExD/H box helicases are present in NS3, including a DECH motif at amino acid position 290154.  NS3 
helicase binds the 3’ end of RNA and unwinds double stranded RNA which has a 3’ overhang.  
Progression of the enzyme is dependent on ATP and proceeds at about 11 base pairs per step, and 
the helicase activity of unwinding the RNA duplex occurs at 3.6 base pairs per step, also dependent 
on ATP binding155.  Recent work has indicated functions of NS3 additional to the replication of RNA.  
Subdomains of the helicase may also be involved in packaging of RNA and assembly of the virion156, 
which is supported by evidence from research on the Flaviviridae members Kunjin virus157 and 
Yellow Fever virus158.  HCV NS3 has been a popular target for drug development.  Protease inhibitors 
targeting NS3 are relatively difficult to design as the active site is a shallow groove, leaving few sites 
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of interaction between the protein and the drug159.   Protease inhibitors such as Ciluprevir64 and 
Telaprevir68 have shown promise in vitro, but have encountered problems in vivo, mostly due to 
undesirable side effects.  Helicase inhibitors have also been difficult to develop as the domains of 
NS3 are conserved across many cellular proteins, making specificity and toxicity the major problems.   
 
NS4B is about 261 amino acids in length.  It is hydrophobic and, once translated, is located in the ER 
membrane.  It is involved in membrane vesicle formation and has been shown to be associated with 
the membranous web structures formed in HCV infected cells160-161, implying a role in the formation 
of replication complexes by influencing the environment in which the HCV proteins can interact.  An 
amphipathic helix at the amino terminal end of NS4B has been hypothesised to be responsible for 
association with lipid rafts162-163.  Another amphipathic helix is present at the carboxy end of NS4B, 
which mediates membrane association and the formation of functional replication complexes164.  
NS4B also has GTPase activity, which is important for efficient RNA replication165. 
 
NS5A is a protein of about 466 amino acids which is present in either a hypophosphorylated (56kDa) 
or hyperphosphorylated (58kDa) state.  The other non-structural proteins can influence the 
phosphorylation state of NS5A, and the state of NS5A influences the replication rate of HCV. In cell 
culture, inhibition of kinases resulting in a increase in the amount of hypophosphorylated NS5A was 
accompanied by an increase in replication166.   NS5A has the ability to bind RNA, with an affinity for 
poly-U tracts such as the one present in the 3’ NTR167.   NS5A also interacts with a number of host 
cell proteins, some of which are mediated through the presence of a Src homology 3 (SH3) binding 
domain, including growth factor receptor bound protein 2 (Grb2)168 and the tumour suppressor 
Bin1169.  Src tyrosine kinases may contribute to phosphorylation of NS5A and NS5A may also interact 
with the tumour suppressor p53170.  NS5A also interacts with host cell proteins involved in immune 
responses.  The region of NS5A from amino acid 240 to 314, called the interferon sensitivity 
determining region (ISDR), was reported to contain clusters of amino acids correlating with the 
ability of patients to achieve SVR from interferon treatment171.  The ISDR interacts with Protein 
Kinase R (PKR)172-173, and an interaction with oligoadenylate synthase (2’-5’ OAS) has also been 
reported174.  NS5A interactions with host proteins also play a role in RNA replication.  The membrane 
vesicle proteins VAP-A and VAP-B enhance HCV RNA replication and their binding to NS5A is 
regulated by the phosphorylation state of NS5A and may aid in positioning proteins in the replication 
complex163,175.  The F box protein FBL2 also interacts with NS5A and is required for HCV 
replication176. 
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NS5B is the RNA-dependent RNA polymerase.  It has a more closed conformation than other 
polymerases, which is due to interactions between the hydrophobic residues in the thumb and 
fingers subdomains, and this may aid the initiation of RNA synthesis de novo as opposed to primer 
initiated synthesis177-179.  NS5B also interacts with host cell factors including VAP-A and VAP-B (as 
NS5A also does) and cyclophilin B, which stimulates the RNA binding activity of NS5B180.  NS5B also 
has a retinoblastoma protein (Rb) binding motif, which, if mutated, results in impaired replication181.  
It is also possible that binding of NS5B targets Rb for degradation and therefore promotes cell 
proliferation182. 
 
 
1.7 HCV Lifecycle 
 
The HCV lifecycle is illustrated by the schematic illustration given in Figure 4101.  The blood-borne 
virus binds to the hepatocyte cell using several host proteins and is internalised by endocytosis.  The 
virus uncoats and the positive strand RNA genome is released into the cytoplasm.  Protein 
translation and RNA replication take place in the cytoplasm, on membranous structures associated 
with the endoplasmic reticulum.    Newly replicated RNA is then packaged in the capsid and the 
particles acquire a membrane and additional factors as the virus matures and is released.   
 
 
 
 
Figure 4: A schematic representation of the lifecycle of hepatitis C virus. 
The lifecycle stages of HCV in its interaction with the host cell are labelled as follows: (a) Virus 
binding and internalization.  (b) Cytoplasmic release and uncoating.  (c) IRES-mediated 
translation and polyprotein processing.  (d) RNA replication.  (e) Packaging and assembly.  (f) 
Virion maturation and release101.   
Cellular and Viral Determinants for HCV Replication  Andrew Baillie 
 
Imperial College London  31 
 
1.8 HCV Entry to the Cell 
 
Entry of HCV into a host cell requires interaction between components of the viral particle and 
cellular factors.  Current research indicates that four cell molecules are required for entry.  An early 
host cell protein to be identified as required for HCV entry was the tetraspannin CD81119. Antibodies 
against CD81 can inhibit entry of HCV in vitro before or after the initial binding of the virus183.  The 
scavenger receptor class B type I (SR-BI) is involved in cholesterol uptake and has affinity for LDL, 
which are often part of infectious virus particle in the host, and HDL which were shown to increase 
infectivity of virus in a dose dependent manner.  SR-BI was initially identified as a candidate HCV 
entry receptor when it was shown to bind E2120.  Both proteins CD81 and SR-BI bind E2 and are 
necessary but not sufficient for HCV entry.  Claudin 1 (CLDN1) is a membrane protein involved with 
tight junctions that has been shown to be involved in HCV entry184.  Occludin (OCCLN) is the most 
recently identified protein to be involved in HCV entry185.  Other proteins shown to interact with 
HCV, but that may not be as important for entry as those already described include; the LDL receptor 
(LDLR), liver/lymph node-specific intercellular adhesion molecule-3-grabbing non-integrin (L-SIGN), 
dendritic cell-specific intercellular adhesion molecule-3-grabbing integrin (DC-SIGN) and heparan 
sulphate.   
 
After binding, HCV is internalised by clathrin-mediated endocytosis186.  This is followed by uncoating 
induced in a low-pH compartment183,187. 
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1.9 HCV Replication Complex 
 
As already described, the HCV proteins are translated and localise to the ER.  Here, HCV rearranges 
internal cellular membranes into structures required for viral replication.  The membranous web 
contains the HCV replication complex including viral proteins NS3, NS4A, NS4B, NS5A, and NS5B, as 
well as viral RNA and host cell factors.  This membranous web forms subcellular locations which 
could help to optimise HCV RNA replication, as well as protect from host nucleases, proteases, 
dsRNA-induced immune responses and presentation of HCV antigens on MHC-I.   
 
Membranous structures have been observed in infected chimpanzee liver cells188, virus infected 
cultured cells108, cells expressing subgenomic RNA replicons161, as well as cells expressing only NS4A-
B precursor protein189 or mature NS4B protein160,189.  Observations have been made using electron 
microscopy where NS4B was expressed alone and found only on the membranous web structure160. 
NS4B has been observed by light microscopy at the ER and at cytoplasmic foci162,190 which seem to 
correspond to vesicles embedded in a membrane matrix which may be the membranous web191.  
Therefore, while all the nonstructural proteins are required for HCV RNA replication and are present 
in the replication complexes, expression of NS4B alone is sufficient to induce morphological changes 
in cellular membranes162,190-195.   
 
The HCV replication strategy is similar to that of other viruses with positive stranded RNA 
genomes196-197.  In particular, they share the feature of using structures derived from cellular 
membranes as sites of RNA replication.  HCV161 and other Flaviviridae (including Kunjin198-199 and 
Dengue200 viruses) create vesicular structures from the ER.  Picornaviridae (such as Polio virus201) 
create clusters of vesicles from the ER, Golgi and lysosomes.  Togaviridae (such as Semliki Forest202 
and Rubella203 viruses) create vacuoles lined with small spheres from endosomes and lysosomes.   
 
RNA replication occurs within the replication complexes constructed inside the membranous web.  
Current models hypothesise a structure similar to that shown in Figure 5B.  It is known that the 
structural proteins are not required for RNA replication, as these are not present in the subgenomic 
RNA replicon cell lines used for in vitro study.  All non-structural proteins are required for RNA 
replication131.  The 5’ NTR contains the IRES required for translation91 and is required for efficient 
RNA replication204.  The 5’ NTR also contains a miR122 binding site that is required for efficient RNA 
replication92.  The 3’ NTR contains stem loops and a U/C-rich region that are required for efficient 
RNA replication93,95-97.  Cellular cofactors have also been identified which are required for, or 
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enhance, HCV RNA replication.  These include cyclophilin B180, which interacts with NS5B, and the 
combination of FKBP8 and Hsp90205. 
 
 
 
Figure 5: Membranous structures created by HCV during viral replication.  
A The membranous web created in Huh7 cells harbouring a subgenomic replicon
101,161
 at (a) low 
power and (b) higher power.  The membranous web is indicated by red arrows.  ER: endoplasmic 
reticulum, M: mitochondrion, N: nucleus.  B A simple schematic representation of the replication 
complex206.   
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1.10 HCV Assembly and Release 
 
The late stages of the HCV lifecycle are less well characterised than other aspects due to the lack, 
until recently, of a good model for in vitro study.  Recent research has identified roles in assembly for 
most of the HCV proteins, and also roles for cellular structures such as lipid droplets.  Assembly and 
release of HCV has been linked to the VLDL synthesis and ESCRT transport pathways.   
 
Most of the viral proteins have some role in HCV assembly.  Core protein is the monomer which 
makes up the HCV capsid.  Once core is cleaved from the polyprotein by signal peptide peptidase, it 
moves to the surface of lipid droplets103, the interactions with which are mediated by the 60 amino 
acids in the C-terminal hydrophobic domain of core105.  The site of capsid assembly is a point of 
interaction between lipid droplets, core protein and HCV RNA delivered by NS5A from the ER.  The 
p7 protein forms α-helical hexa- or heptameric complexes126 which have the ability to channel 
cations207.  The precise function of p7 is uncertain, but it is essential for the assembly and release of 
infectious HCV208-209.   It has been proposed that p7 may protect virus particles during assemble by 
preventing acidification of intracellular compartments210.  NS2 is also essential for assembly, but the 
protease activity is not required208,211.  NS2 may have a role in maturation after assembly of the 
virus212-214.  NS3 has been implicated as having a role in the assembly process.  Mutational analysis 
identified that domains in the NS3 helicase are required for assembly at a stage after recruitment of 
NS5A to the lipid droplet and before formation of dense intracellular viral particles156.  This is 
supported by evidence from research on other viruses related to HCV, such as the Flaviviridae 
members Kunjin virus157 and Yellow Fever virus158.  NS4B may also play a role in HCV assembly.  
Trans-complementation studies showed that NS4B was capable of modulating infectious virus 
production215.  NS5A contains three domains, of which Domain 3 has been identified to be required 
for HCV assembly216-219.  Phosphorylation of a serine by casein kinase II may regulate the interaction 
of NS5A with core, and therefore may affect assembly216,219.  Deletion of Domain 3 of NS5A results in 
NS5A and core no longer localising to the same lipid droplets218.   
 
Several host factors play a role in the assembly and release of HCV.  Lipid droplets are an important 
cellular feature required for the assembly of the HCV virion.  Lipid droplets are usually present in the 
cell and form storage organelles for neutral lipids.  The association of HCV core protein with lipid 
droplets is essential for assembly as the inhibition of signal peptide peptidase prevents core 
localisation to lipid droplets and virion production220.  Non-structural proteins, including NS5A, also 
interact with lipid droplets and colocalise with core.  Prevention of NS5A from localising to lipid 
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droplets, or with core, can also block virus production218,221.  Many of the host factors involved in the 
assembly and release of HCV are also involved in the VLDL pathway.  VLDL assembly requires apoB 
and microsomal triglyceride (MTP).  Briefly, apoB translocates to the ER lumen, where it forms a 
cavity.  MTP inserts lipids (phospholipids and triglycerides) into the cavity.  This process forms a 
spherical particle which can then be secreted222-223.  ApoE is essential for assembly and is a 
component of infectious HCV particles224-227.  ApoE has a molecular weight of 34kDa and is involved 
in the transport of lipids.  When (the C-terminal domain of) apoE is associated with lipids, the N-
terminal region of the protein is capable of binding LDL family receptors228.   ApoB has a molecular 
weight of 500kDa.  It is the only apolipoprotein that remains after conversion of VLDL to LDL by 
lipases, and there is only one molecule present per lipoprotein particle.  Binding of apoB to the LDL 
receptor initiates endocytocis229.  The importance of apoB to the production of infectious HCV 
particles is not yet clear.  Some groups have found inhibition of apoB by RNA interference, or 
inhibition of MTP, to impair HCV production230-231.  However, other groups have found that by RNA 
interference of apoE reduced virus production, but that knockdown of apoB and inhibition of MTP 
did not reduced virus production224-226.  The ESCRT (endosomal sorting complex required for 
transport) system is involved in membrane remodelling for protein sorting, creating multivesicular 
bodies, cytokinesis and budding of enveloped viruses (e.g. HIV-1232 and Ebola233).  Briefly, ESCRT 
complexes I, II and III are recruited in order to the membrane of endosomes to sequester proteins 
for transport and encourage vesicularisation.  The ESCRT system is disassembled and recycled when 
Vps4 (an AAA ATPase) is recruited to ESCRT III234.  Knockdown of TSG101 (a component of ESCRT I), 
CHMP4b (ESCRT III), Alix (a TSG101 and CHMP4b binding protein), and Vps4b reduced extracellular 
infectious viral titre and the amount of core released by cells235.  A study expressing dominant 
negative copies of CHMP proteins and Vps4 also showed reduced infectious virus production236.  
HCV core, but not NS5A, has been observed to colocalise with CHMP4b235.  Heat shock cognate 
protein 70 (hsc70) has been seen to colocalise with HCV proteins on lipid droplets, affect the size of 
lipid droplets, and affect the production of infectious virus particles237.  Annexin 2 (ANXA2) has been 
observed in proteomic analysis of membranous replication complexes, and knockdown of ANXA2 by 
RNAi resulted in impaired viral assembly 238. 
 
There are currently two major theories as to how capsid assembly occurs.  One model suggests that 
lipid droplets are transport vehicles which take core to the site of assembly, where it acquires RNA 
from the replicase or NS5A. This is supported by evidence that lipid droplets can transport along 
microtubules, and that use of antibodies against dyenin or nocodazole impairs HCV assembly239.  An 
alternative theory is that capsids are formed on the surface of lipid droplets, and viral RNA is 
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delivered by NS5A which also localises to the lipid droplets.  This is supported by the fact that the N-
terminal domain of NS5A can target lipid droplets 240-241.   
 
The maturation and release of the HCV particle is linked to the VLDL pathway224,226,230-231.  Core 
protein has been shown to accumulate in detergent resistant lipid fractions which contain 
cholesterol and sphingolipids in high amounts242, both of which are also present in HCV particles and 
are important factors in determining infectivity243.  The capsid is inserted into an ER luminal lipid 
droplet, but it is uncertain how E1 and E2 are targeted to this site.  It has been suggested that NS2 
plays a role in pulling together the envelope proteins and other non-structural proteins (particularly 
NS3) by protein-protein interactions212-214,244.    The precise method of incorporation of 
apolipoproteins into the viral particle is unclear.  The ER luminal lipid droplet containing the virus 
and apoE may fuse with VLDL particles containing apoB, resulting in a mature lipo-viral particle.  The 
ESCRT system has been shown to be required for the release of infectious HCV particles235-236.  
However, inhibition of ESCRT components does not prevent assembly of intracellular infectious 
particles, so it is likely that ESCRT is only involved in the late stages of release of the virus from the 
cell. 
 
 
HCV particles released from cells have been profile using density gradients.  There is a 
heterogeneous mix of HCV particle densities observed in patients, partly due to the association of 
HCV with VLDL/LDL and other factors82-84,245.  These range from around 1.04g/ml to 1.25g/ml81,83,245-
246.  The lower density particles (<1.06g/ml) are more infectious than higher density particles.  
Around 40% of total HCV RNA in the plasma is associated with these lower density particles, 
although it varies between patients84,245.  The low density particles are associated with VLDL/LDL 
containing apoB, apoE and apoC, as well as triglycerol, and can be complexed with 
antibodies83,245,247.  Higher density particles can also be infectious, and these may include particles 
that contain apoE and apoC but not apoB, and therefore have less lipid volume.  These are the major 
types of particle that have been observed by production of HCV in cell culture, with an average 
density of around 1.1g/ml248.  HCV particles containing RNA, with a density between 1.06g/ml and 
1.17g/ml, may be free virus particles247,249.  HCV RNA present in particles with density above 
1.18g/ml is thought to be in structures such as the capsid or capsid complexed with antibodies249-250.  
Examples of determination of HCV buoyant density in iodixanol gradients are shown in Figure 6248,251.  
These demonstrate the different densities of HCV particles produced in cell cultures and from 
chimpanzees, reflecting the compositional differences described above.   
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Figure 6: Density profiles of HCV particles. 
These examples of density profiles show the approximate buoyant densities of HCV particles, 
and demonstrate the differences that can be observed in particle density. A Buoyant density in 
iodixanol gradients248 of HCV from i) cell culture, ii) plasma from chimpanzee 4x0483 at 3 weeks 
postinfection, and iii) virus recovered from chimpanzee 4x0483 week 3, then passaged in cell 
culture for 9 days.  A Buoyant density in iodixanol gradients251 of HCV from i) Huh7 cell culture, 
ii) primary hepatocyte cell culture, and iii) virus recovered from primary hepatocyte cell culture, 
then re-cultured in Huh7 cells.   
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1.11 Immune Response to Infection and Viral Evasion 
 
In the majority of cases, HCV is not cleared and the individual goes on to develop a chronic infection.  
In roughly 20% of cases, only an acute infection occurs and the virus is cleared within six months.  
The immune response to infection plays a role in determining the outcome of infection, and 
although the mechanisms are not fully understood, some of the determinants and features involved 
have been identified.  Both the adaptive and innate aspects of the immune system have roles to play 
in fighting viral infection, and HCV must have means to evade these responses in order to establish a 
chronic infection.   
 
The adaptive immune response to infection is made up of the humoral response (production of 
antibodies by B cells) and the cellular response (including CD4+ helper T cells and CD8+ cytotoxic T 
cells).   
 
The time to seroconversion varies, but the average is around 10-12 weeks post infection with 
HCV90,252.  Antibody titres are generally low and can become undetectable in some patients after 
resolution of acute infection.  HCV has been shown to be neutralised by antibodies in 
chimpanzees253-255 and cell culture256-260.  Neutralising epitopes exist in E2254,256,261.  However, 
neutralising antibodies do not always appear in acutely infected patients who resolve infection, 
indicating that the humoral response to HCV may not be the most important factor in clearance of 
the virus262-263.  It is also possible for humans and chimpanzees who have recovered from the virus to 
become infected on subsequent exposure to the virus.   
 
Adaptive cellular immunity is an important determinant of infection outcome.  A T cell response is 
measurable in most individuals, but it is slow to develop, and it can be between 5 and 10 weeks post 
HCV infection before CD8+ T cells are observed in blood252,264-267.  Intrahepatic T cells have been 
observed in infected chimpanzees 4-8 weeks after viraemia was detected252,264.   
 
A strong CD4+ T cell response has been associated with resolved infections268-271, and these CD4+ 
responses are usually aimed at non-structural proteins (including some frequently observed epitopes 
in NS3)270,272.  There is a relationship between the expansion of HCV-specific CD8+ T cell responses 
and the decline in viraemia during acute infection252,265,269,271,273.  Strong CD8+ T cell responses, 
targeting up to 8-12 HCV epitopes have also been reported as present in patients who resolved HCV 
infection265,274.  CD4+ and CD8+ T cell responses can remain detectable after clearance of the 
Cellular and Viral Determinants for HCV Replication  Andrew Baillie 
 
Imperial College London  39 
 
virus265,275 even when antibodies are undetectable276.  There have been cases of multiple acute 
infections of humans and chimpanzees277-282 indicating a lack of immunity to subsequent infection.  
However, a study has shown that previously HCV-infected patients were about half as likely to 
develop new viraemia283.  Studies in chimpanzees have also shown that second infections were 
cleared much more quickly that primary infections266,284.  Chimpanzees that have been immunised 
with HCV proteins that are not the targets of neutralising antibodies have a reduced viraemia90.   
 
Animals with depleted CD4+ or CD8+ T cells have persistent HCV infections when re-challenged with 
the virus.  Depletion of CD8+ T cells caused prolonged viraemia266, and depletion of CD4+ T cells 
caused persistent infection despite the presence of memory CD8+ T cells from a previous infection284. 
As clearance of the virus only occurs in about 20% of patients, the cellular immune response 
observed in acute resolving infections must not work in the majority of cases.  This may be due to 
mechanisms such as primary T cell failure, T cell exhaustion, T cell dysfunction and viral escape 
mutations274,285.  
 
Patients with chronic HCV may not have strong or multispecific CD8+ T cell responses.  This could 
happen if the cells are not initially primed, and has been shown in some early acute chimpanzees 
and humans252,264,286.  Impaired priming may occur where there are low numbers of antigen 
presenting cells285,287-288 but this is contested285,289-290.  Impaired T cell activation has been observed 
in the presence of HCV core protein, through its interaction with complement receptor gC1qR291-292.  
There have also been cases observed where a T cell response existed early in infection but then 
disappeared, but the mechanism for this is unknown265,269.  CD4+ help is required for a good CD8+ 
response, so the weak CD4+ response seen in chronic HCV293 and impaired CD4+ which produce low 
levels of IL-2294 could contribute to a weak cellular immune response to HCV.   
 
The programmed cell death-1 (PD-1) receptor is known to be a marker for exhaustion in CD8+ T cells, 
and blockage of the interaction of receptor and ligand can restore cytokine secretion, cell 
proliferation, and cytotoxicity ability295.  During acute HCV infection, PD-1 is upregulated on CD8+ T 
cells.  It has been observed that patients who resolved infection had an early decrease in PD-1 
expression, but patients who developed a chronic infection maintained PD-1 levels296-298.   
The T cells involved in the response to infection can be influence by regulatory T cells.  CD4+ CD25+ T 
cells suppress CD8+ T cells and have been found in chronically infected patients at higher levels than 
in resolved or uninfected individuals299-300.  There are also regulatory CD8+ T cells which express IL-
10, and can suppress the virus-specific CD8+ T cells301.   
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Viral mutation can result in alteration of epitopes recognised by T cells302-304.  Mutation can also 
affect the abil304ity of cells to process antigens for presentation on MHC, and the ability of epitopes 
to bind MHC303.  There has also been a case described where a mutation resulted in diminished T cell 
recognition of the presented epitope , and therefore failure to prime T cells305.   
 
There are therefore several potential mechanisms which could contribute to the ability of HCV to 
evade the cellular immune response and establish a persistent infection. 
 
 
The infected individual also has innate immune responses with which it can fight infection.  HCV 
must evade the innate response in hepatocytes in order to replicate within the cell and establish an 
infection.  The innate response is activated when pattern associated molecular patterns (PAMPs) are 
detected by pattern recognition receptors (PRRs).  PRRs include Toll-like receptors (TLRs), RIG-I-like 
receptors (RLRs), and nucleotide oligomerisation domain-like receptors (NLRs)306.  Recognition of 
viral PAMPs by TLRs and RLRs leads to activation of interferon regulatory factors (IRFs), nuclear 
factor-κB (NF-κB) and eventually IRF3 target genes, IFN and interferon stimulated genes (ISGs), and 
cytokines.  Recognition of PAMPs by NLRs activates caspase 1, then cytokines such as IL-1 which 
have an antiviral inflammatory effect.  NLRs are thought to be primarily involved in sensing 
bacteria307-308.  Several TLRs are involved in sensing viral PAMPs. TLR2 and 4 can detect viral proteins 
on the cell surface, and TLR2 has been shown to be activated by HCV core and NS3307-308.  TLR3, 
TLR7/8 and TLR9 all detect nucleic acids, and are all expressed in endosomes, with TLR3 also 
expressed on the cell surface.  TLR7/8 detects U- and G-rich ssRNA, and TLR9 detects CpG in DNA, 
and TLR3 detects dsRNA.  Hepatocytes are deficient in TLR signalling309, so they are unlikely to 
provide a primary defence against infection by HCV.  However, HCV does have a method for evasion 
of the TLR3 mediated immune response.  NS3 is able to cleave TRIF147, a mediator of TLR-3 signalling.  
Without functional TRIF, TLR3 cannot signal the presence of dsRNA by subsequent activation NF-κB 
and IKK, and cannot induce an interferon response148.  NS5A can prevent TLR induction of cytokines 
in macrophages by binding the major signalling adaptor MyD88 (which is not used by TLR3)310.   
RIG-I can detect PAMPs including dsRNA, 5’ triphosphates and U- or A-rich RNA152-153,311-314.  When 
RIG-I detects a PAMP, it oligomerises and exposes its CARD domain.  This CARD domain interacts 
with the card domain of MAVS, and signals an interferon response through IRF7149-150,312-313,315-317.  
The polyU/UC region of the 3’ end of the HCV genome, and the 5’ triphosphate end of the genome 
have been shown to be recognised by RIG-I312,314,316,318.  It is possible that HCV RNAs in replication 
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complexes in the membranous web are protected from detection by RIG-I160-161, however there is 
still likely to be RNA present at other sites in the cytoplasm.  HCV can disrupt RIG-I signalling by 
cleavage of MAVS using the NS3/4A protease.  Cleavage of MAVS releases it from the membrane 
and stops oligomerisation, both of which prevent signal transduction149-151,319-320.   
 
HCV can also evade the innate immune response by attenuation of IFN signalling through the 
Jak/STAT pathway.  HCV core protein can bind STAT1 to prevent phosphorylation and therefore 
activation of ISGs321-323.  HCV is also able to directly interfere with the action of some ISGs.  E2 can 
inhibit PKR kinase ability by competing with eIF2 to bind PKR324.  NS5A can also block PKR173,325, as 
well as blocking 2-5’ OAS by direct interaction174.   
 
The ability of HCV to evade innate immune responses is likely to be an important feature in the 
establishment of chronic infection.   
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1.12 HCV Animal Models of Replication 
 
The study of HCV has been limited by the difficulty of developing and identifying suitable model 
systems.  In vivo studies of HCV in animal models have been restricted to chimpanzees, which are 
the only animal other than humans that can truly be infected by HCV326.  Surrogate animal models 
have been used with some success.  The GB virus B (GBV-B) is classed as a hepacivirus (see 
phylogeny dendrograms Figure 1).  GBV-B infects tamarins, resulting in an acute infection which lasts 
for 16 weeks, after which time the infection is cleared.  This differs from the usual progression of 
HCV to chronic infection in the human host, limiting comparative studies.  GBV-B also infects 
marmosets.  There are similarities in sequence and substrate specificity of HCV and GBV-B viral 
proteins327.  This has allowed the use of GBV-B animal models in the testing of some potential HCV 
therapeutics328.  Chimpanzee infection with HCV is a more accurate model of human infection with 
HCV.  The acute resolving infection lasts for 12-24 weeks, and many infections proceed to a chronic 
state, although with a lower rate of progression to chronicity in chimpanzees than in humans329-330.  
Fibrosis in the chimpanzee is usually milder than in humans, and occurrence of cirrhosis and HCC is 
less frequent.  However, most countries have recently banned, or are considering banning, medical 
testing on chimpanzees.  This means that the option to study this in vivo model is no longer 
available.  The current area of development is in mouse models.  There have been a number of 
models generated where constitutive expression of HCV proteins (individual, combinations and the 
full polyprotein) has been achieved.  Another approach has been to introduce human liver cells into 
the mouse, providing a more natural habitat for the virus. SCID (severe combined immune deficient) 
mice have been used for this purpose to prevent immune rejection of human cells.  In addition, a 
transgenic mouse was developed carrying the mouse urokinase type plasminogen activator (uPA) 
gene under the control of the mouse albumin enhancer/promoter (called SCID-Alb/uPA mice)331.  
The expression of this gene results in toxicity to the mouse hepatocytes, and therefore allows the 
introduced human hepatocytes a growth advantage, meaning that repopulation of the liver is 
performed by the human hepatocytes332.  Another xenograft mouse model called Trimera was 
created by irradiating mice, then reconstituting liver with marrow from SCID mice and human liver 
cells333.  
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1.13 HCV Replicon Cell Culture Models 
 
An advance in the ability to study HCV in vitro was made when the replicon cell culture system was 
developed131.  The first subgenomic replicons described were based on genotype 1b HCV (an isolate 
called Con1)131.  Replicons were subsequently developed using a genotype 1a HCV consensus clone 
called H77334.  Subgenomic RNA replicons typically consist of the HCV 5’ NTR (containing the HCV 
IRES) to drive RNA replication and translation of a neomycin resistance gene (neo) gene for antibiotic 
selection of cells containing the replicon.  The coding sequence for the non-structural proteins, from 
NS3 to NS5B, is present and under the translational control of an EMCV (encephalomyocarditis virus) 
IRES.  The 3’ NTR of the HCV genome is also present.  This design may have been influenced by the 
existing subgenomic replicons for other viruses e.g. poliovirus335, bovine viral diarrhoea virus 
(BVDV)336, and Kunjin virus337.  In developing the HCV replicon systems, it was found that some 
mutations were required for efficient replication of the replicons.  Cell culture adaptive mutations 
were found in NS3, NS4 and NS5A, and worked individually or cooperatively338.   Potential functions 
for these mutations include action by enhancing HCV polyprotein cleavage, and HCV protein 
interaction, by enhancing interaction with the cellular components of the replicase complex, or by 
more efficiently inhibiting the cellular anti-viral defences.  Establishment of replicons based on 
genotypes other than genotype 1 did not occur until later, possibly because genotype 1 is the most 
common in patients from Europe and the USA and therefore the most likely to be studied.  However, 
in 2003 a genotype 2a clone isolated from a Japanese patient with fulminant hepatitis was used to 
create a subgenomic replicon339.  The consensus clone generated from this patient was designated 
JFH-1340.  The JFH-1 subgenomic replicon gave a higher number of colony forming units per µg of 
RNA than genotype 1b replicons and, importantly, was able to replicate without the need for the cell 
culture adaptive mutations required by previous replicons.  The major problem with the use of 
subgenomic replicons for the study of HCV is that they lack the coding sequence for structural 
proteins.  This means that subgenomic replicons cannot produce infectious virus particles and the 
full viral life cycle cannot be studied.  Therefore the description of the full-length JFH-1 HCV clone in 
2005, which can replicate in Huh7 cells without adaptive mutations, was a major advance in HCV 
research.   
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Figure 7: Structures of HCV replicons341.  
A Schematic representation of the HCV genome. The 5’ and 3’ NTRS are indicated by white bars. 
B and C The structures of bicistronic selectable subgenomic replicons. They are composed of the 
HCV 5’NTR directing translation of the neo gene, the IRES of the encephalomyocarditis virus (E-I), 
the HCV replicase genes NS3–NS5B (A) or NS2–NS5B (B) and the 3’NTR. D Structure of a 
selectable reporter replicon. This construct encodes a luciferase–ubiquitin–neomycin 
phosphotransferase fusion protein in the first cistron. The RNA supports stable expression of 
luciferase; ubiquitin (ubi) is used to trigger proteolytic removal of the neomycin 
phosphotransferase from the fusion protein. E The structure of a subgenomic Con1 luciferase 
(Luc) reporter replicon that is used for transient replication assays.  F Structure of a 
monocistronic reporter replicon. A gene encoding luciferase is fused in frame to the viral 
replicase genes NS3–5B via ubiquitin. The entire polyprotein is translated by the HCV IRES. 
 
 
  
A 
C 
E 
B 
D 
F 
Cellular and Viral Determinants for HCV Replication  Andrew Baillie 
 
Imperial College London  45 
 
1.14 HCV Infectious Cell Culture Models 
 
When the full-length JFH-1 HCV clone was generated, it was found to be able to undergo complete 
viral replication when transfected into cultured hepatoma cells79-80.  This was the first sequence to 
be identified to allow HCV replication in vitro and derivatives of this genome are still by far the most 
efficient at replication and production of HCV in vitro.  Other HCV isolates have been tested for their 
ability to replicate in cell culture, with varying degrees of success.  Most research has been put into 
genotype 1 isolates.  The genotype 1a isolate H77 requires adaptive mutations for RNA replication 
and has shown a small amount of virus production334,342. Isolate H77C also showed a low level of RNA 
replication, and its cell culture adapted derivative H77S replicated RNA to a higher level, and 
produced some infectious virus 338,343-344.  The genotype 1b isolate HCV-N could replicate RNA with 
NS5A adaption, but did not produce virus345-347, and isolate HCV-CG1b replicated RNA under a T7 
driven system and was capable of producing some infectious virus348.  The genotype 1b isolate Con1 
wild type was capable of some RNA replication and transient virus production, but its cell culture 
adapted derivative, whilst capable of high levels of RNA replication, could not produce virus130-131,349-
350.  Two genotype 1b isolates with genotype 1a 3’NTRs called BK351and HC-J4352 showed a small 
amount of RNA replication, with no reported virus production. 
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Figure 8: Structure of JFH-1 derived genomes341.   
A Schematic representation of the HCV genome. The 5’ and 3’ NTRS are indicated by white bars.  
B Schematic representation of a bicistronic full length JFH-1 reporter genome. The HCV 5’ NTR 
directs translation of the firefly luciferase gene (Luc) whereas translation of the HCV polyprotein 
is under the control of the EMCV IRES (E-I). C Chimaeric genomes are composed of the region 
encoding core to transmembrane segment 1 of NS2 (C3 position) of HCV isolates Con1, H77 or J6 
fused to the remainder of the JFH-1 isolate. In case of the 452 chimera, the region encoding core 
to the C-terminus of NS2 (C6 position) was fused to the JFH-1 replicase genes. Junction sites are 
indicated by an arrow. The highly assembly competent J6/JFH-1 chimera is also called Jc1. D 
Schematic diagram of a monocistronic Renilla luciferase (RLuc) reporter genome. E Structure of a 
monocistronic Jc1 reporter virus applicable for live cell imaging. The gene encoding the green 
fluorescent protein (GFP; striped box) is inserted in-frame into domain 3 of NS5A. 
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1.15 Chimaeric HCV Genomes 
 
There have also been attempts to improve upon and add to the JFH-1 infectious virus system.   
The use of reporters in the viruses, whilst usually conferring a replicative disadvantage, is useful in 
that it allows for additional methods to measure the replication of the virus.  Luciferase reporter 
viruses have been created, with several different construction morphologies.  Bicistronic vectors 
have been created where, in a similar way to the subgenomic replicons, the reporter is under the 
translational control of the HCV IRES, and the HCV polyprotein is under the control of an EMCV IRES 
(Figure 8B).  Reporter genes have been inserted into the polyprotein, for example GFP at domain 3 
of NS5A353 (Figure 8E).  A common reporter virus has the reporter inserted after p7, and then has an 
FMDV (foot and mouth disease virus) 2A sequence between the reporter and NS2208 (Figure 8D).  
The function of the FMDV 2A is to autocleave the reporter from the HCV non-structural proteins.  
The use of chimaeric viruses has been pursued in order to improve the replicative efficiency of 
viruses, and to provide models for study of genotypes other than genotype 2a.  Studies have found 
that it is possible to exchange the structural protein coding region of JFH-1 for those of other viruses 
and still achieve HCV replication in cell culture.  Chimaeric JFH-1 sequences were created with the 
junctions located at various sites in p7 and NS2, mostly at sites between the transmembrane 
domains.  It was found that most chimaeras replicated most efficiently when the junction between 
sequences was located after the first transmembrane domain of NS2.  Intergenotypic and 
intragenotypic chimeras have been made using this technique.  A chimaera of the non-structural 
region of JFH-1 with the structural region of another genotype 2a clone, J6, created a virus that 
could yield infectious titres of 100 times higher than JFH-1 alone.  This chimaera was designated Jc1.  
Replicating chimaeras were also made during the same study by fusion of the non-structural regions 
of JFH-1 with the structural regions from isolates of genotypes 1a (H77), 1b (Con1), and 3a (452), in 
the case of which, the fusion junction was at the end of NS2)354 (Figure 8C).  Chimaeric viruses 
incorporating the structural genes of JFH-1 and the non-structural genes of other viruses have not 
been able to replicate in cell culture.   
 
Studies into the importance of non-structural regions in the replication of HCV JFH-1 have been 
attempted.  Intergenotypic and intragenotypic chimaeras of subgenomic and full length JFH-1 have 
been used to identify viral determinants involved with HCV replication.   
A study has been performed using intragenotypic chimaeric subgenomic replicons and full length 
infectious HCV as the bases for study355.  Using the JFH-1 sequence as a backbone, J6 isolate 
sequences corresponding to the individual non-structural proteins were incorporated into a panel of 
subgenomic replicons and replication at 24 and 48 hours post electroporation was assessed by 
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luciferase activity.  Four chimaeras were observed to have reduced replication when compared to 
JFH-1 wild type.  These chimaeras were those containing J6 sequences in the following positions: 
NS5B and 3’NTR; NS3 helicase and NS5B; NS3 helicase and 3’ NTR; NS3 helicase, NS5B and 3’ NTR.  In 
a complementary experiment it was shown that introduction of the JFH-1 NS3 helicase, NS5B and 3’ 
NTR sequences could rescue the replication of a (non-JFH-1) genotype 2a replicon.  These regions 
were also investigated in full length infectious systems.  It was found that a J6 backbone (which 
cannot replicate alone) containing the NS3 helicase, NS5B and 3’ NTR sequences from JFH-1 was able 
to replicate and produce infectious virus, although infectivity was about 100 times less than JFH-1 
wild type.  Chimaeric viruses based on a JFH-1 backbone could replicate with minimal introduction of 
J6 sequence, for example the chimaera with only J6 3’ NTR replicated at levels approaching wild type 
JFH-1, but when the NS3 helicase, NS5B and 3’ NTR sequences from J6 were introduced into the JFH-
1 backbone, there was no replication observed.   
 
A separate study was conducted into the importance of non-structural regions in the replication of 
HCV RNA using intergenotypic chimaeric subgenomic replicons356.  This study investigated the effect 
of exchanging genotype 2a JFH-1 sequence for genotype 1b Con1 sequence, with emphasis on the 
NTRs, helicase, NS5A and NS5B.  Several of the various combinations of these sequences replicated, 
but to levels lower than the wild type JFH-1 replicon.  One chimaera which replicated almost to JFH-1 
levels, although with slower kinetics, was the construct containing the NTRs, helicase, NS5A and 
NS5B from JFH-1 and other sequences from Con1.  This study was more focused on the interactions 
between the NTRs and proteins, but provided evidence for genotype specific interactions between 
the NS3 helicase, NS5A and NS5B. 
 
Natural chimaeras are rare but have been observed.  For example a 2k/1b chimaera exists in Europe, 
and has the recombination site in NS2357.  A 2b/1b chimaera has been reported in the Philippines358, 
and a 2k/5a in France359, both of which have the recombination site in NS2.  A 1a/1b chimaera 
identified in South America has the recombination site in NS5B360. 
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1.16 Mutation in the HCV Genome 
 
The heterogeneity of the HCV genome is an important feature of its strategy for survival and has an 
important bearing on the scientific study of the virus.   
 
The HCV polymerase is typical of RNA dependent RNA polymerases in that it has a relatively high 
error rate in replication of RNA (compared to DNA polymerases).  A major contributing factor to the 
error rate is that the HCV polymerase lacks the ability to proofread the replicated strand by 5’ to 3’ 
exonuclease activity361.  Estimates of the in vivo nucleotide mutation rate are around 1.4-1.9 x 10-3 
substitutions per nucleotide per year, based on work performed in chimpanzees and humans362-363.  
Other estimates have suggested that there is roughly one mutation per replication of the genome.  
Of the mutations which occur, within the protein coding region some will be synonymous and have 
no effect, some will be non-synonymous but have no great effect on replication and some will have 
an effect on replication, although these will mostly be detrimental.  The non-coding regions of the 
genome are much less permissive to mutation, and the mutations which occur here will largely 
result in defective genomes.  Over the six major genotypes of HCV, nucleotide sequences can differ 
by 30%, and even within some genotypes there can be differences of up to 25%.  The 5’ NTR has 90% 
sequence conservation across all genotypes, and the capsid is also well conserved.  The region of the 
HCV genome coding for the envelope proteins includes two regions of high diversity called Hyper 
Variable Regions (HVR) 1 and 2.  HVR-1 is located at the amino terminus of the E2 protein, and can 
have 50% sequence diversity in different patients.  This is thought to be part of a viral strategy to 
avoid detection by the host adaptive immune system by constantly changing the epitopes 
presented.  Evidence for the importance of the HVR-1 in the humoral immune response is limited, 
and other regions may be just as important for development of immune responses261,364.  A 
phylogenetic study of HCV failed to find an association between viral persistence in patients and 
specific mutations in E1 and E2365.  Another key region of sequence diversity is the interferon 
sensitivity determining region (ISDR) located in NS5A.  This region has been noted to mutate in 
patients as well as cell culture, and amino acid mutations have been observed to affect the ability of 
patients with HCV genotypes 1 and 2 to respond to interferon therapy171,366-368.   Sequence diversity 
occurs more generally across the non-structural proteins and this may have an effect on the variable 
pathologies of different HCV genotypes, activities of their proteins, and their ability to replicate in 
cell culture (as discussed in section 1.15 on the study of artificial chimaeric HCV constructs).  The NS3 
coding region shares 70% nucleotide sequence identity and 80% amino acid identity across all 
genotypes (Figure 9A-C).  The helicase domain has less homology between genotypes than the 
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protease domain (Figure 9D-E) and genotype 2a has the lowest score when compared to the other 
genotypes, indicating that it has more unique sequence. 
 
A 1a 1b 2a 3 4 5 6  B 1a 1b 2a 3 4 5 6  C 1a 1b 2a 3 4 5 6 
1a    
Nucleotide Identity 
NS3 Full Length 
 1a    Amino Acid Identity 
NS3 Full Length 
 1a    
Amino Acid Similarity 
NS3 Full Length 
1b 79    1b 92    1b 97   
2a 69 69       2a 80 80       2a 88 88      
3 69 70 68      3 81 82 80      3 89 90 89     
4 73 74 69 70     4 85 87 78 81     4 92 93 87 88    
5 72 72 69 69 72    5 84 84 79 81 82    5 92 92 88 89 90   
6 73 70 69 69 72 71   6 86 86 80 81 84 84   6 92 92 88 89 90 91  
                          
D 1a 1b 2a 3 4 5 6  E 1a 1b 2a 3 4 5 6          
1a    
Amino Acid Identity 
NS3 Protease 
 1a    Amino Acid Identity 
NS3 Helicase 
         
1b 88    1b 94            
2a 70 69       2a 83 84               
3 76 77 71      3 83 84 83              
4 81 83 71 75     4 87 88 81 83             
5 80 79 71 76 79    5 86 86 82 83 84            
6 83 83 74 79 82 82   6 87 87 83 82 85 85           
 
Figure 9: NS3 sequence similarity between different HCV genotypes.  
Example sequences from each HCV genotype were selected and compared for similarity.  
Sequences compared were: genotype 1a HCV isolate H77 (accession number AF011753); 
genotype 1b Con1 (AJ238799); genotype 2a JFH-1 (AB047639); genotype 3a 452 (DQ437509); 
genotype 4a ED43 (NC_009825); genotype 5a SA13 (AF064490); genotype 6a EUHK2 (Y12083). 
 
 
The ability to study HCV in the laboratory has been linked to specific details of the HCV sequence.  
The replication in cell culture of the majority of replicon models has depended on specific amino acid 
mutations.  However the HCV isolate consensus sequences do not usually replicate efficiently in cell 
culture, and the ability to replicate efficiently is conferred by the presence of cell culture adaptive 
mutations.  Sequence analysis of one of the first replicons, the genotype 1b subgenomic replicon 
I377/NS3-3’
131, showed several mutations were selected in NS5A, each of which enhanced the 
transduction efficiency of the replicon when engineered into the replicon RNA130.  A particular 
mutation was seen to arise on multiple occasions in separate replicon cell clones, where the serine 
residue at amino acid position 1179 of the subgenomic HCV polyprotein in the original replicon was 
mutated into an isoleucine in the adapted replicon (S1179I).  It has become common practice to use 
replicons bearing cell culture adaptive mutations for the study of HCV.  Studies of replicons in cell 
culture, particularly genotype 1b, have yielded a number of potential cell culture adaptive 
mutations, some of which are described in Figure 1086,350.  Most mutations found prove not to 
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endow a replicative advantage when deliberately recloned349.  Some mutations, such as S1179I 
(described as S2204I in Figure 10), have been shown to give a strong replicative advantage, and 
some mutations have been shown to confer weak replicative advantages.  A few mutations have 
been shown to work together in producing additive effects (such as E1202G, T1280I and S2197P 
increasing the number of colony forming units per microgram of replicon RNA used to transfect 
Huh7 cells349).   
 
 
 
 
Figure 10: Mutations observed in replicon cell clones86. 
The conserved mutations in Con1 replicons isolated from 26 independently selected cell 
clones350 are shown on a schematic representation of the HCV non-structural proteins from NS3 
to NS5B.  Amino acid positions given refer to the Con1 polyprotein (AJ238799).  Numbers in 
parenthesis indicate the frequency with which a given mutation was found in independent 
replicon cell clones. Mutations identified as the only conserved alteration in at least one cell 
clone are underlined. The circles illustrate clusters of adaptive mutations. 
 
 
It has been shown that some mutations that are beneficial to the replicative ability of the virus in cell 
culture can be detrimental in vivo.  Intra-hepatic transfections of chimpanzees with a cell culture 
adapted Con1 genome carrying the mutations E1202G, T1280I and S2197P349 did not result in the 
production of infectious virus, whereas the wild-type Con1 did produce infectious virus369.   
 
 
1.17 Cell Lines Capable of Supporting Replication of Infectious HCV 
 
The viral sequence is not the only determinant involved in achieving in vitro HCV RNA replication or 
virus production.  The search for appropriate host cells has been as difficult as that of finding 
replicative HCV isolates.  The cell line shown to achieve the highest levels of HCV replication is the 
hepatocellular carcinoma line Huh7 and its derivatives.  This cell line has supported all isolates so far 
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found to replicate in vitro.  A few other cell lines have also been shown to support replication of 
some HCV isolates, such as the hepatoma lines HuH6 (supporting Con1 and JFH-1370), HepG2 (JFH-
1371) and IMY-N9 (JFH-1371).  The cervical carcinoma line HeLa (Con1, JFH-1372-373) and the embryonic 
kidney line 293 (Con1, JFH-1372), as well as the mouse lines MEF374 and Hepa1-6373, have shown some 
ability to support HCV RNA replication.  Huh7 cells were isolated from a 57 year old Japanese male 
patient with liver cancer in 1982.  These cells support HCV replication, and there has also been the 
development of cell lines, derived from Huh7, with enhanced capacity for HCV replication.  Many of 
these have been achieved by selecting for cells which host efficiently replicating HCV replicons.  It 
was found that Huh7 cells which had hosted HCV replicons, and were cured of their replicons, 
subsequently often became more permissive to HCV replication.  These cells include the lines Huh7.5 
and Huh7.5.1.  To generate Huh7.5 cells375, interferon cured replicon cells were separated by limiting 
dilution in order to obtain clonal lines, before their ability to support HCV RNA replicon replication 
was assessed.  This study discovered a line, Huh7.5, which supported higher levels of RNA replication 
than the parental Huh7 cell line.  Other cured cell lines have been generated, from Huh7 cell lines 
hosting different replicons, and by using interferon or other anti-virals.  It has not always been 
possible to identify the properties of the cured cells that make them more permissive to HCV 
replication.  In the case of Huh7.5 cells, a mutation was identified in a gene called RIG-I (retinoic acid 
inducible gene I)318.  This gene was known to be involved in immune regulation, and was later found 
to be a sensor for double-stranded RNA and 5’ triphosphates on RNA152-153.  The detection of these 
patterns by RIG-I initiates an interferon response, signalled through a protein called MAVS 
(mitochondrial antiviral signalling protein, also known as IPS-1, VISA and Cardif). MAVS is associated 
with membranes near the mitochondria and, in response to signals from the RIG-I and Mda5 
proteins, will induce an interferon response via IRF7149-150,315.   
There may be additional determinants which contribute to the ability of Huh7 cells to support HCV 
replication.  For example, Huh7 cells do not express toll-like receptor 3 (TLR3)376 that initiates an 
immune response upon sensing double-stranded RNA.  The Huh7 cell line is a hepatocellular 
carcinoma line, and certain properties of these differentiated cells may contribute to their ability to 
support HCV replication.  This is not simply a product of the fact that Huh7 is a cancer line, as most 
of the cell lines so far tested for the ability to support HCV replication were cancer lines.  It may be 
properties specific to the Huh7 cancer.  Studies involving HCV have tended to be performed in 
Huh7.5 cells since their discovery, rather than Huh7 cells.  This is because of the higher levels of RNA 
replication that can be attained in Huh7.5 cells.  A study has compared several clonal lines of Huh7 
cells from different sources, and Huh7.5 cells377.  Similar HCV replication kinetics were demonstrated 
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in Huh7 and Huh7.5 cell lines.  Both cell types could therefore be viable options for performing gene 
expression analyses, and results from different studies may be compared. 
 
Cell culture is a very useful model for studying human disease but there are limitations to this model. 
The cells used here are cultured cancer cells in culture not primary hepatocytes.  This means that the 
cells have already undergone changes in order to make them immortal.  In addition, these cells have 
been cultured since isolation from the donor (in the cases of Huh7, since 1982) during which time 
other phenotypic alterations may have occurred to alter them from the normal state of primary 
hepatocytes.  In the JFH-1 culture model of HCV, all cells can be infected whereas only a proportion 
(maybe 10%) of hepatocytes in a liver will be infected, and hepatocytes themselves are only part of 
the cell population of the liver.  A higher intracellular titre of HCV RNA can be achieved in cell culture 
than in the liver.  There will be fewer quasispecies in culture, where there is less time for them to 
develop (days rather than years).  If mutations do arise in HCV during cell culture this may be 
advantageous to the study of the virus.  Any cell culture adaptive mutations which allow for a higher 
titre virus will aid the study of HCV.  This situation is already apparent from the work on subgenomic 
replicons, where all replicons used in cell culture now have adaptive mutations to allow more 
efficient replication.  This has become a standard model.  There is also less of a selection pressure on 
HCV in culture as there are no antibodies, and Huh7 cells have impairments to their innate immune 
responses.  There is also a more homogenous cell population (i.e. all hepatocytes, no other cells such 
as white blood cells).  This will lead to different intercellular signalling so some gene inductions may 
be different. 
 
There are clear advantages to using a cell culture model however.  It is possible to perform 
destructive tests where samples cannot be recovered, and which are not harmful to a patient.  It is 
possible to perform larger numbers of multiple tests, with more samples, and these can be 
controlled much more easily than is possible in tests using clinical samples. 
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1.18 HCV and Host Cell Gene Expression 
 
The investigation of host cell gene expression changes due to the presence of HCV has so far been 
performed in models using replicons, and by expression of individual HCV proteins.  These studies 
have identified gene expression changes in the host cell in both cases; during HCV RNA replication, 
and due to the presence of HCV proteins.  Gene expression has also been investigated in 
chimpanzees infected with HCV. 
 
Microarray analyses of gene expression in acutely and chronically infected chimpanzees have been 
performed.  HCV infection of chimpanzees is more likely to be an acute infection than in humans, as 
greater than 60% of inoculated animals will clear the virus330,378.  The first microarray studies 
performed on chimpanzees were therefore performed on animals with acute infections.  Bigger et 
al379 infected an individual chimpanzee with genotype 1a HCV, which experienced loss of viraemia at 
8 weeks and clearance of viral RNA from the liver at 14 weeks post infection.  Microarray analyses 
were performed on RNA from liver biopsies taken at 2 and 7 days post infection and 2, 4, 6, 8, and 12 
weeks post infection.   Changes in gene expression were made in comparison to day 0, before HCV 
infection.  327 genes were observed to change by a fold change of ≥3.5, with 162 of these at more 
than one timepoint.  Expression levels of interferon response genes were observed to have changed, 
as well as cytokines and growth factors, genes involved in cell regulation and replication, and 
immune cell markers.    Genes involved in other aspects of HCV infection were also onserved to 
change in expression levels.  These genes included adipophilin (involved in steatosis), IFI44 (also 
known as HCV-associated microtubule aggregate protein), and Mac-2BP (a possible marker for IFN-α 
unresponsiveness).  Su et al380 performed a study using three chimpanzees, all infected genotype 1a 
HCV, but from different sources.  One animal achieved sustained clearance, one was persistently 
infected but initially transiently cleared, and one was persistently infected.  Gene expression 
changes were measured from liver biopsy RNA.  All chimpanzees showed expression changes in IFN-
α response genes, but only the animals which cleared the virus showed an induction of IFN-γ 
induced genes.  Genes involved in lipid metabolism were also observed to be regulated in the 
animals which cleared the virus.  These included PPARα, hepatic lipase C, UDP-glucose ceramide 
glucosyltransferase, and SREBP pathways related genes.  A study looking at gene expression 10 
persistently infected chimpanzees was performed by Bigger et al329.  One animal was infected with 
HCV genotype 3a, three with genotype 1b and six with genotype 1a.  The animals had been infected 
for between 7 and 20 years, and had varying levels of viraemia.  Gene expression was compared to 
six controls, from four uninfected animals and two pools of uninfected material.  Up to 971 genes 
were observed to be altered in expression level in infected chimpanzees compared to uninfected 
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animals.   As in the previous studies of acutely infected animals, these chronically infected 
chimpanzees were shown to have many interferon stimulated genes transcriptionally elevated.  
Expression changes of several ISGs were confirmed by quantitative PCR.  Other genes observed to 
change in expression included those involved in modulation of immune cell activity, cytokines and 
chemokines, MHC-related components, and lipid metabolism. 
 
Studies performed using replicon models have shown expression changes in genes involved in 
biological processes including lipid metabolism, immunity, cell proliferation and apoptosis, and 
intracellular transport.  Several studies have utilised subgenomic replicon models to identify gene 
expression changes that occur during HCV RNA replication.  Abe et al compared gene expression in 
Huh7 cells harbouring genotype 1b subgenomic replicons with expression in their interferon-cured 
counterparts381.  This study used microarrays containing probes to around 10,000 genes to identify 8 
genes commonly regulated in the replicon cell lines.  In total, 101 and175 genes were regulated in 
the two different replicon lines tested, with 12 and 24 genes being regulated by more than three 
fold.  Commonly regulated genes included the upregulated genes phosphatidylserine-specific 
phospholipase A1α and oncostatin M receptor, and the downregulated genes large multifunctional 
protease 2, large multifunctional protease 7, and serine proteinase inhibitor clade C.  Nishimura-
Sakuri et al compared gene expression in genotype 1b and genotype 2a subgenomic replicons with 
their interferon cured counterparts, and with their parental line of naive Huh7 cells382.  This study 
used whole genome microarrays to identify 372 probe sets which were regulated by more than 1.2 
fold in replicon cells compared to cured cells, of which 15 changed by more than two fold.  This 
study also showed altered gene expression in cured cells compared to parental naive Huh7 cells.  
Steroid biosynthesis, MAPK signalling and TGF-β signalling processes were identified as altered in 
replicon cells compared to cured cells.  Steroid biosynthesis, sphingolipid biosynthesis and TGF-β 
signalling processes were identified as altered in cured cells compared to naive cells.  This study 
emphasised the role that alterations in lipid metabolism including cholesterol and sphingolipid 
biosynthesis may be important for HCV replication.  Agonists of peroxisome proliferator activated 
receptor alpha (PPARα) were shown to suppress HCV replication and agonists of PPARγ augmented 
HCV replication, suggesting HCV replication was affected by the production of fatty acids.  
Expression studies have also been undertaken which focused on specific groups of genes.  Fillebeen 
et al used a microarray targeted to iron metabolism genes383.  This study identified expression 
changes which resulted in reduced iron uptake and increased iron release capacity.  Several genes 
were observed to be altered in expression in replicon cells compared to Huh7 cells, including 
upregulation of ceruloplasmin and ferroportin and downregulation of transferrin.  As NS5B has 
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previously been shown to be inactivated by iron384, these gene expression changes were 
hypothesised as possibly providing a mechanism to avoid NS5B inactivation by iron.  Curing replicon 
cells with interferon partially reversed the iron-deficient phenotype and restored the ability of cells 
to retain iron.  Itsui et al performed a study focused on interferon stimulated genes (ISGs)385.  17 ISGs 
were identified as being downregulated in replicon cells compared to naive Huh7 cells, and when 
overexpressed in replicon cells, eight of these ISGs had inhibitory effects on HCV replication.   
 
As well as using subgenomic replicons, some groups have made use of full length replicons to 
perform expression studies.  This allows for gene expression changes induced by the complete range 
of HCV proteins, however, there is still no entry or exit of infectious virus, and there are the 
additional genetic elements of the replicon present in these systems.  Ciccaglione et al compared 
gene expression in two cell lines harbouring a full length genotype 1b replicon with naive parental 
Huh7 cells and cured replicon cells386.  This study used whole genome microarrays to identify 38 
genes commonly regulated in all comparisons of replicon clones versus naive or cured cells.  In each 
individual comparison, between 534 and 654 genes were seen to be regulated by presence of the 
replicon.  Genes involved in biological processes including lipid metabolism, the extracellular matrix, 
cytoskeleton, histones, ribosomal proteins, and intracellular transport were observed to be 
regulated by presence of the HCV replicon.  Scholle et al used whole genome microarrays to identify 
changes in gene expression between cells harbouring a full length genotype 1b replicon with cured 
cells387.  This study identified 57 genes regulated by more than two fold by one replicon clone.  This 
study showed HCV genome replication to be dependent on cellular proliferation, and that replication 
was enhanced in the S phase of the cell cycle.  However, this study did not identify a significant 
alteration of the cell cycle by presence of the replicon at times up to 24 hours after release from the 
cell cycle block.  Cao et al used microarray analysis to identify arginase 1 as being elevated in HepG2 
cells harbouring a full length replicon388.  A three fold increase in expression was observed in cell 
culture.  The expression of arginase 1 was observed to be elevated in 75% of HCV patients 
(compared to patients with hepatocellular carcinoma).  This study observed that the presence of the 
replicon induced growth of HepG2 cells (but not Huh7 cells).  Inhibition of arginase 1 by siRNA 
inhibited the ability of the replicon to induce growth, and also increased nitric oxide synthase, nitric 
oxide and cell death.  It was hypothesised that HCV regulation of cell growth and survival could occur 
through altering arginine metabolism.   
 
The influence of individual HCV proteins on host gene expression has also been investigated by some 
groups.  Whilst these studies do not involve any HCV RNA replication, the proteins are effectors of 
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changes in the host cell.  These studies have used a variety of protein delivery methods and cell 
lines.  Vandermeeren et al expressed the full polyprotein from a vaccinia virus vector in HeLa cells389.  
After 6 hours morphological changes were observed in the ER, Golgi and mitochondria, and gene 
expression changes were observed.  Microarray analysis of around 20,000 genes identified 231 
genes regulated at 6 hours and 81 genes regulated at 16 hours after induction of polyprotein 
expression.  This study identified genes involved in apoptosis, oxidative stress, mitochondrial 
functions, lipid metabolism, cell cycle, signalling and immune responses to be regulated during 
polyprotein expression.  Budhu et al used adenoviral vectors to express core, NS3 and NS5A, 
separately and in combination, in primary human hepatocytes390.  Using microarray profiling of 
around 22,000 genes, these HCV proteins were found to induce expression changes in genes 
involved in cell regulation, transcription, immune response transport and metabolism.  This study 
also compared expression levels in HCV infected patients liver with samples from chronic liver 
disease patients, and highlighted the upregulation of interferon inducible gene 27 in HCV liver and in 
cells expressing HCV core protein.  Dou et al used plasmid expression vectors to deliver core protein 
of genotypes 1b, 2a and 4d into HepG2 cells391.  This study identified 264 genes associated with 
expression of the genotype 1b core, 172 with 2a, and 285 with 4d.  There was some overlap in the 
genes observed to be expressed in the presence of the different genotypes, but most genes were 
unique to each genotype.  However, the biological processes these genes were involved in were 
common to all genotypes.  This study identified that expression of HCV core protein regulated 
expression of genes involved in transport, signal transduction, transcription regulation, protease 
activity and both pro- and anti-apoptotic functions.   Another study performed by Dou et al used 
whole genome microarrays to compare the expression profiles induced by genotype 1b core protein 
and core shadow protein (the core protein equivalent translated from the alternative reading frame) 
in Huh7 cells392.  This study identified that the core shadow protein could also influence the 
expression of genes involved in both pro- and anti-apoptotic mechanisms.  Aizaki et al used cDNA 
expression vectors to express full and partial HCV polyproteins in HepG2 cells393.  Microarray analysis 
of the cell line expressing full length polyprotein identified 16 genes to be regulated compared with 
control.  These included genes involved in cell growth regulation and major histocompatibility 
complex (MHC) regulation.  Basu et al used a plasmid expression vector to introduce genotype 1a 
core protein into primary hepatocytes394.  Using whole genome microarrays, 1918 transcripts were 
identified as being differentially expressed by more than two fold in cells with core.  This study 
focused on the increase in genes involved in Stat3 signalling (IL-6, gp130, leptin receptor, stat3).  
Presence of core was also found to regulate genes involved in biological processes including cellular 
growth, immune regulation, oxidative stress and apoptosis. 
Cellular and Viral Determinants for HCV Replication  Andrew Baillie 
 
Imperial College London  58 
 
Some gene expression studies have been performed using liver material from HCV infected patients.  
Hagist et al focused on the role of iron and oxidative stress in liver disease395.  This study used a 
combination of microarray data from HepG2 cells challenged with iron and oxidative stress, and 
microarray data from HCV patient liver.  One gene (natriuretic peptide precursor B) was observed to 
be regulated in HepG2 challenged with iron, in HCV patient liver but not in patients with severe iron 
deposition.  A small number of genes involved in oxidative stress, iron metabolism, RNA processing 
and cell proliferation were also observed to be regulated in HCV patients.  Smith et al used 
microarrays to compare expression levels of around 13,600 genes between HCV infected cirrhotic 
liver material and control normal liver material396.  This study excluded cancer related genes and 
identified 132 annotated genes to be regulated in at least 5 of their 7 experiments.  These genes 
were categorised into functions including genes expressed in activated lymphocytes and 
macrophages, extracellular matrix and cell-cell interactions, cytoskeleton, Bcl-2 anti-apoptotic 
pathway, oxidative stress, and anti-viral immune response.  Other studies using HCV infected liver 
have focused on specific functions.  A study performed by Walters et al in HCV infected patients 
observed a subset of patients where there was a decrease in genes involved in the FAS-apoptotic 
pathway, and impaired interferon responses, which was similar to gene expression patterns in 
patients who develop fibrosis soon after liver transplant397.  Helbig et al used whole genome 
microarray analysis to compare gene expression HCV infected liver with normal liver398.  This was 
performed using both human and chimpanzee liver samples.  This study found that CXCR3 family 
cytokines were elevated in expression, including CXCL10 and CCXCL11.  CXCL10 was also observed to 
be elevated in serum.  CXCL11 was observed to increase in response to IFNγ and TNFα in cell culture 
using JFH-1, but this feature was also observed using dsRNA, indicating that this is a general 
response, and not specific to HCV. 
 
The fact that these observations have been made in previous studies is a good indication that it is 
worth pursuing the investigation of host cell gene expression changes during HCV infection.  These 
studies have provided important information on host gene expression during HCV RNA replication, 
and the interaction between HCV and the cell.  However, the use of infectious virus in a gene 
expression study would induce a more biologically relevant change in the host cells.  Areas of 
potential significance include genes involved in RNA replication, immune responses, lipid 
metabolism, oxidative stress, apoptosis and cellular proliferation.  The use of infectious virus would 
mean that the processes of entry, assembly and exit were affecting the cell.  The proper interactions 
of all HCV proteins with each other, and with host cell proteins, will also be allowed to take place. 
Thus, the use of the infectious JFH-1 HCV in a whole genome expression study could yield useful and 
novel information about the state of HCV infected cells.    
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1.19 Aims and Hypotheses 
 
The genotype 2a HCV isolate JFH-1is the only isolate discovered to replicate efficiently in cell culture.  
It is predicted that this quality is due to specific sequence determinants unique to JFH-1.  It has been 
shown that the structural regions of JFH-1 can be exchanged for those of other genotypes, and still 
replicate in cell culture.  This implies that the viral determinants for the ability of JFH-1 to replicate in 
cell culture lie in the non-structural region of the genome.  This work will focus on the NS3 region, as 
this is a multifunctional protein with vital roles in RNA replication as a helicase, in polyprotein 
processing as a protease and in interactions with cellular proteins as a protease.  The hypothesis that 
genotype specific NS3 sequence determinants are required for efficient HCV replication in cell 
culture will be tested by creating chimaeric JFH-1 genomes containing genetic sequence from other 
HCV genotypes, and assessing the replication capacity of these chimaeras in cell culture. 
Hypothesis: The NS3 coding regions contain genotype specific sequence determinants that allow 
JFH-1 to replicate efficiently in cell culture. 
 
The host cell has been found to be crucial in the efficient replication of HCV in cell culture.  It is 
predicted that HCV infection will induce expression changes in the host genes involved in processes 
related to HCV replication.  These are predicted to include genes involved in the regulation of the 
biological processes required for the HCV lifecycle.  Genes involved in lipid metabolism are predicted 
to change in expression as the virus alters cell membranes and lipid droplets.  Genes involved in cell 
cycle including proliferation and death are predicted to change as the virus replicates and the cell 
responds to its presence.   Genes related to oxidative and ER stresses are predicted to change as the 
virus replicates.  It is also predicted that innate immune genes involved in the host’s response to 
infection with HCV will be altered in expression levels. These predictions will be tested by application 
of whole genome expression analysis of HCV JFH-1 infected cells using microarray technology.   
Hypothesis: HCV infection will alter the host gene expression patterns, including those of processes 
directly related to the replication of HCV and the host response to infection. 
 
It is predicted that, of the host genes identified to be regulated in expression level during HCV 
infection, some host genes will be required for the replication of HCV.  Selected genes, identified as 
being upregulated during HCV infection, will be inhibited prior to infection of cells with HCV to 
determine whether these genes are required for HCV replication. 
Hypothesis: Genes upregulated in expression levels during HCV infection are required for efficient 
HCV replication.  
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Methods 
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2.1 Cell Culture 
Huh7 and Huh7.5 cells were grown in Dulbecco’s modified Eagles Medium (DMEM) supplemented 
with 10% foetal bovine serum (FBS), 100U/ml penicillin and 100µg/ml streptomycin at 37°C with a 
5% CO2 atmosphere.  All cell culture reagents were purchased from Invitrogen.  Cell lines containing 
selectable sub-genomic HCV replicons (Rep4 and Rep4.5) were grown as for Huh7 cells, but in 
medium supplemented with 500µg/ml geneticin.  Cells were passaged by trypsinisation.  Huh7.5 
cells were obtained from Charles Rice. 
 
2.2 HCV Constructs 
The infectious clone JFH-1, replication deficient mutant JFH-1 GND, and envelope protein deletion 
mutant JFH-1 deE1E2 were obtained in their plasmid vectors from Takaji Wakita.  Jc1p7FLuc2A was 
created by Shihyun You using Jc1p7GLuc2A from Charles Rice.  Genotype 1b subgenomic replicon 
S1179I, also known as BB7, was obtained from Charles Rice.  Replicon cell line 15.53 contains a 
genotype 2a subgenomic replicon created by Cindy Richards at GlaxoSmithKline (GSK).   
 
 
2.3 JFH-1 Infectious Virus Cell Culture System 
 
2.3.1 Plasmid Preparation 
Plasmid pJFH-1 was produced by transformation of Library Efficiency E. coli DH5α (Invitrogen) 
according to manufacturer’s instructions.  10ng of JFH-1 plasmid DNA was mixed with 50µl of E. coli 
and incubated on ice for 30 minutes.  Bacteria were heat shocked at 42°C for 40 seconds and 
incubated on ice for two minutes.  450µl SOC medium was added and the bacteria were shaken at 
200rpm for one hour at 37°C.  200µl of the transformation mix was plated onto Luria Bertani (LB) 
agar containing 100µg/ml ampicillin and incubated overnight at 37°C.  The following day, 
transformed bacterial colonies were picked and grown overnight at 37°C in 5ml LB medium 
containing 100µg/ml ampicillin.  pJFH-1 DNA was prepared from the transformed DH5α cultures 
using the Plasmid Mini Kit (Qiagen) according to the manufacturer’s instructions.   
 
For larger scale plasmid preparations, 5µl of pJFH-1 DH5α glycerol stock was used to seed 5ml of LB 
medium containing 100µg/ml ampicillin and grown for 8 hours at 37°C with shaking at 200rpm.  50µl 
of the 5ml culture was used to seed 50ml of LB medium containing 100µg/ml ampicillin and grown 
overnight at 37°C with shaking at 200rpm.  pJFH-1 DNA was prepared from the 50ml cultures using 
the HiSpeed Plasmid Midi Kit (Qiagen) according to the manufacturer’s instructions. 
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2.3.2 In Vitro RNA Transcription 
20µg of pJFH-1 was linearised with 150 units of 100U/µl restriction enzyme XbaI (NEB) and 5µl 10x 
NEBuffer 2 (NEB) in a final volume of 50µl, which was incubated at 37°C for 2 hours.  The linearised 
DNA was purified by phenol-chloroform extraction and ethanol precipitation.  The 50µl restriction 
digestion was made upto 200µl with tris-EDTA (1mM Tris-Cl, 1mM EDTA, pH8.0).  An equal volume 
of phenol-chloroform (25:24:1 phenol:chloroform:isoamyl alcohol, Sigma) was added, the mixture 
shaken vigorously, and then centrifuged at 16,000g for 15 minutes.  The upper, aqueous phase was 
transferred to a new 1.5ml eppendorf tube, and an equal volume of chloroform was added.  Samples 
were shaken, and then centrifuged at 14,000g for 5 minutes.  The upper, aqueous phase was 
transferred to a new 1.5ml eppendorf tube, where 0.1 volume 3M sodium acetate and 2.5 volumes 
of ethanol were added, and incubated overnight at -20°C.  DNA was pelleted by centrifugation at 
14,000g for 20 minutes at 4°C, and the supernatant removed.  The pellet was washed by adding 
0.5ml 75% ethanol and centrifuging at 14,000g.  After air-drying, the pellet was resuspended in 45µl 
nuclease-free water.  3’ overhanging DNA was removed by digestion with 30 units Mung Bean 
Nuclease (NEB) for 30 minutes at 30°C.  The digestion mix was treated with 0.5% SDS and 40µg 
Proteinase K (Invitrogen) in a final volume of 200µl for 1 hour at 50°C.  The DNA was purified by 
phenol-chloroform extraction and ethanol precipitation as before, and the DNA pellet resuspended 
in 20µl nuclease-free water.  JFH-1 RNA transcripts were generated from pJFH-1 using the T7 
MEGAscript In Vitro RNA Transcription kit (Ambion).  RNA transcription was performed using 1µg of 
linearised plasmid DNA and T7 MEGAscript In Vitro RNA Transcription reactions were incubated at 
37°C for 6 hours.  1µl DNase was added and incubated at 37°C for 15 minutes.  15µl stop solution 
was added, and water was added to a final volume of 250µl.  750µl Trizol LS (Invitrogen) was added, 
and JFH-1 RNA transcripts were purified according to the Trizol LS manufacturer’s instructions.  RNA 
was finally resuspended in 20µl nuclease-free water. 
 
2.3.3 RNA Transfection of Huh7.5 Cells 
The JFH-1 RNA transcript was transfected into Huh7.5 cells using Lipofectamine 2000 (Invitrogen).  
Huh7.5 cells were seeded at a density of 6x105 in a 6-well plate. The following day, with cells at 80% 
confluency, growth medium was replaced with OptiMEM medium (Invitrogen) and the cells were 
incubated for four hours.  5μg JFH-1 RNA and 10μl Lipofectamine 2000 were each diluted in 500μl of 
OptiMEM and incubated at room temperature for 20 minutes.  The dilutions were then mixed, and 
incubated at room temperature for 20 minutes.  The growth medium was removed from the cells 
and they were washed with 1ml OptiMEM.  The 1ml RNA/Lipofectamine 2000 transfection mixture 
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was then added to the cells.  After an eight hour incubation period, the transfection medium was 
replaced with 2ml normal growth medium and the cells were incubated overnight.  The following 
day, transfected cells were passaged into a 25cm2 flask.  Transfected cells were then expanded into 
75cm2 flasks for large scale production of JFH-1 infectious virus.   1.5ml of growth medium 
containing infectious virus was used to infect naive Huh7.5 cells at 50% confluency in 75cm2 flasks.  
 
2.3.4 Harvest of Infectious JFH-1 Virus 
Growth media were collected from 75cm2 flasks of Huh7.5 cells infected with JFH-1 virus.  Pooled 
media were clarified by centrifugation in a Mistral 3000 Benchtop Centrifuge (MSE) at 1500rpm for 
10 minutes, after which the supernatant was filtered through 0.45µm sterile filter units. JFH-1 virus 
in the filtered medium was concentrated using Amicon Ultra-15 filtration units (Millipore) by 
centrifugation at 3600 rpm at 4°C for 20 minutes.  Retentate containing concentrated JFH-1 virus 
was collected and stored at -20°C. 
 
2.3.5 Titration of JFH-1 Virus Stocks 
Huh7.5 cells were seeded into 8-well chamber slides at a density of 0.8x105 to be at 100% confluency 
for infection.  Three 10-fold serial dilutions of the concentrated JFH-1 virus stocks (corresponding to 
1µl, 0.1µl and 0.01µl per well) were used to infect the Huh7.5 cells in duplicate.  After 36 hours, the 
chamber slides were stained for HCV core protein and foci were counted using immunofluorescence 
microscopy. Total numbers of HCV Core-positive foci were counted per well at the appropriate 
dilution and averaged.  Titres of infectious JFH-1 virus in the concentrated stock were calculated as 
focus forming units per ml (ffu/ml). 
 
2.3.6 Staining for HCV Core Protein 
Chamber slides were fixed in 4% paraformaldehyde for 30 minutes.  Cells were washed in PBS for 10 
minutes and permeabilised in 0.1% Triton X-100 for 20 minutes.  The anti-core antibody, mouse 
monoclonal C7-50 (Abcam), was diluted 1 in 400 in 1% BSA in PBS.  20µl of diluted C7-50 was applied 
to each well and incubated for one hour in a humidity chamber.  Chamber slides were washed in PBS 
times in PBS for five minutes each wash.  Fluorescent secondary antibody, AlexaFluor 594 
conjugated donkey anti-mouse polyclonal (Invitrogen), was diluted 1 in 1000 in 1% BSA in PBS.  20µl 
of the diluted secondary antibody was applied to each well and incubated for one hour in a humidity 
chamber.  Chamber slides were again washed three times with PBS, and briefly rinsed once with 
water to remove salts.  The slides were mounted using 10µl per chamber of Mowiol mounting 
medium, containing the nuclear stain DAPI.  Fluorescent staining was observed using the Zeiss 
Axiovert 200M fluorescent microscope, and Axiovision 4.6 software for image acquisition. 
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2.3.7 JFH-1 Virus Production by Media Passage 
Huh7.5 cells were seeded to be 25% confluent in 75cm2 cell culture flasks.  The cells were infected 
with JFH-1 virus at a multiplicity of infection (MOI) of 0.1.  Infected Huh7.5 cells were incubated for 
four days and the growth medium was collected and clarified.  Huh7.5 cells were also seeded in 
75cm2 flasks, were each infected with 1.5ml of clarified medium containing JFH-1 virus.  The 
remaining clarified medium was concentrated, as described, and stored at -20°C. Infectious clarified 
medium was serially passaged onto naive Huh7.5 cells every four days to provide a supply of high 
titre JFH-1 stocks.   
 
The growth media from flasks of uninfected Huh7.5 cells were also collected and treated by the 
same method to generate mock medium for mock infected controls in infection experiments.   
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2.4 Jc1 Infectious Virus Production 
 
2.4.1 Plasmid Preparation 
Plasmid pJc1p7FLuc2A was produced as pJFH-1.  All work using Jc1p7FLuc2A was performed at the 
GSK laboratories, NC, USA. 
 
2.4.2 In Vitro RNA Transcription 
10µg of pJc1p7FLuc2A was linearised with 100 units of restriction enzyme XbaI (NEB) and purified 
using the PCR MinElute Clean-Up kit (Qiagen).  Jc1 RNA transcripts were generated from 
pJc1p7FLuc2A using the T7 RiboMax Express kit (Promega).  RNA transcription was performed using 
2µg of linearised plasmid DNA and reactions were incubated at 37°C for one hour.  The transcription 
reaction was treated with DNA-free Turbo DNAse (Ambion) to remove the remaining linearised 
pJc1p7FLuc2A DNA.  Jc1 RNA transcripts were purified using the RNeasy kit (Qiagen), and eluted in 
80µl nuclease-free water.  
 
2.4.3 RNA Electroporation of Huh7.5 Cells 
10µg Jc1 RNA transcript was mixed with 1 x 107 Huh7.5 cells suspended in 0.8ml PBS, in a 4mm gap 
electroporation cuvette.  Gene Pulser Xcell (Bio-Rad) electroporation equipment was set to deliver a 
pulse with voltage of 270V and capacitance at 975µF.  The electroporated cells were left to stand for 
5 minutes and then transferred into a 225cm2 flask containing growth medium.  The following day, 
growth medium was replaced.  On the second day post-electroporation the Huh7.5 cells were split 
into two 225cm2 flasks.  
 
2.4.4 Harvest of Infectious Jc1 Virus 
Growth media containing infectious Jc1 virus from 225cm2 flasks of Jc1 RNA electroporated Huh7.5 
cells were collected every day for five days after electroporation and pooled.   
 
2.4.5 Titration of JFH-1 Virus Stocks (TCID50) 
Huh7.5 cells were seeded in a 96-well plate at a density of 8 x 103.  Two separate 10-fold serial 
dilutions (from 10-1 to 10-5) of the Jc1 virus stock were prepared and added to the wells, with eight 
replicates per dilution.  Infected cells were incubated for 72 hours, at which time the cell culture 
medium was removed and replaced with 25µl of SteadyGlo Luciferase reagent (Promega).  After 10 
minutes incubation shaking at room temperature in the dark, luciferase activity was measured.  
Wells were scored as positive or negative for luciferase activity and TCID50 was calculated.  
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2.5 Microarray Studies 
 
2.5.1 Titration Assay 
Cells were seeded at a density of 0.5 x 105 in 24-well plates, and infected with JFH-1 virus at MOIs 
from 0.01 to 3.  After 48 hours incubation, total intracellular RNA was extracted and JFH-1 RNA levels 
were quantified using quantitative real-time PCR. Cells were also seeded at a density of 0.5x105 on 
glass coverslips placed into 24-well plates. These cells were infected with JFH-1 virus at MOIs ranging 
from 0.01 to 3, incubated for forty-eight hours and then stained for HCV core protein.  The 
percentage of cells infected with JFH-1 was estimated by counting the numbers of cells which 
stained positively for HCV core protein within a field of view. 
 
2.5.2 Infection of Huh7.5 Cells (Initial Method) 
Huh7.5 cells were seeded at a density of 5 x 105 cells in 4ml of growth medium in 25cm2 flasks. The 
next day, either concentrated JFH-1 stock or mock medium was added to the flasks.  Cells were 
infected at an MOI of 3, and the volume added to each flask was 1ml.  Conditions were performed in 
triplicate.  Four hours post-infection, the media were removed from all flasks and cells were washed 
with PBS at 37°C.  5ml of normal growth medium at 37°C was added to each flask.   At the indicated 
timepoints, media were removed from the flasks of infected and mock infected cells.  The cells were 
washed with PBS at 37°C.  3ml of Trizol (Invitrogen) was added to each flask and incubated for five 
minutes at room temperature.  Trizol-cell lysates were then homogenised by pipetting up and down, 
and transferred into cryovials for storage at -80°C. 
 
2.5.3 Infection of Huh7.5 (Revised Method) 
Huh7.5 cells were seeded at a density of 5 x 105 cells in 4ml of growth medium in 25cm2 flasks. The 
next day, either concentrated JFH-1 stock or mock medium was added to the flasks.  Cells were 
infected at an MOI of 3, and the volume added to each flask was 1ml.  Conditions were performed in 
triplicate.  At the indicated timepoints, media were removed from the flasks of infected and mock 
infected cells.  3ml of Trizol was added to each flask and incubated for five minutes at room 
temperature.  Trizol-cell lysates were then homogenised by pipetting up and down, and transferred 
into cryovials for storage at -80°C. 
 
2.5.4 Infection of Huh7 Cells and Addition of Protease or Polymerase Inhibitors 
Huh7 cells were seeded at a density of 5 x 105 cells in 3.5ml of growth medium in 25cm2 flasks. The 
next day, either concentrated JFH-1 stock or mock medium was added to the flasks.  Cells were 
infected at an MOI of 3, and the volume added to each flask was 1ml.  At 12 hours post-infection, 
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NM107 (final concentration of 50µM), BILN2061 (final concentration of 10µM), or DMSO control was 
added to the flasks in a volume of 0.5ml normal growth medium.  Conditions were performed in 
triplicate.  At the indicated timepoints, media were removed from the flasks of infected and mock 
infected cells.  3ml of Trizol was added to each flask and incubated for five minutes at room 
temperature.  Trizol-cell lysates were then homogenised by pipetting up and down, and transferred 
into cryovials for storage at -80°C. 
 
2.5.5 RNA Extraction 
Extraction of total cell RNA from Trizol-cell lysates, was performed by Expression Analysis (North 
Carolina, USA).  RNA quality was assured to be suitable for microarray analysis by assessment with 
Agilent Bioanalyzer equipment.   
 
2.5.6 Microarray Data Aquisition 
Hybridisation to microarrays and fluorescent data acquisition was performed by Expression Analysis.  
The GeneChip Human Genome U133 Plus 2.0 array (Affymetrix) was used to obtain expression 
profiles of all genes in the human genome.  One array was used per RNA sample extract.   
 
2.5.7 Microarray Data Processing 
Fluorescence data were analysed at GSK (North Carolina, USA) using Array Studio software 
(OmicSoft).  Affymetrix CEL data files were imported into Array Studio using RMA signal extraction.  
A log2 transformation was performed on the data prior to analysis.  Quality control of the data 
obtained from the arrays was performed by the principal components analysis and correlation based 
quality control methods available in Array Studio.  For correlation based quality control, arrays with 
a MADScore of less than -5 were considered outliers.  For the Huh7.5 JFH-1 infection study, one 
array was identified as an outlier and excluded from the study before data analysis.  This was a 6 
hour timepoint, JFH-1 infected sample.  Therefore the 6 hour JFH-1 infected data analysis and 
comparison with mock infected samples were performed with duplicate infected sample data.  For 
the Huh7 study, two outliers were identified and excluded before further analysis.  These were a 0 
hour sample, and a 6 hour JFH-1 infected sample.  Again, this meant that the data analysis of the 6 
hour infected timepoint, and its comparison with mock infected samples were performed with 
duplicate infected sample data.  Data were analysed by two-way analysis of variance (ANOVA) in 
Array Studio to compare the differences in gene expression between JFH-1 infected and mock 
infected samples at each timepoint.  The cut off criteria applied for identification of genes 
differentially expressed between infected and mock infected samples were a modulus fold change of 
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greater than 2 and a p-value of less than 0.05.  Fold changes were not considered significant if the 
average fluorescence levels of compared conditions were both within background fluorescence 
levels. In the Array Studio analysis this meant that the maximum LSMean (least squares mean – the 
statistically adjusted average data for a condition group) for probe sets in comparisons had to be 
greater than 5 on the log2 scale.     
 
Analysis of biological pathways was performed using Panther and Ingenuity software programs.  
Panther (http://www.pantherdb.org/)399-400 was used to identify the biological pathways containing 
genes regulated during HCV infection.  Using the gene expression data analysis tool, the list of genes 
observed to change by at least 2-fold with JFH-1 infection, were input into the online program.  
Separate lists were used for each timepoint, and a list compiled of these genes from all timepoints 
was also used.  Panther statistically compared uploaded lists of genes to a reference list (all 
H.sapiens genes in the NCBI reference) to look for under- and over-represented biological processes.  
The Bonferroni correction for multiple testing was applied. 
Ingenuity Pathway Analysis (http://www.ingenuity.com/) was used to analyse the fold change data 
for all probe sets.  This program was used as a reference tool to obtain further information on the 
functions of genes of interest, and the associated pathways.    
 
Heatmaps for representation of gene expression were created using MeV (MultiExperiment Viewer), 
part of the TM4 Microarray Software Suite401.  Data were imported into MeV using tab delimited text 
files containing gene descriptors and fold change data expressed on a log2 scale.  Hierarchical 
clustering was performed in MeV using Pearson correlation. 
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2.6 Validation of Microarray Data by Quantitative PCR 
 
2.6.1 Infection and RNA Extraction 
Huh7 and Huh7.5 cells were seeded at a density of 5 x 105 cells in 4ml of growth medium in 25cm2 
flasks. The next day, either concentrated JFH-1 stock or mock medium was added to the flasks.  Cells 
were infected at an MOI of 3, and the volume added to each flask was 1ml.  Conditions were 
performed in triplicate.  At the indicated timepoints, media were removed from the flasks of 
infected and mock infected cells.  3ml of Trizol was added to each flask and incubated for five 
minutes at room temperature.  Trizol-cell lysates were then homogenised by pipetting up and down, 
and transferred into 15ml tubes.  600µl chloroform was added, samples shaken for 20 seconds and 
incubated at room temperature for 2 minutes.  Each 3.6ml sample was divided between four 1.5ml 
eppendorf tubes, and centrifuged at 12,000g for 10 minutes at 4°C. The upper, aqueous phase was 
transferred to a new 1.5ml eppendorf tube, an equal volume of isopropanol added, and incubated at 
-20°C for 1 hour.  RNA was pelleted by centrifugation at 12,000g for 20 minutes at 4°C, and the 
supernatant removed.  The pellets were washed twice by adding 1ml 75% ethanol and centrifuging 
at 10,000g.  Pellets were resuspended in nuclease-free water and the four pellets from each sample 
recombined.  RNA was rigorously treated with 2 units DNA-free Turbo DNAse (Ambion) per 5µg RNA 
to remove any genomic DNA.   
 
2.6.2 Synthesis of cDNA 
Reverse transcription was performed on total cell RNA samples to generate cDNA.  2µg of total RNA 
and 1µg of oligo dT primer (Invitrogen) were heated to 70°C for 5 minutes to melt secondary 
structure, after which the sample was placed immediately on ice.  200 units Moloney Murine 
Leukaemia virus reverse transcriptase (M-MLV RT, Promega), 5µl 5x M-MLV buffer, 1µl 40mM dNTP 
mix, 25 units RNasin ribonuclease inhibitor (Promega) and nuclease-free water were added to a final 
reaction volume of 25µl.  The reaction was incubated at 42°C for 1 hour and then reverse 
transcriptase activity was inactivated by heat treatment at 70°C for 10 minutes. 
 
2.6.3 Quantitative PCR 
Validation of host gene expression seen in microarray data was performed by real-time quantitative 
PCR (qPCR) on cDNA samples generated from separate infection experiments from those used in the 
microarray studies.  qPCR was performed using QuantiTect SYBR Green PCR kit (Qiagen) and 
Lightcycler equipment (Roche).  10µl reactions were performed using 125ng cDNA as template, and 
0.5µM final concentration of each primer.  Primers were designed using Primer 3 software to amplify 
a 100 -150bp product.  The annealing temperature used for all primer pairs was 57°C.  Data 
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acquisition was performed at a temperature 3°C below the melting temperature of the PCR product. 
Please see Appendix (A1) for sequences of primers.  For each run, a reaction was performed with 
water as template to control for contamination of reagents with RNA or DNA.  The threshold cycle 
(CT) was determined by the LightCycler software using the second derivative maximum method.  
Relative gene expression was calculated using the comparative CT method, with GAPDH as the 
normalising control gene.   
 
Validation of host gene expression seen in microarray data was also performed by real-time 
quantitative reverse transcription PCR (qRT-PCR) on RNA samples generated from separate infection 
experiments from those used in the microarray studies, as well as the remaining material from 
original samples used in microarray studies.  JFH-1 intracellular RNA titres were also measured by 
qRT-PCR.  qRT-PCR was performed using QuantiTect SYBR Green RT-PCR kit (Qiagen) and Lightcycler 
equipment (Roche).  10µl reactions were performed using 125ng RNA as template, and 0.5µM final 
concentration of each primer.  Primers were designed using Primer 3 software to amplify a 100 -
150bp product.  The annealing temperature used for all primer pairs was 57°C.  Data acquisition was 
performed at a temperature 3°C below the melting temperature of the PCR product. Please see 
Appendix (A1) for sequences of primers.  For each run, a reaction with no reverse transcriptase and a 
reaction with water as template were included to control for genomic DNA contamination of the 
samples and contamination of other reagents respectively.  The threshold cycle (CT) was determined 
by the LightCycler software using the second derivative maximum method.  Relative gene expression 
was calculated using the comparative CT method, with GAPDH as the normalising control gene.   
 
Absolute expression of RNA was calculated by including a series of six standards of known amount in 
10-fold dilutions from 4ng to 40fg.  The standards were generated by in vitro transcription.  The 
qPCR amplicon was amplified from pJFH-1 and introduced by the TA cloning method into plasmid 
pCR2.1 (Invitrogen), generating plasmid pCR2.1HCV2aRTqPCR.  To prepare for transcription this 
plasmid was linearised with restriction enzyme HindIII (NEB).  RNA was transcribed from linearised 
pCR2.1HCV2aRTqPCR using the T7 MEGAscript In Vitro RNA Transcription kit (Ambion).  RNA 
transcription was performed using 1µg of linearised plasmid DNA and reactions were incubated at 
37°C for 6 hours.  RNA transcripts were purified using phenol-chloroform extraction and isopropanol 
precipitation.  RNA was rigorously treated with 2 units DNA-free Turbo DNAse (Ambion) per 5µg RNA 
to remove the remaining linearised plasmid DNA. 
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2.7 The Effect of Host Gene Knockdown by RNA Interference on HCV Replication 
 
2.7.1 Jc1 Infectious Virus Model System 
0.2µl Lipofectamine 2000 and 0.1µl 20µM siRNA were separately diluted into 17.5µl OptiMEM each 
and left to incubate at room temperature for 5 minutes.  Both solutions were then added into a 96-
well plate and left to incubate at room temperature for 20 minutes.  5 x 103 Huh7.5 cells in 50µl 
normal growth medium were added to the well giving a final siRNA concentration of 25nM.  After 48 
hours incubation at 37°C, the transfection medium was replaced with 100µl of normal growth 
medium containing Jc1 virus at an MOI of 0.1.  Infection was allowed to proceed for 48 hours before 
measuring Jc1 replication by luciferase assay.  The media were removed from the wells and replaced 
with 25µl SteadyGlo luciferase assay reagent (Promega).  96-well plates were incubated on an orbital 
shaker, at room temperature, in the dark for 10 minutes.  Luciferase activity was read on an EnVision 
Luminometer (Perkin-Elmer).  For each experiment, four replicates were performed per siRNA. 
Viability of cells after transfection with siRNA was tested by Cell Titer-Glo assay (Promega).  Cells 
were transfected with siRNA as described and at 48 hours post-transfection medium was replaced 
with 25µl Cell Titer-Glo reagent.  96-well plates were incubated on an orbital shaker, at room 
temperature, in the dark for 10 minutes.  Luciferase activity was read on an EnVision Luminometer 
(Perkin-Elmer).  For each experiment, four replicates were performed per siRNA.  Please see 
Appendix (A2) for siRNA sequences.  All siRNAs were transfected as individual duplexes, except for 
DDX3X, used as a positive control known to knockdown HCV replication, which was a pool of four 
siRNA duplexes.  Luciferase activities for all four replicates of the negative control siRNA were 
averaged.  The luciferase activity of each replicate was then expressed as a ratio of the negative 
control.  These ratios were used to calculate averages and standard deviations for each siRNA.   
 
2.7.2 JFH-1 Infectious Virus Model System 
1 x 105 cells were seeded in 0.5ml normal growth medium in 24-well plates.  The next day, growth 
medium was removed, cells were washed with OptiMEM, and then incubated in 0.5ml OptiMEM for 
2 hours, during which time transfection mixtures were prepared.  1µl Lipofectamine 2000 and 1.5µl 
20µM siRNA (consisting of two duplexes targeted against the same gene) were separately diluted 
into 50µl OptiMEM each and incubated at room temperature for 5 minutes.  The two solutions were 
mixed together and incubated at room temperature for 20 minutes.  The 100µl mixture was then 
added to the 0.5ml OptiMEM already in the well, giving a final siRNA concentration of 50nM for the 
combination of the two duplexes.  After 8 hours incubation, transfection medium was replaced with 
0.5ml normal growth medium.  48 hours post-transfection, cells were infected with JFH-1 virus at an 
MOI of 3.  After 48 hours, the cell culture medium was removed and cells washed with PBS.  150µl 
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Trizol was added, and left to incubate for 5 minutes.  The Trizol-cell lysate was then homogenised by 
pipetting up and down, and then transferred into a 1.5ml eppendorf tube.  30µl chloroform was 
added, shaken for 20 seconds and incubated at room temperature for 2 minutes, before 
centrifugation at 12,000g for 10 minutes at 4°C. The upper, aqueous phase was transferred to a new 
1.5ml eppendorf tube, an equal volume of isopropanol added, and incubated at -20°C for 1 hour.  
RNA was pelleted by centrifugation at 12,000g for 20 minutes at 4°C, and the supernatant removed.  
The pellet was washed twice by adding 0.5ml 75% ethanol and centrifuging at 10,000g.  After air-
drying, the pellet was resuspended in nuclease-free water.  RNA was rigorously treated with 2 units 
DNA-free Turbo DNAse (Ambion) per 5µg RNA to remove any genomic DNA.  RNA levels of target 
host gene and JFH-1 were measured by qRT-PCR as described.    
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2.8 Protein Level Analysis of Genes of Interest 
 
2.8.1 Protein Preparation 
Cells were harvested from 25cm2 flasks after treatment (timecourse infection, or 48 hour siRNA 
transfection followed by 48 hour infection).  0.5ml Lysis buffer (please see Appendix A3 for recipe) 
was added to the flask and incubated at room temperature for 2 minutes.  Any remaining adherent 
cells were scraped from the flask, the lysate was transferred to a 1.5ml eppendorf tube, and 
incubated on ice on a rocker for 30 minutes.  The lysate was homogenised by passing through a 
narrow bore blunt needle, and stored at -80°C.  Protein was quantified by Bradford Assay or 
absorbance at 280nm.  For Bradford assay a series of bovine serum albumin (BSA) standards of 
known concentration were prepared.  Dilutions of protein lysate or BSA standard were mixed with 
Bradford Assay Reagent, and absorbance at 495nm was measured.  Protein concentrations of cell 
lysates were calculated by comparison with a curve generated from the BSA standards.    
 
2.8.2 SDS-PAGE and Western Blotting 
SDS-PAGE gels were made with 10% acrylamide resolving and 4% acrylamide stacking phases please 
see Appendix A3 for recipes).  100µg protein lysate was mixed with denaturing loading buffer and 
heated to 90°C for 10 minutes to denature the protein and then placed on ice.  Samples were loaded 
on the gel, and BenchMark protein ladder (Invitrogen) was included in one well.  Gels were run at 
200V for one hour in Mini-Protean Tetra (Bio-Rad) apparatus.  For western blotting in Mini Trans-
Blot (Bio-Rad) apparatus, pre-soaked nitrocellulose membrane was used, and the blot was 
performed at 100V for one hour at 4°C.  The membrane was washed in 5ml PBS-T (PBS with 0.1% 
Tween 20), and blocked with 5ml 4% milk in PBS for 1 hour at room temperature.  Primary 
antibodies were diluted 1:1000 in blocking buffer, and membranes were incubated in 4ml dilute 
primary antibody overnight at 4°C.  HCV Core was detected with mouse monoclonal C7-50 (Abcam), 
TXNIP with mouse monoclonal anti-VDUP (MBL), metallothioneins by anti-MT (MBL) and β-actin 
with mouse monoclonal anti- β-actin (Abcam).  The membrane was washed in 5ml PBS-T three times 
for five minutes each, and then incubated with 4ml 1:1000 HRP-conjugated anti-mouse secondary in 
blocking buffer, for 1 hour at room temperature.  The membrane was washed in PBS-T three times 
for five minutes each to remove excess unbound antibody.  1ml of SuperSignal West Pico detection 
reagent (Thermo Scientific) was added to the membrane for 5 minutes, then the excess shaken from 
then blot.  Western blots were visualised using the ChemiDoc-It system (UVP), with dynamic 
integration of images taken every minute for 40 minutes (alternatively, blots were visualised by 
exposure of photographic film to the blot for five minutes). 
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2.9 Sequencing of JFH-1  
 
2.9.1 RNA Transfection of Huh7.5 Cells 
JFH-1 RNA transcript was transfected into Huh7.5 cells using Lipofectamine 2000 (Invitrogen).  
Huh7.5 cells were seeded at a density of 6x105 in a 6-well plate. The following day, with cells at 80% 
confluency, growth medium was replaced with OptiMEM medium and the cells were incubated for 
four hours.  5μg JFH-1 RNA and 10μl Lipofectamine 2000 were each diluted in 500μl of OptiMEM and 
incubated at room temperature for 20 minutes.  The dilutions were then mixed, and incubated at 
room temperature for 20 minutes.  The growth medium was removed from the cells and they were 
washed with OptiMEM.  The 1ml RNA/Lipofectamine 2000 transfection mixture was then added to 
the cells.  After an eight hour incubation period, the transfection medium was replaced with normal 
growth medium and the cells were incubated overnight.   
 
2.9.2 Passage of Transfected Huh7.5 Cells 
The following day, 50% of the transfected cells were passaged into a 25cm2 flask.  The remaining 
50% of cells were prepared for RNA extraction by Trizol.  Every three days, 25% of the transfected 
cells were passaged into a new 25cm2 flask, and 50% of the transfected cells were prepared for RNA 
extraction by Trizol.     
 
2.9.3 Reverse Transcription 
Reverse transcription was performed on total cell RNA samples to generate cDNA of JFH-1 RNA.  2µg 
of total RNA and 1µg of primer HVC2aRT9482 were heated to 70°C for 5 minutes to melt secondary 
structure, after which the sample was placed immediately on ice.  200 units Moloney Murine 
Leukaemia virus reverse transcriptase (M-MLV RT, Promega), 5µl 5x M-MLV buffer, 1µl 40mM dNTP 
mix, 25 units RNasin ribonuclease inhibitor (Promega) and nuclease-free water were added to a final 
reaction volume of 25µl.  The reaction was incubated at 42°C for 1 hour and then reverse 
transcriptase activity was inactivated by heat treatment at 70°C for 10 minutes. 
 
2.9.4 PCR and Sequence Analysis 
To amplify cDNA in preparation for sequencing, PCR was performed to generate fragments of JFH-1 
cDNA.  PCR was performed using Accuzyme polymerase (Bioline) and 1µl cDNA reaction as template.  
Annealing temperature for all primer sets was 57°C, and extension time was one minute per kb 
amplicon size.  PCR products were then purified using PCR Purification Kit (Qiagen) and eluted in 
30µl water.  PCR products were sequenced using the same forward and reverse primers as for 
amplification.  Sequencing reactions were performed by the Imperial Genomics Core Facility at 
Hammersmith Hospital Campus.  Sequences were compared and analysed using BioEdit software402.  
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2.10 Chimaeric JFH-1 Construction and Replication 
 
2.10.1 Cloning of Chimaeric JFH-1 Constructs 
 
The large size of pJFH-1 means that there are few unique restriction sites to facilitate cloning.  In 
order to create chimaeric JFH-1 constructs containing NS3 regions from other genotypes, a cloning 
strategy was devised, using an NS3 shuttle plasmid in which cloning could be more easily performed.  
Briefly, the AflII- NsiI region of JFH-1 was introduced into pCR2.1 (Invitrogen) at the corresponding 
restriction sites by ligation with T4 DNA ligase (Invitrogen).  This vector had a BlpI restriction site 
introduced by site directed mutagenesis using the QuikChange kit (Stratagene) and primers 
QCNS32aBlpIF and QCNS32aBlpIR.   NS3 sequence from other HCV genotypes was then introduced 
into the shuttle plasmid using the appropriate restriction enzymes.  Finally the AflII-NsiI region from 
the shuttle vectors were introduced back into pJFH-1, creating a panel of chimaeric JFH-1 constructs.   
 
20µg pJFH-1 and 10µg pCR2.1 were double digested with 50 units of both restriction enzymes AflII 
and NsiI (NEB) in NEBuffer 2 at 37°C for 2 hours.  Restriction digests were run on a 1% agarose TBE 
gel and the required DNA fragments excised and purified by Qiaquick Gel Extraction kit (Qiagen).  
100ng vector fragment and 300ng insert fragment were ligated overnight at 4°C using 2 units T4 
DNA ligase in a 10µl reaction.   
 
5µl ligation reaction was mixed with 50µl of Library Efficiency E. coli DH5α (Invitrogen) and 
incubated on ice for 30 minutes.  Bacteria were heat shocked at 42°C for 40 seconds and incubated 
on ice for two minutes.  450µl SOC medium was added and the bacteria were shaken at 200rpm for 
one hour at 37°C.  200µl of the transformation mix was plated onto Luria Bertani (LB) agar 
containing 100µg/ml ampicillin and incubated overnight at 37°C.  The following day, transformed 
bacterial colonies were picked and grown overnight at 37°C in 5ml LB medium containing 100µg/ml 
ampicillin.  Plasmid DNA was prepared from the transformed DH5α cultures using the Plasmid Mini 
Kit (Qiagen) according to the manufacturer’s instructions.   
 
A BlpI restriction site was introduced into the shuttle plasmid by site directed mutagenesis using the 
QuikChange kit (Stratagene).  PCR was performed using primers QCNS32aBlpIF and QCNS32aBlpIR 
for 15 cycles, with an extension time of 6m30s.  DpnI was incubated with the PCR reaction for 1 hour 
at 37°C to remove the parent plasmid.  E. coli XL-1 Blue were transformed with 5µl PCR reaction 
according to manufacturer’s protocol, and plasmid prepared as described above. 
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NS3 sequence fragments were generated by PCR from plasmids pS1179I (genotype 1b) and pHCV1a.  
The primers used are given in the Appendix (A1.1).  PCR was performed using Accuzyme polymerase 
(Bioline) in 50µl reactions.  PCR reactions were purified by Qiaquick PCR Purification kit (Qiagen).  
Purified PCR reactions were digested with the appropriate restriction enzymes.  Digestions were 
then treated with 0.5% SDS and 200µg/ml Proteinase K (Invitrogen) for 1 hour at 50°C.  Samples 
were made up to 200µl with water, and 200µl phenol-chloroform was added.  Samples were shaken, 
and then centrifuged at 16,000g for 20 minutes at 4°C.  The upper, aqueous phase was transferred 
to a new 1.5ml eppendorf tube, an equal volume of chloroform was added.  Samples were shaken, 
and then centrifuged at 14,000g for 20 minutes at 4°C.  The upper, aqueous phase was transferred 
to a new 1.5ml eppendorf tube, where 0.1 volume 3M sodium acetate and 2.5 volumes of ethanol 
with were added, and incubated overnight at -20°C.  DNA was pelleted by centrifugation at 14,000g 
for 20 minutes at 4°C, and the supernatant removed.  The pellet was washed by adding 0.5ml 75% 
ethanol and centrifuging at 14,000g.  After air-drying, the pellet was resuspended in nuclease-free 
water. 
 
Digested PCR products and complementary vector fragments of shuttle vector were ligated with T4 
DNA ligase as described above.  Transformation into E. coli DH5α, and plasmid production were also 
performed as described above. 
 
In vitro transcription of chimaeric constructs was performed as for pJFH-1.  20µg of plasmid was 
linearised with 150 units of restriction enzyme XbaI (NEB) and purified using phenol-chloroform 
extraction and ethanol precipitation.  3’ overhanging DNA was removed by digestion with 30 units 
Mung Bean Nuclease (NEB) for 30 minutes at 30°C, and DNA purified by phenol-chloroform 
extraction and ethanol precipitation.  RNA transcripts were generated from plasmid using the T7 
MEGAscript In Vitro RNA Transcription kit (Ambion).  RNA transcription was performed using 1µg of 
linearised plasmid DNA and reactions were incubated at 37°C for 6 hours.  RNA transcripts were 
purified using phenol-chloroform extraction and isopropanol precipitation.  RNA was treated with 
DNA-free Turbo DNAse (Ambion) to remove the remaining linearised plasmid DNA.  
 
 
2.10.2 RNA Transfection of Huh7.5 Cells 
The RNA transcripts were transfected into Huh7.5 cells using Lipofectamine 2000.  Huh7.5 cells were 
seeded at a density of 6x105 in a 6-well plate with 2ml DMEM. The following day, with cells at 80% 
confluency, growth medium was replaced with 1ml OptiMEM medium and the cells were incubated 
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for four hours.  5μg RNA and 10μl Lipofectamine 2000 were each diluted in 500μl of OptiMEM and 
incubated at room temperature for 20 minutes.  The dilutions were then mixed, and incubated at 
room temperature for 20 minutes.  The growth medium was removed from the cells and they were 
washed with 2ml OptiMEM.  The 1ml RNA/Lipofectamine 2000 transfection mixture was then added 
to the cells.  After an eight hour incubation period, the transfection medium was replaced with 2ml 
normal growth medium (DMEM) and the cells were incubated overnight.  For each experiment, 
transfections were performed in triplicate. 
 
2.10.3 Passage of Transfected Huh7.5 Cells 
The following day, 50% of the transfected cells were passaged into a 25cm2 flask.  The remaining 
50% of cells were prepared for RNA extraction by Trizol.  Every three days, 25% of the transfected 
cells were passaged into a new 25cm2 flask, and 50% of the transfected cells were prepared for RNA 
extraction by Trizol.     
 
2.10.4 Quantification of Intracellular JFH-1 
Levels of intracellular JFH-1 and its derivatives were measured by real-time qRT-PCR using 
QuantiTect SYBR Green RT-PCR kit (Qiagen) and Lightcycler equipment (Roche).  10µl reactions were 
performed using 125ng RNA as template, and 0.5µM final concentration of each primer.  Primers 
(described in the Appendix A1.4) amplify a 150bp product.  The annealing temperature used was 
57°C.  Data acquisition was performed at 80°C.  For each run, a reaction with no reverse 
transcriptase and a reaction with water as template were included to control for non-specific 
amplification and contamination of other reagents respectively.  The threshold cycle (CT) was 
determined by the LightCycler software using the second derivative maximum method.  Absolute 
expression of RNA was calculated by including a series of six standards of known concentration in 
10-fold dilutions from 4ng to 40fg.  The standards were generated by in vitro transcription.  The 
qPCR amplicon was amplified from pJFH-1 and introduced by the TA cloning method into plasmid 
pCR2.1 (Invitrogen), generating plasmid pCR2.1HCV2aRTqPCR.  To prepare for transcription this 
plasmid was linearised with restriction enzyme HindIII (NEB).  RNA was transcribed from linearised 
pCR2.1HCV2aRTqPCR using the T7 MEGAscript In Vitro RNA Transcription kit (Ambion).  RNA 
transcription was performed using 1µg of linearised plasmid DNA and reactions were incubated at 
37°C for 6 hours.  RNA transcripts were purified using phenol-chloroform extraction and isopropanol 
precipitation.  RNA was rigorously treated with 2 units DNA-free Turbo DNAse (Ambion) per 5µg RNA 
to remove the remaining linearised plasmid DNA. 
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2.11 Magnetic Resonance Spectroscopy 
 
5x105 Huh7.5 cells were seeded per 25cm2 flask in 4ml normal growth medium.  The next day JFH-1 
virus at an MOI of 3, or mock medium was added to the cells in a volume of 1ml.  At 48 hours post-
infection, media were removed from the flasks, the cells were washed with 5ml warm PBS and 
trypsinised with 0.5ml of 1x trypsin-EDTA (Invitrogen).  Trypsinisation was stopped with 4.5ml 
normal growth medium (containing FBS), and cells were counted so that each sample had the same 
number of cells.  The cell suspensions were centrifuged for 5 minutes at 1500rpm in a Mistral 3000 
Benchtop Centrifuge (MSE).  The supernatant was discarded and the cell pellets resuspended in PBS 
to wash away any medium.  Cells were centrifuged for 5 minutes at 1500rpm and the supernatants 
discarded.  The cell pellets were resuspended in PBS to a final volume of 20µl and loaded into MRS 
sealing cells (XC4 Kel-F, Doty Scientific).  Samples were transported on ice to the 500MHz MRS 
facility at Hammersmith Hospital where 1H MAS MRS was performed.  Further details on the MRS 
machine, its operational procedures and procedures for obtaining data can be found in the cited 
references403-404.  Briefly, the sealing cell was inserted into the ceramic rotor (XC4 Kel-F, Doty 
Scientific) and placed in the MAS probe (Doty Scientific).  The probe was interfaced with a JEOL 
Eclipse 500+ spectrometer and an 11.75T superconducting magnet (Oxford Instruments).  Samples 
were spun at 4000Hz, and maintained at 4°C to minimise sample degradation.  Suppression of the 
water signal was performed to allow better resolution of metabolite signals. 
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Results and Discussion  
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3.1 Viral Determinants for JFH-1 Replication 
 
3.1.1 Role of NS3 Sequence Determinants in JFH-1 Replication 
 
It has been shown by other groups that replication levels of JFH-1 can be maintained and even 
enhanced by the substitution of the structural protein coding region for that from other genotypes.  
However, the same is not true for the non-structural coding region.  This implies that the non-
structural protein coding region contains determinants essential for the efficient replication of JFH-1.  
To investigate whether the NS3 region contains essential determinants for JFH-1 replication, 
chimaeric viruses were constructed.  These viruses contained the coding region either for full length 
NS3, the helicase or protease domain, or subdomain regions.  Inserted coding regions were from 
HCV genotypes 1a and 1b.  Chimaeric RNA was transfected into Huh7.5 cells by either 
electroporation or lipofection.  In each experiment, wild type JFH-1 RNA was included as a positive 
control and GND and delE1E2 mutants were included as negative controls.  Intracellular HCV RNA 
was measured at multiple time points.  The method for construction of chimaeric JFH-1 genomes is 
outlined in Figure 11, and images from gel electrophoresis of restriction digestions performed as 
confirmation of cloning steps are shown in Figure 12-Figure 16.   
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3.1.2 Construction of Chimaeric JFH-1 
 
In order to study the effects of NS3 components from different genotypes in the JFH-1 infectious 
culture system, a strategy was designed to create chimaeric viruses.  pJFH-1 is a large plasmid of 
12kb and therefore has few unique restriction sites to facilitate cloning.  Therefore, it was decided to 
move the region of interest, NS3, into another vector where it could be more easily manipulated.  
Unique restriction sites AflII and NsiI were the closest to the NS3 boundaries.  The AflII site is 129 
amino acids upstream of NS3 in NS2, and the NsiI site is 4 amino acids into the C-terminal end of 
NS3. 
 
Figure 11 shows the cloning strategy represented by plasmid maps with the relevant restriction sites 
indicated.  Some examples of the confirmatory agarose gels generated at each step of the process 
are shown in Figure 12-Figure 16. 
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Figure 11: Major steps in the cloning of chimaeric 
JFH-1 viruses.   
Plasmid diagrams include the restriction sites of 
importance.  Protein coding regions are shown by 
the grey arrows, corresponding to the polyprotein 
in plasmids containing the complete genome, and 
NS3 in the intermediate vectors.  Construction of 
chimaeric plasmids was performed as follows.  The 
AflII-NsiI fragment of pJFH-1 was amplified by PCR 
and TA cloned into the vector pCR2.1.  A second 
NsiI site in this plasmid was removed by digestion 
with NsiI and re-ligation of the plasmid.  The 
resulting plasmid was designated pAflNS3Nsi2a.  
This plasmid has a unique ClaI restriction site at the 
protease/helicase boundary of NS3, but no unique 
site at the N terminal end of NS3.  A BlpI site was 
introduced by site directed mutagenesis to a 
position six amino acids into NS3, creating plasmid 
pAflNS3Nsi2aBlpI.  This plasmid was now ready to 
receive NS3 sequences from other genotypes.  
Sequences corresponding to the full length NS3 and 
protease and helicase domains were amplified by 
PCR from plasmid pHCV1aFull Length (genotype 1a) 
and plasmid S1179I (genotype 1b), incorporating 
the appropriate restriction site into the primers.  
These fragments were TA cloned into pCR2.1, 
creating vectors pNS31aFL, pNS31aPro, pNS31aHel, 
pNS31bFL, pNS31bPro and pNS31bHel.  These 
plasmids were then digested with the relevant pair 
of enzymes to release the desired NS3 fragment.  
pAflNS3Nsi2aBlpI was digested with the same enzymes, and the vector portion was ligated with 
the desired NS3 fragments.  This resulted in the donor plasmids pAflNS3Nsi2a_NS31aFL, 
pAflNS3Nsi2a_NS31aPro, pAflNS3Nsi2a_NS31aHel, pAflNS3Nsi2a_NS31bFL, 
pAflNS3Nsi2a_NS31bPro and pAflNS3Nsi2a_NS31bHel.  The final stage in the construction of the 
chimaeric plasmids was to digest pJFH-1 and the donor plasmids with AflII and NsiI, and perform 
a sticky-end ligation. 
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The AflII-NsiI fragment of pJFH-1 was cloned into pCR2.1 to create plasmid pTANS32a.  This plasmid 
was then altered by site directed mutagenesis to create plasmid pTANS32aBlpI, which contains a BlpI 
restriction site at the start of the NS3 coding region.  Figure 12A shows pTANS32a digested using 
AflII, NsiI and BlpI and demonstrating the electrophoresis pattern consistent with pCR2.1 containing 
the AflII-NsiI fragment of pJFH-1, and that the fragment contains only AflII and NsiI sites (not BlpI).  
Figure 12B shows pTANS32aBlp (the product of site directed mutagenesis of pTANS32a) also 
digested with AflII, NsiI and BlpI and demonstrating the electrophoresis pattern consistent with the 
introduction of a BlpI site to the plasmid. 
 
 
  
Figure 12: Agarose gel electrophoreses as confirmation of site directed mutagenesis insertion of 
BlpI restriction site in pTANS32a.  
A Lane 1: TANS32a digested with AflII, NsiI and BlpI, Lane 2: 1kb DNA ladder.  B  Lane 1: 
Undigested TANS32aBlp, Lane 2: TANS32aBlp digested with AflII, NsiI and BlpI, Lane 3: 1kb DNA 
ladder.   
 
 
 
The regions of HCV genotype 1a and 1b sequence corresponding to the full length NS3, protease and 
helicase domains were amplified by PCR using primers incorporating the required restriction sites.  
The AflII-NsiI region of JFH-1 was also amplified for TA cloning.  Example agarose gels of PCRs are 
given in Figure 13A-C. 
 
 
A B 
 1     2       1      2      3 
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Figure 13: Agarose gel electrophoreses as confirmations of successful PCR of NS3 coding 
sequences.  
A Lane 1: Full length NS3 PCR product, Lane 2: 1kb DNA ladder.  B Lane 1: 100bp DNA ladder, 
Lane 2: NS3 protease domain PCR product, Lane 3: No template negative control PCR.  C Lane 1: 
NS3 helicase domain PCR product, Lane 2: 1kb DNA ladder. 
After cloning the PCR products (Figure 13) into pTANS32aBlp, the resulting plasmids and pJFH-1 were 
digested with AflII and NsiI for cloning of the chimaeric NS3 regions into pJFH-1.  The digested 
plasmids are shown in Figure 14, in agarose gels prior to gel extraction and cloning. 
 
Figure 14: Agarose gel electrophoresis of AflII/NsiI digests of constructs prior to final cloning 
step.  
A Lane 1: 1kb DNA ladder, Lane 2: Undigested pJFH-1, Lane 3: pJFH-1 digested with AflII and NsiI.  
This analytical gel shows the expected pattern of bands after complete digestion of pJFH-1.  B 
Lane 1: 1kb DNA ladder, Lane 2: pJFH-1 digested with AflII and NsiI.  This gel was used for gel 
extraction of the large band, which contains the majority of pJFH-1.  C Lane 1: Incomplete 
digestion of pTANS32a_NS31aFL with AflII and NsiI, Lane 2: 1kb DNA ladder, Lane 3: 
pTANS32a_NS31aFL digested with AflII and NsiI, Lane 4: pTANS32a_NS31aPro digested with AflII 
and NsiI, Lane 5: pTANS32a_NS31aHel digested with AflII and NsiI.  The largest band in Lane 1 
shows the linearised form of pTANS32a_NS31aFL, a result of incomplete digestion.  This band is 
absent from Lanes 3-5, indicating complete digestion of these plasmids. 
A B C 
A B C 
 1     2               1      2       3            1      2 
 1     2       3            1                2                   1             2             3             4              5 
A B C 
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After cloning the chimaeric AflII-NsiI sequences into the JFH-1 backbone, the final constructs were 
analysed by gel electrophoresis to confirm the cloning was successful (Figure 15).  Example 
restriction digests are shown in Figure 16, with comparison to the original JFH-1 constructs. 
 
 
 
 
Figure 15: Agarose gel electrophoresis of final chimaeric constructs.  
Lane 1: 1kb DNA ladder, Lane 2: pJFH_NS31aFL, Lane 3: pJFH_NS31aPro, Lane 4: pJFH_NS31aHel, 
Lane 5: pJFH_NS31bFL, Lane 6: pJFH_NS31bPro, Lane 7: pJFH_NS31bHel, Lane 8: 1kb DNA 
ladder.  This gel shows all the final constructs to be of the same size, and therefore incorporating 
the chimaeric AflII-NsiI fragments (all plasmids are in their supercoiled form, as derived from 
DNA miniprep). 
 
 
 
 
Figure 16: Agarose gel electrophoresis of JFH-1 constructs digested with AflII and NsiI.  
Lane 1: 1kb DNA ladder, Lane 2: Undigested pJFH-1, Lane 3: Digested pJFH-1, Lane 4: Undigested 
pJFH-1 GND, Lane 5: Digested pJFH-1 GND, Lane 6: Undigested pJFH-1 delE1E2, Lane 7: Digested 
pJFH-1 delE1E2, Lane 8: 1kb DNA ladder, Lane 9: Undigested pJFH_NS31aFL, Lane 10: Digested 
pJFH_NS31aFL, Lane 11: Undigested pJFH_NS31aPro, Lane 12: Digested pJFH_NS31aPro, Lane 
13: Undigested pJFH_NS31aHel, Lane 14: Digested pJFH_NS31aPro, Lane 15: 1kb DNA ladder. 
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3.1.3 Replicative Ability of Chimaeric JFH-1 
 
Chimaeric RNA was transfected into Huh7.5 cells by lipofection.  In each experiment, wild type JFH-1 
RNA was included as a positive control and GND and delE1E2 mutants were included as negative 
controls.  Intracellular HCV RNA was quantified as a measure of the ability of the chimaeric genomes 
to replicate in cell culture. 
 
As can be seen in Figure 17, the replacement of JFH-1 full length NS3 with that from genotypes 1a or 
1b resulted in a replication deficient virus.  The RNA observed in the initial measurements is input 
RNA, and follows a similar pattern of decline in titre to the replication deficient GND mutant.   
 
Having established that substitution of full length NS3 resulted in replication deficient RNA, domain 
level chimaeras were constructed in an attempt to identify which region of the NS3 coding sequence 
conferred replicative deficiency.  The protease and helicase domains of JFH-1 were substituted for 
those of genotypes 1a and 1b.  Figure 17 shows that these chimaeric RNAs also failed to replicate 
when transfected into Huh7.5 cells.   
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Figure 17: Replication of chimaeric JFH-1.   
Huh7.5 cells were transfected by lipofection with viral RNA and intracellular RNA titres were 
measured every passage by qRT-PCR.  JFH-1 RNA.  Data presented are the means and standard 
errors from two separate experiments performed with duplicate transfections.  JFH-1, the wild 
type virus, shows an initial decrease in RNA levels followed by an increase as replication occurs.  
GND, the non-replicative mutant, shows a decrease in RNA levels which does not recover.  The 
delE1E2 mutant shows a more gradual decline in RNA levels.  Quantitation of RNA levels of 
transfected the JFH-1 chimaeric RNAs containing sequence elements from the NS3 region of 
genotype 1a and genotype 1b HCV all showed a pattern of decline in RNA over time.  The decline 
in levels of chimaeric RNAs were similar to that of the non-replicating GND construct, and as 
there were also no increases in RNA levels as achieved by wild type JFH-1, it can be concluded 
that the chimaeric viruses were unable to replicate and establish a persistent infection.   
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3.1.4 NS3 Sequence Determinants for JFH-1 Replication 
 
JFH-1 is the only natural isolate of HCV capable of highly efficient replication in cell culture.  Some 
other isolates have achieved lower levels of replication344, and some isolates have been adapted to 
confer replicative ability338, but these do not match JFH-1.  This implies that JFH-1 possesses some 
specific genetic features which enable its ability to replicate in cell culture.  It has been shown that 
the structural region of the JFH-1 genome can be exchanged for those of other genotypes (Figure 
8C), and a relatively high replication rate be maintained354.  However, it is not possible to exchange 
the non-structural regions of the virus for those of other genotypes and maintain efficient 
replication.  This implies that the major sequence determinants for the ability of JFH-1 to replicate in 
cell culture may be in the non-structural protein coding region of the genome.   
 
The NS3 protein plays a number of roles in HCV replication including a role as a protease with viral 
and cellular targets, a role as a helicase involved in RNA replication, and a role in viral assembly.  
Across HCV genotypes, shared nucleotide identity of NS3 sequence is around 70%, and amino acid 
identity around 80%, with amino acid similarity approaching 90% (see Figure 9).  There is therefore 
potential for unique sequence determinants to exist in JFH-1 NS3 that allow replication in cell 
culture.   
 
Chimaeric JFH-1 genomes incorporating genetic elements from genotype 1 HCV NS3 were created to 
test this hypothesis.  Genotypes 1a and 1b are the most common in Europe and the USA, and most 
research is focused on these genotypes when possible.  Chimaeric JFH-1 genomes were tested for 
their replication ability by transfection of in vitro transcribed RNA (corresponding to the viral 
genome) into Huh7.5 cells.  The control constructs used were wild type JFH-1, JFH-1 GND and JFH-1 
delE1E2.  JFH-1 GND is a replication deficient virus with a mutation in the viral polymerase, NS5B. 
JFH-1 delE1E2 is RNA replication competent, but cannot produce infectious virus as it lacks the 
envelope proteins E1 and E2.  The first constructs to be tested were JFH-1 genomes containing full 
length NS3 from genotypes 1a and 1b.  It can be seen in Figure 17 that neither full length NS3 
chimaera replicated in cell culture.  This implies that NS3 contains genotype specific sequence 
elements which determine replication capacity of the virus.  In this case, it was demonstrated that 
genotype 1 NS3 genes were not compatible with genotype 2a JFH-1 for replication.  It was then 
attempted to elucidate which specific regions of the NS3 sequence were responsible for this 
observation.  Chimaeric JFH-1 genomes were constructed containing only the protease or helicase 
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domains from genotype 1 sequences.  Figure 17 shows that none of these chimaeras were capable 
of establishing a persistent infection of cultured cells.   
 
The data obtained from the experiments performed here imply that both the protease and helicase 
sequences are essential for the ability of JFH-1 to replicate in cell culture.  The method used 
measured RNA levels, and therefore only the replication capacity of the virus.  It is hard to 
distinguish, using this method, between viruses which are RNA replication incompetent (such as the 
JFH-1 GND) and those which cannot produce infectious viral particles (such as JFH-1 delE1E2).  As 
both domain level chimaeras failed to replicate in cell culture, it may be that both the protease and 
helicase functions of JFH-1 NS3 are determinants in allowing JFH-1to replicate in cell culture.  
However, it is also possible that the sequence of each domain is capable of influencing the function 
of the other.  Possible ways to test this would be to knock out the specific functionality of each 
domain.  Helicase activity can be eliminated by mutating the aspartate of the essential DECH motif 
to an alanine (resulting in a non-functional AECH motif)405. Protease activity can be eliminated by 
mutating any of the amino acids which make up the catalytic triad His-Asp-Ser140.  The functionality 
of NS3 in the chimaeric viruses should be tested to determine whether the loss of ability to replicate 
in cell culture is due to an inability to replicate RNA or a loss of protease function.  The protease 
function could be assessed by performing in vitro translation of the polyprotein from the chimaeric 
genomes and observing the level of polyprotein cleavage.   This observation could be made either by 
radiolabelling protein with 35S-methionine and photographing a protein blot of SDS-PAGE, or by SDS-
PAGE and western blotting for the cleaved forms of viral proteins.  Alternatively, purified bacterially-
expressed chimaeric NS3 proteins could be assessed in vitro for protease function by measuring their 
ability to cleave polypeptides labelled with a fluorescent marker and quencher.   Confirmation of the 
ability of chimaeric genomes to proteolytically cleave the polyprotein would imply that any inability 
to replicate in cell culture is not caused by protease deficiency, but by RNA replication deficiency.   It 
is possible to test helicase functionality in vitro by purifying bacterially expressed chimaeric NS3 
protein and performing a dsDNA or dsRNA unwinding assay, using oligonucleotide duplexes 
containing one strand labelled with a fluorophore and the other strand labelled with a quencher406.    
Since the functional elements of all chimaeras created were still in place, it is unlikely that the 
protease and helicase activities of NS3 were completely lost.  It is more probable that there was a 
reduction of activities due to genotype specificities.  The proposed experiments would be able to 
quantify the reduction in protease and helicase activities of the chimaeras.  The reduction in 
activities was sufficient that HCV replication was reduced to a level where it could not combat the 
host cell defences and achieve a persistent infection of the cultured cells.  Further assessments could 
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then be performed on sub-domain level chimaeras, where sequence exchange focused on smaller 
regions where there is genetic divergence between genotypes.  This focusing down on particular 
amino acids would identify the precise sequence determinants which allow JFH-1 to replicate in cell 
culture. 
 
Whilst performing this work, a similar study was published by Imhof and Simmonds in which 
protease elements from different genotypes were inserted into a genotype 2a backbone407.  In 
common with the work presented in this thesis, it was found that insertion of the NS3 protease 
domain alone resulted in replication deficient viral genomes.  The one exception was where a 
genotype 5a sequence was inserted, where replication was achieved after acquiring adaptive 
mutations.  In an attempt to rescue the replication deficient chimaeras, NS4A sequences from the 
same genotype as the introduced NS3 protease sequences were inserted into the viral genomes.  As 
NS4A is a cofactor that can greatly enhance NS3 protease activity and this would also have been the 
next logical step to rescue replication deficient chimaeras created during the work presented in this 
thesis.   Replication competent chimaeras were created by Imhof using sequence from genotypes 
1b, 2a, 3a, 5a and 6a, with varying degrees of success.  The chimaera containing genotype 1b 
sequence was detected in 50% of cells four days post transfection, but subsequently cleared.  
Genotype 2a and 5a chimaeras were detected in almost all cells at two days post transfection.  
Genotype 3a and 6a chimaeras were detected in 80% of cells after eclipse periods of 6 and 33 days 
respectively.  This study indicates that incorporating NS4A sequences, of the same genotype as the 
NS3 protease sequences, into the chimaeras created for the work presented in this thesis may be a 
method for acquiring replicative ability. 
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3.2 Mutation in the JFH-1 Genome during Cell Culture 
 
Replication of the JFH-1 in cell culture is possible by the isolate consensus sequence79.  This differs 
from replicon models based on genotypes 1a334 and 1b131, which require adaptive mutations to 
replicate in cell culture.  However, it has been previously observed79 that the titre of infectious JFH-1 
virus produced in cell culture, and the titre of intracellular JFH-1 RNA, will increase over time.  This 
indicates that the virus may be adapting to the cell culture environment.  It is possible that these 
adaptations could be at the genetic level.  In order to monitor the mutations that could arise in JFH-
1, a strategy for sequencing was devised involving reverse transcription of intracellular JFH-1 RNA 
and PCR amplification of multiple regions of the genome in order to acquire material for sequencing. 
 
3.2.1 Testing of Primers for PCR of Regions of JFH-1 to be Sequenced 
 
In order to establish the efficacy of the primers chosen for sequencing, test PCRs were performed 
using plasmid DNA (Figure 18A) and cDNA (Figure 18B) templates.  All reactions were observed to 
produce amplified target sequence.  The cDNA template resulted in some non-specific products, but 
in all reactions the desired product was the most highly amplified. 
 
 
 
Figure 18: Amplification of targets for sequencing of JFH-1 genome.  
PCRs of JFH-1 plasmid DNA (A) and cDNA (B) were performed as described in the Methods 
section (2.9) and 10µl of the reactions were run on 1% agarose gels.  The reactions in both 
images are in the same order.  Lane 1: 1kb ladder, Lane 2: Product of reaction using primer JFH 
64F + primer JFH 829R, Lane 3: 637F + 1303R, Lane 4: 1158F + 2348R, Lane 5: 637F + 2348R, Lane 
6: 2305F + 3491R, Lane 7: 3484F + 4648R, Lane 8: 4566F + 5951R, Lane 9: 2305F + 4648R, Lane 
10: 3489F + 5951R, Lane 11: 2305F + 5951R, Lane 12: 5902F + 6983R, Lane 13: 6967F + 8015R, 
Lane 14: 7472F + 8872R, Lane 15: 8700F + 9262R, Lane 16: 8700F + 9482R. 
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3.2.2 Identification of Mutations in Cell Cultured JFH-1 
 
Mutations accumulated by the virus over time in cell culture were identified by sequencing JFH-1 
RNA isolated after 23 passages of JFH-1 transfected cells.  The six mutations identified are shown in 
Table 1.  Two occurred in the NS5A coding region, and one each in NS4b, NS3, E2 and the IRES.  All 
the mutations in the protein coding region were nucleotide point mutations that resulted in a 
change of amino acid at their codon.   
 
 Nucleotide Mutation Amino Acid Mutation 
Region From Position To From Position To 
IRES G 179 A - - - 
E2 A 1590 G 
Asparagine 
 
416 
Alanine 
 
NS3 G 3715 T 
Glutamate 
 
1171 
Aspartate 
 
NS4B A 6132 G 
Asparagine 
 
1930 
Serine 
 
NS5A A 6587 G 
Lysine 
 
2350 
Glutamate 
 
NS5A T 7217 C 
Tyrosine 
 
2292 
Histidine 
 
 
Table 1: Mutations identified in cell cultured JFH-1. 
Huh7.5 cells were transfected with JFH-1 RNA and continuously passaged.  After 23 passages of 
transfected JFH-1 cells, intracellular JFH-1 RNA was extracted, the positive strand converted to 
cDNA, amplified by PCR and sequenced.  Six point mutations were identified and the 
corresponding amino acid change is given where relevant.  Nucleotide positions refer to the JFH-
1 genome, and amino acid positions refer to the JFH-1 polyprotein.  
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3.2.3 Mutation in the JFH-1 Genome during Cell Culture 
 
The ability of full length JFH-1 to replicate in cell culture made it unique amongst HCV isolates when 
first identified.  Since then, other HCV isolates, even of other genotypes, have been identified that 
can replicate in cell culture, but none as efficiently as JFH-1.  The exception is the artificial chimaera 
J6/JFH-1.  Many of the genomes so far described to replicate in cell culture require the presence of 
cell culture adaptive mutations.  Cell culture adaptive mutations were identified in the replicon 
models developed since the late 1990s, originally by observation of spontaneous mutation in the 
subgenomic replicons.   
 
In this study, after continuous passage of Huh7.5 cells harbouring JFH-1 for 3 months, the 
intracellular JFH-1 RNA was sequenced, revealing six mutations from the consensus sequence.   
A mutation was observed to occur in the IRES region of the genome.  The nucleotides of the IRES do 
not contribute to protein coding, but are still vital to the lifecycle of HCV.  The IRES is strongly 
conserved both intra- and inter-genotypically (as observed when comparing the sequences stored on 
www.HCVdb.org).  The IRES is known to be of importance in interactions with other molecules, such 
as miR122, for which mutations have been shown to disrupt the base pairing and therefore impair 
replication efficiency.  The secondary structure of the IRES is also known to be of importance in 
controlling HCV RNA replication and translation.  The IRES stem-loop structures are predicted to be 
important in interaction with proteins and other regions of the HCV genome.  The nucleotide 
mutation observed, G179A, is located in the stem-loop III.  This base is predicted to be paired with a 
cytosine.  However, there was no complementary mutation to this nucleotide observed.  G179A 
would therefore result in a bulge in the stem, possibly an enlargement of the loop.  This could 
further be investigated by a bioinformatic prediction of the structure of the IRES including the 
observed mutation, as well as studies into crystal structures or protein binding affinity assays.  There 
was one observed mutation in the E2 coding region, A1590G which results in amino acid substitution 
N416A.  E2 contains two hypervariable regions (HVRs) which, in vivo, are observed to be regions of 
sequence diversity.  E2, as an envelope glycoprotein, is visible to antibodies and its sequence 
variability helps the virus to evade detection.  As the model system used in this study is a cell culture 
system, there is no antibody pressure on the virus to select mutations at this region, so there is 
unlikely to be a mutation rate higher than for other parts of the genome.  The mutation observed 
lies between the two HVRs.  The mutation from asparagines to alanine is one from a polar 
uncharged residue to a small hydrophobic residue.  One amino acid change, E1171D, was observed 
in the NS3 coding region, located in the protease domain.  This change was between two amino 
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acids of very similar properties.  Glutamate was converted to aspartate, both of which have a –COOH 
group, but with inverted =O, and is therefore unlikely to have a significant effect on interactions or 
conformation, but may subtly enhance some positioning.  The point mutation observed in the NS4B 
coding region converts an asparagine into a serine (N1930S).  Both residues are polar and 
uncharged, but the serine contains an –OH group, which is often reactive in proteins and could, for 
example, be phosphorylated.  Two mutations resulting in amino acid changes were observed in 
NS5A.  This protein coding region is also known to be a region for the occurrence of mutations.  In 
particular, the region known as the interferon sensitivity determining region (ISDR) has been 
documented as a region for accumulation of adaptive mutations in replicon cell models and in vivo.  
The mutation of lysine to glutamate (K2350E) converted a long positive amino acid into a long 
negatively charged amino acid.  In the second mutation, Y2292H, both tyrosine and histidine contain 
rings, but tyrosine is a hydrophobic six carbon ring with an –OH group, and histidine is a positively 
charged residue with a five membered ring containing two nitrogen atoms.  Of the mutations 
observed by this study, only one has been reported before.  The mutation K2350E in NS5A was seen 
in another study based on replicon cells349, but showed no significant enhancement of replication 
when deliberately introduced as a mutation in the parental replicon.  It is unlikely that any 
consistently recurring mutations will be found in JFH-1 during cell culture to explain the increase in 
titre over time.  A number of different mutations have been seen by groups at many positions, and 
very few of these have been shown to have a large effect on HCV replication.   A larger scale 
investigation would need to be performed to identify any mutations that may induce a replicative 
advantage.  The observed mutations would need to be artificially engineered into the JFH-1 genome 
both individually and in combination, to identify any replicative advantage conferred.   
 
A similar recent study408 identified only one mutation out of many observed that had a significant 
effect on replication when deliberately engineered into JFH-1 (and other intergenotypic chimaeras). 
Since starting this work, other groups have attempted to identify cell culture adaptive mutations in 
JFH-1.  As with the studies performed in replicon models, only a few of the mutations identified 
confer a replicative advantage to the virus.  A study focusing on the structural region of the genome 
was performed using JFH-1 in Huh7 cells409.  JFH-1 was sequenced after six serial infections with virus 
harvested from cell culture (with two cell passages between each infection).    Three mutations were 
identified in the E2 gene, comprising two silent nucleotide mutations (G1843A and U1912C) and one 
mutation (U1942A) which lead to a change in amino acid from asparagine to lysine (N534K).  This 
N534K mutation occurred at a site of N-glycosylation.  Introduction of this mutation into the JFH-1 
genome created a virus which gained a slight replicative advantage over the wild type JFH-1 (103.9 
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f.f.u./ml, compared to 103.3 f.f.u./ml for wild type).  This same study observed that a chimaera of 
JFH-1 containing the core gene from a genotype 1a isolate had a replicative advantage over JFH-1.  
Incorporation of two amino acids from the genotype 1a sequence into JFH-1 (cysteine and serine at 
positions 172 and 173), plus the N534K resulted in a virus which produced higher infectious virus 
titres in cell culture much more quickly than wild type JFH-1 (105.7 f.f.u./ml, compared to 102.9 
f.f.u./ml for wild type after one infection). 
 
Another study continuously passaged infected Huh7.5 cells in order to identify possible cell culture 
adaptive mutations408.  Two cultures were performed.  In the culture passaged 11 times, 7 mutations 
were identified, and in the culture passaged 6 times, 3 mutations were identified.  Of these 
mutations, two conferred an increase in released infectious virus when deliberately introduced into 
the genome.  One of these mutations was amino acid substitution N765D in the p7 protein.  In 
addition, when this mutation was incorporated along with two others (I1316V in NS3 and Y2103H in 
NS5A), an increase in released infectious virus was observed compared to wild type JFH-1.  The other 
mutation observed to enhance viral titres was amino acid substitution V2440L in NS5A.  This 
mutation was also capable of enhancing viral titres in intergenotypic chimaeras (including those in 
Figure 8C), but not in the intragenotypic chimaera Jc1.  Again, most of the mutations observed in 
cultured JFH-1 did not confer a replicative advantage upon the virus when deliberately introduced. 
 
The protocol for sequencing described, involved taking total intracellular RNA samples and 
synthesising cDNA from the positive strand of the HCV genome, and generating PCR products from 
this cDNA for sequencing.  Multiple rounds were performed on the same sample of RNA.  Similar 
methods have also been used in other published work409.  This method has certain advantages and 
disadvantages in sequencing analysis, e.g. it will generate a consensus sequence from the culture.  
The advantage of a consensus is that it identifies the mutations which occur in the majority of 
genomes in the cell.  It is possible that there are time-dependent mutations which may occur at a 
certain passage and disappear over time so that if the same culture were sequenced at a later 
timepoint the same mutations may not appear.  However this method will not identify mutations in 
individual genomes in the population.  In the human host HCV is a heterogeneic virus with a 
population made up of genetic quasispecies.  In order to identify mutations in each genome present, 
the original RNA isolate would have to be diluted out so that samples containing (less than) one 
genome could be synthesised for cDNA synthesis.  PCR products of cDNA would have to be cloned 
into bacterial vectors and multiple clones sequenced for each region of interest and for each 
genome.  Given the high number of genomes (108 per µg total cellular RNA), this would be a massive 
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task, but would provide excellent data on quasispecies genetic makeup.  This was not required here, 
however as the goal was to find potential cell culture adaptive mutations responsible for the overall 
higher levels of replication.   
 
Alternative explanations, not part of this study, for the apparent increasing fitness of JFH-1 in cell 
culture over time include selection of cells for those which can support higher viral and cellular 
replication.  It is known that cultured cells mutate over time.  The Huh7 line is a hepatocellular 
carcinoma line, and as a cancer line it may inherently have some deficiencies in the proofreading 
element of their replication machinery.  Huh7 cultures are known to be heterogeneous both within 
individual cultures and between different laboratory sources.  The line was first isolated in 1982, and 
nearly 30 years is a long time when considering cell doubling times of around 24 hours, giving lines 
plenty of time to diverge genetically and phenotypically, even with good laboratory practice of 
making stocks of low passage cells.  As already described, the clearest evidence for a case of the host 
cell being responsible for an observed high level of HCV replication is that of Huh7.5 cells375, which 
contain a defect in the RIG-I gene, thus impairing the cell’s ability to detect HCV RNA.   
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3.3 Identification of Host Genes Regulated During HCV Infection 
 
The ability of JFH-1 to replicate in cell culture allows for the investigation of events occurring in the 
cell during HCV infection.  The goal of these experiments was to identify host genes and biological 
processes regulated during HCV infection.  To this end, the described infection experiments were 
performed and the RNA extracted from samples for microarray analysis.  The use of Affymetrix 
GeneChip Human Genome U133 Plus 2.0 arrays allowed relative expression levels of all genes in the 
human genome to be quantified.  These arrays contain around 55,000 probe sets corresponding to 
the roughly 30,000 genes in the human genome, with some genes represented by more than one 
probeset.  An initial timecourse experiment was performed which yielded information on the most 
appropriate protocols to use in these experiments.  This information was used to perform the 
experiments from which the data on the effect of HCV infection on host gene expression is drawn.  
An experiment was performed comparing the gene expression between JFH-1 infected and mock 
infected Huh7.5 cells.  A second experiment was performed to compare the gene expression 
between JFH-1 infected and mock infected Huh7 cells.  This experiment using Huh7 cells also 
incorporated an experiment investigating the effect of anti-viral inhibitors on the expression of host 
genes in JFH-1 infected Huh7 cells. 
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3.3.1 Initial Timecourse 
 
An initial timecourse experiment was designed to establish the correct protocol for infection of 
samples for microarray analysis, and to determine the effect of HCV infection on gene expression in 
Huh7.5 cells.  The MOI used in experiments was essentially determined by the amount and titre of 
virus it was possible to produce.  The highest MOI possible would give the most cells infected for the 
course of the experiment.  The highest MOI it was possible to consistently obtain, given the target 
experimental setup of 25cm2 flasks and a 1 ml volume of virus to be added, was an MOI of 3.  Figure 
53 (Appendix A6) shows that any MOI of above 1 would have given maximal infection levels at 48 
hours post-infection, as represented by intracellular RNA levels.  In addition to the experimental 
evidence, it can be calculated theoretically using a Poisson distribution, that there is a 95% chance 
that any given cell will be infected by at least one focus forming unit when infecting with an MOI of 3 
focus forming units. 
 
The infection protocol for the microarray experiment was performed (as described in the Methods 
2.5.2).  Briefly, Huh7.5 cells were seeded in 25cm2 cell culture flask.  The next day, cells were washed 
with PBS and then were either infected at an MOI of 3 or mock infected.  At 4 hours post-infection, 
the infection and mock media were removed, cells were washed with PBS, and normal growth 
medium was added.  At 0, 6, 12, 18, 24, and 48 hours post-infection, growth medium was removed 
and cells were washed with PBS before total cell RNA was extracted by the Trizol method.  
Microarray hybridisation and data analyses were performed as described using Affymetrix GeneChip 
Human Genome U133 Plus 2.0 arrays and Array Studio software.   
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Fold Change in Expression 
Gene Symbol Probe Set 6 hours 12 hours 18 hours 24 hours 48 hours 
RPS6 211690_at 580.04 592.22 942.27 744.43 1552.09 
SAA1 214456_x_at 1.00 1.28 1.19 1.07 2.28 
--- 232504_at 1.26 1.12 1.12 1.23 2.13 
ATF3 202672_s_at 1.04 1.29 0.73 0.96 2.04 
MLCK 238834_at 1.93 0.63 1.04 0.86 0.49 
OLFML2A 213075_at 0.39 0.51 0.60 0.81 0.44 
GPC4 204984_at 0.67 0.65 0.82 0.84 0.44 
TCF7L1 221016_s_at 1.03 1.00 0.93 1.17 0.41 
FAT3 236029_at 0.48 0.70 0.69 0.78 0.34 
Table 2: Host genes most highly regulated during JFH-1 infection of Huh7.5 cells identified by the 
initial microarray experiment. 
Huh7.5 cells were infected with JFH-1 at an MOI of 3 or mock infected, and RNA was extracted at 
0, 6, 12, 18, 24, and 48 hours post-infection.  All conditions were performed in triplicate.  
Affymetrix GeneChip Human Genome U133 Plus 2.0 arrays were used for hybridisation and Array 
Studio software was used for analysis.  One array was used per RNA sample.  Genes listed are 
those that were observed to change in expression by more than 2 fold at 48 hours post-infection 
in JFH-1 infected cells compared to mock infected cells. 
 
To determine the consistency of the assay over time, gene expression at each designated time point 
was compared with gene expression at the 0 hour time point.  Changes in gene expression were 
observed over time in both the mock infected and the infected cells.  When compared against the 
time 0 hours mock infected Huh7.5 cells, 3414 genes were seen to change in expression levels in the 
mock infected Huh7.5 cells over all timepoints.  These genes were discounted from the analysis, 
generating a list of the genes which changed in expression level only between infected cells and 
mock infected cells.  284 genes are listed in this analysis.  Genes exhibiting expression changes of 4 
fold or more were chosen as significant for further investigation.  As can be seen in Table 2, very few 
genes were observed to change in expression by a modulus fold change of greater than 2 during 
infection at 48 hours post infection.  Only one gene changed by more than 4 times: RPS6 (ribosomal 
protein S6).  RPS6 had a greater than 512 fold increase in transcript levels across all time points.  
More genes were observed to be down-regulated by a significant amount, especially at early 
timepoints, although most had highly variable expression levels across time points.  This variability 
across timepoints is demonstrated in Figure 19, where the number of genes overlapping between 
different timepoints is very small. 
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Figure 19: Number of genes changing in expression level at multiple time points in the initial 
microarray analysis of JFH-1 infected Huh7.5 cells. 
The number in each circle represents the number of genes that changed in expression level, to 
any degree, in infected Huh7.5 cells compared to mock infected Huh7.5 cells.  A Comparison 
infected versus mock at 6 (blue), 12 (red) and 18 (green) hour timepoints. B Comparison infected 
versus mock at 18 (blue), 24 (red) and 48 (green) hour timepoints. C Comparison infected versus 
mock at 6 (blue), 24 (red) and 48 (green) hour timepoints.  These diagrams show that genes seen 
to change in expression level changed at only one time point. Only one gene, ribosomal protein 
S6, was seen to change in expression level over all time points 
 
 
It was therefore determined that analysis of this data would not yield useful information.  A new 
experiment with a modified protocol for infection was designed.  The primary function of the revised 
protocol, used in all further infection experiments, was to limit the number of manipulations of the 
cells, and therefore limit as far as possible the physical and environmental stresses put on the cells. 
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3.3.2 Identification of Host Genes Regulated During HCV Infection of Huh7.5 Cells 
 
A timecourse experiment with a revised infection protocol was designed to determine the effect of 
HCV infection on gene expression in Huh7.5 cells by microarray analysis. The infection protocol was 
performed, as described in Methods (2.5.3), with the aim of reducing the number of manipulations 
of the cells to an absolute minimum.  Briefly, Huh7.5 cells were seeded in 25cm2 cell culture flask.  
The next day, cells were infected at an MOI of 3, mock infected or not infected.  At 0, 6, 12, 18, 24, 
and 48 hours post-infection, growth medium was removed and total cell RNA was extracted by the 
Trizol method.  Microarray hybridisation and data analyses were performed as described.  Raw 
microarray data were analysed using Array Studio software.  After consultation with statisticians and 
researchers with experience of microarray analysis, specific parameters were decided upon for the 
analyses.  Fold changes identified were not considered significant if the mean fluorescence signal of 
the maximally fluorescent condition was below the background level.  A cut-off of 2-fold change in 
expression and a p-value of 0.05 were used to determine whether a gene was significantly regulated 
during infection.   
 
After analysis, 2851 probe sets (comprising of 1477 named genes and 996 poorly characterised loci 
or transcripts) were found to be altered in expression by at least 2-fold for at least one timepoint in 
JFH-1 infected cells compared to mock infected cells.  Table 3 describes the number of probe sets 
found to be significantly differentially expressed between JFH-1 infected and mock infected Huh7.5 
cells.  The genes observed to be most highly regulated during JFH-1 infection are described in Table 
4, and the genes observed to be significantly regulated across all timepoints are described in Table 5.   
 
 6 hours 12 hours 18 hours 24 hours 48 hours 
Fold change > 2 527 203 226 179 180 
Fold change < -2 891 433 719 525 413 
|Fold Change| > 2 1418 636 945 704 593 
Table 3: Number of probe sets significantly regulated between JHF-1 infected and mock infected 
Huh7.5 cells.  
Huh7.5 cells were infected with JFH-1 at an MOI of 3 or mock infected, and RNA was extracted at 
0, 6, 12, 18, 24, and 48 hours post-infection.  All conditions were performed in triplicate.  
Affymetrix GeneChip Human Genome U133 Plus 2.0 arrays were used for hybridisation and Array 
Studio software was used for analysis.  One array was used per RNA sample.  Microarray data 
were analysed by Array Studio software, and cut-offs for significant changes in expression were 
set selected as a fold change in expression of greater than two, with a significance of p<0.05.  
The number of probe sets identified as meeting these conditions at each timepoint is given. 
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To aid interpretation of the data comprising the large number of genes identified as changing during 
infection, further bioinformatic analysis was performed.  Use of Panther software allowed 
identification of the biological pathways represented in the genes identified as changing during 
infection.  Table 6 describes the major biological processes identified to be affected during infection.   
Several processes of particular interest to the study of HCV, based on current knowledge, were 
identified.  These included immunity, apoptosis, cellular proliferation, signalling, and lipid 
metabolism. 
 
The results obtained by microarray analysis were validated by a second method, in this case, 
quantitative PCR.  A separate infection experiment was performed, using the same infection 
protocols, and RNA was extracted by the Trizol method.  However, in this case, the relative 
expression levels of specific genes were quantified by quantitative PCR instead of microarray 
analysis.  This process allows the confirmation of expression changes for  specific genes of interest, 
and, if most gene expression levels assessed by quantitative PCR a shown to be in agreement with 
microarray data, it validates the use of microarray analysis for studying gene expression in this 
model system.  Figure 22 and Figure 23 show that most expression levels determined by quantitative 
PCR were in agreement with the data generated by microarray analysis.    
 
Genes were identified that exhibited increased expression during HCV infection.  Some of these 
genes were selected for investigation of their requirement for HCV replication.  Genes were chosen 
for further study based primarily on two criteria; the levels of fold change observed, and the 
potential for roles in HCV replication based on current knowledge or predictions of their function.  
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Fold Change in Expression 
Gene Gene Title Probe Set Id 6 hr 12 hr 18 hr 24 hr 48 hr 
MGAM maltase-glucoamylase (alpha-glucosidase) 206522_at 1.01 1.31 1.06 1.43 5.62 
CD300LF CD300 molecule-like family member f 1553043_a_at 2.22 3.05 3.94 2.75 4.56 
RIN2 Ras and Rab interactor 2 233811_at 1.34 1.04 -1.25 1.12 3.89 
LGALS3 lectin, galactoside-binding, soluble, 3 1557197_a_at 1.21 1.36 -1.16 1.44 3.53 
CCL3 chemokine (C-C motif) ligand 3 205114_s_at 1.13 1.85 1.46 1.39 3.36 
LBP lipopolysaccharide binding protein 214461_at 1.09 1.45 2.19 2.51 3.34 
ANKRD60 Ankyrin repeat domain 60 230683_at 1.09 1.64 1.16 -1.72 3.34 
SLC10A7 solute carrier family 10, member 7 1555108_at -1.25 1.80 1.62 -1.03 3.23 
SOD2 superoxide dismutase 2, mitochondrial 215078_at 1.06 1.88 2.14 2.50 3.20 
TXNIP thioredoxin interacting protein 201008_s_at 1.24 1.92 1.66 1.21 3.18 
ANXA13 annexin A13 208323_s_at 1.92 -1.16 1.28 -1.61 3.18 
RECQL5 RecQ protein-like 5 1561720_at -2.27 -1.47 -1.35 1.15 3.16 
TXNIP thioredoxin interacting protein 201010_s_at 2.04 1.52 2.60 1.40 3.03 
LBP lipopolysaccharide binding protein 211652_s_at 1.26 1.27 1.79 2.03 2.99 
SAA1/2 serum amyloid A1 / A2 208607_s_at 1.22 1.97 2.33 3.07 2.97 
BATF2 basic leucine zip tcriptn factor, ATF-like 2 228439_at 3.05 -1.25 1.01 1.13 2.95 
SLC6A4 solute carrier family 6, member 4 242009_at 2.33 1.12 1.31 1.37 2.91 
VNN3 vanin 3 220528_at 1.04 2.28 2.53 1.78 2.89 
ZNF24 zinc finger protein 24 1554045_at -1.20 -1.14 1.27 1.39 2.89 
MBD2 methyl-CpG binding domain protein 2 214397_at -1.45 -1.61 -1.02 1.75 2.87 
ABLIM3 actin binding LIM protein family, 3 205730_s_at -1.64 -1.32 1.14 1.68 2.85 
FXYD3 FXYD dom. cont. ion transport regulator 3 202489_s_at 1.31 1.04 1.06 -1.10 2.85 
STAT4 signal tducer and activator of tcriptn 4 206118_at -1.16 -1.49 -1.41 -2.78 -4.17 
COL1A1 collagen, type I, alpha 1 202310_s_at -1.67 -3.85 -2.33 -6.67 -4.17 
MT1M metallothionein 1M 217546_at -1.64 -2.78 -5.00 -7.69 -4.17 
SUSD4 sushi domain containing 4 219389_at -4.35 -5.00 -3.57 -8.33 -4.35 
SDPR serum deprivation response 222717_at -1.67 1.01 -2.13 -2.50 -4.35 
MAB21L2 mab-21-like 2 (C. elegans) 210302_s_at -1.75 -2.33 -1.56 -5.00 -4.35 
NOX4 NADPH oxidase 4 219773_at -1.04 1.05 -1.49 1.13 -4.55 
ERBB4 
v-erb-a erythroblastic leukemia viral oncogene 
homolog 4 (avian) 
214053_at -3.23 -2.00 -2.50 -3.70 -4.55 
MT1G metallothionein 1G 204745_x_at -1.33 -2.13 -2.86 -3.57 -4.55 
FBN1 fibrillin 1 235318_at -2.44 -3.03 -3.85 -4.17 -5.00 
NPPB natriuretic peptide precursor B 206801_at -2.04 -2.50 -5.88 -7.69 -5.00 
MT1F metallothionein 1F 217165_x_at -1.59 -2.56 -3.23 -4.17 -5.26 
LOXL4 lysyl oxidase-like 4 227145_at -3.45 -3.57 -4.17 -4.55 -5.26 
MT1F metallothionein 1F 213629_x_at -1.43 -2.50 -3.03 -4.00 -5.26 
ADH1A alcohol dehydrogenase 1A,α polypeptide 207820_at -1.45 -1.32 2.33 -1.75 -5.56 
TAGLN transgelin 1555724_s_at -2.00 -2.27 -3.85 -6.25 -5.56 
MT1E metallothionein 1E 212859_x_at -1.79 -2.94 -3.23 -3.57 -5.56 
FAT3 FAT tumor suppressor homolog 3 236029_at -3.23 -2.78 -1.43 -7.69 -6.25 
FLRT2 Fibronectin Leu rich transmembrane 2 240259_at -2.17 -2.22 -3.45 -4.76 -6.25 
NPNT nephronectin 225911_at -2.86 -3.03 -3.03 -4.17 -7.14 
NCF2 neutrophil cytosolic factor 2 209949_at -6.25 -8.33 -14.29 -25.00 -7.69 
TAGLN transgelin 205547_s_at -1.96 -2.27 -4.55 -7.14 -8.33 
LEFTY2 left-right determination factor 2 206012_at -14.29 -8.33 -12.50 -16.67 -12.50 
COL1A1 collagen, type I, alpha 1 1556499_s_at -5.26 -8.33 -4.35 -16.67 -14.29 
Table 4: Host genes most highly regulated at 48 hours post-infection of Huh7.5 cells. 
Huh7.5 cells were infected with JFH-1 at an MOI of 3 or mock infected, and RNA was extracted at 
0, 6, 12, 18, 24, and 48 hours post-infection.  All conditions were performed in triplicate.  
Affymetrix GeneChip Human Genome U133 Plus 2.0 arrays were used for hybridisation and Array 
Studio software was used for analysis.  One array was used per RNA sample.  Probe sets which 
were not ascribed to a specific named gene have not been included in this table. 
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Gene Symbol Gene Title probe set id 6 12 18 24 48 
CD300LF CD300 molecule-like family member f 1553043_a_at 2.22 3.05 3.94 2.75 4.56 
HLF hepatic leukemia factor 204754_at 2.19 2.75 2.14 2.00 2.03 
ACADL acyl-Coenzyme A dehydrogenase, long chain 206069_s_at -4.59 -3.78 -2.50 -3.84 -2.06 
UACA 
uveal autoantigen with coiled-coil domains and ankyrin 
repeats 
238868_at -4.69 -4.00 -3.71 -3.76 -2.23 
SEMA3C 
sema domain, immunoglobulin domain (Ig), short basic 
domain, secreted, (semaphorin) 3C 
203789_s_at -2.04 -2.50 -2.79 -4.29 -2.28 
LMCD1 LIM and cysteine-rich domains 1 242767_at -4.72 -3.12 -3.03 -7.57 -2.39 
SERPINE2 
serpin peptidase inhibitor, clade E (nexin, plasminogen 
activator inhibitor type 1), member 2 
212190_at -2.11 -2.20 -2.79 -3.01 -2.41 
NRP2 Neuropilin 2 228699_at -3.97 -4.14 -4.59 -3.27 -2.41 
DPYSL3 dihydropyrimidinase-like 3 201431_s_at -2.03 -3.34 -2.83 -6.15 -2.43 
TIMP4 TIMP metallopeptidase inhibitor 4 206243_at -3.32 -2.50 -2.60 -5.03 -2.48 
CUX2 cut-like homeobox 2 213920_at -3.46 -2.14 -2.39 -2.31 -2.50 
MICAL2 
microtubule associated monoxygenase, calponin and 
LIM domain containing 2 
212472_at -2.58 -3.05 -2.60 -3.68 -2.55 
JAK1 Janus kinase 1 (a protein tyrosine kinase) 239695_at -4.66 -2.36 -3.18 -2.23 -2.58 
KLRC1 /// 
KLRC2 
killer cell lectin-like receptor subfamily C, member 1 /// 
killer cell lectin-like receptor subfamily C, member 2 
206785_s_at -3.46 -2.75 -3.51 -2.85 -2.60 
NODAL nodal homolog (mouse) 230916_at -13.00 -7.01 -4.35 -6.68 -2.60 
PRSS23 protease, serine, 23 202458_at -2.19 -2.33 -3.18 -3.68 -2.66 
MICAL2 
microtubule associated monoxygenase, calponin and 
LIM domain containing 2 
212473_s_at -2.71 -2.77 -2.83 -3.43 -2.69 
ANGPTL2 angiopoietin-like 2 213004_at -5.10 -5.66 -2.45 -7.89 -2.79 
HAO2 hydroxyacid oxidase 2 (long chain) 220801_s_at -4.41 -6.06 -4.44 -4.56 -2.83 
LOC728449 hypothetical protein LOC728449 1557094_at -2.22 -2.20 -2.45 -2.69 -2.85 
DPYSL3 dihydropyrimidinase-like 3 201430_s_at -3.16 -3.81 -4.86 -8.17 -2.99 
ENTPD4 /// 
LOXL2 
ectonucleoside triphosphate diphosphohydrolase 4 /// 
lysyl oxidase-like 2 
202998_s_at -2.07 -2.99 -2.81 -6.82 -3.27 
TNFRSF19 tumor necrosis factor receptor superfamily, member 19 227812_at -4.29 -2.77 -3.46 -4.29 -3.27 
PRSS23 protease, serine, 23 226279_at -2.39 -2.20 -3.76 -10.06 -3.56 
NRP2 Neuropilin 2 228103_s_at -4.11 -3.43 -4.29 -5.35 -3.56 
PALMD palmdelphin 218736_s_at -2.62 -2.31 -2.30 -3.34 -3.86 
ANGPTL2 angiopoietin-like 2 213001_at -5.39 -7.01 -5.21 -4.32 -3.89 
LEFTY1 left-right determination factor 1 206268_at -3.10 -8.63 -5.78 -9.45 -3.97 
DACT1 
dapper, antagonist of beta-catenin, homolog 1 
(Xenopus laevis) 
219179_at -14.03 -8.51 -3.68 -11.24 -3.97 
SUSD4 sushi domain containing 4 219389_at -4.26 -4.99 -3.63 -8.06 -4.32 
FBN1 fibrillin 1 235318_at -2.43 -2.99 -3.86 -4.08 -4.92 
NPPB natriuretic peptide precursor B 206801_at -2.06 -2.51 -5.82 -7.94 -4.96 
LOXL4 lysyl oxidase-like 4 227145_at -3.51 -3.53 -4.17 -4.53 -5.28 
TAGLN transgelin 1555724_s_at -2.00 -2.27 -3.92 -6.15 -5.54 
FLRT2 Fibronectin leucine rich transmembrane protein 2 240259_at -2.16 -2.23 -3.41 -4.82 -6.23 
NPNT nephronectin 225911_at -2.83 -2.99 -3.05 -4.20 -7.26 
NCF2 neutrophil cytosolic factor 2 209949_at -6.28 -8.63 -13.64 -23.10 -7.73 
LEFTY2 left-right determination factor 2 206012_at -13.93 -8.46 -12.38 -16.68 -12.04 
COL1A1 collagen, type I, alpha 1 1556499_s_at -5.39 -8.17 -4.44 -18.00 -15.35 
 
Table 5: Probe Sets regulated during infection of Huh7.5 cells by a greater than 2-fold change at 
all timepoints. 
46 probe sets were observed to be regulated by greater than 2-fold across all timepoints during 
infection of Huh7.5 cells with JFH-1.  These probe sets are sorted by fold change at 48 hours 
post-infection.  Probe sets without an assigned named gene are not shown.   
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6 hours 12 hours 18 hours 24 hours 48 hours 
Biological Process Observed Expected P-Value Observed Expected P-Value Observed Expected P-Value Observed Expected P-Value Observed Expected P-Value 
Biological process unclassified 31 95.27 1.64E-19 17 49.41 1.71E-09 143 201.21 4.55E-07 99 146.01 2.25E-06 93 122.87 5.00E-03 
Signal transduction 75 28.66 2.67E-14 36 14.87 6.56E-06 113 60.54 8.85E-10 96 43.93 1.52E-12 63 36.96 4.30E-04 
Cell surface receptor mediated signal transduction 37 13.78 6.18E-06 22 7.15 3.12E-04 50 29.11 2.32E-02 39 21.13 2.69E-02 34 17.78 3.46E-02 
Developmental processes 41 18.11 2.09E-05 24 9.39 5.06E-04 86 38.25 4.10E-11 62 27.76 6.34E-08 55 23.36 7.07E-08 
Immunity and defence 28 11.09 2.23E-04 15 5.75 1.95E-02 41 23.43 1.36E-02 36 17 6.92E-04 27 14.3 4.01E-02 
Angiogenesis 4 0.45 2.40E-01 4 0.24 2.01E-02 6 0.96 9.29E-02 6 0.7 1.67E-02 6 0.59 6.47E-03 
Inhibition of apoptosis 6 1.08 1.20E-01 5 0.56 3.86E-02 6 2.28 1.00E+00 9 1.65 7.74E-03 3 1.39 1.00E+00 
Lipid, fatty acid and steroid metabolism 14 6.48 1.88E-01 10 3.36 6.42E-02 29 13.69 4.94E-03 17 9.93 7.34E-01 17 8.36 1.53E-01 
Receptor protein tyrosine kinase signalling pathway 7 1.78 4.47E-01 6 0.92 6.96E-02 14 3.75 6.90E-03 10 2.72 9.79E-02 8 2.29 4.74E-01 
Apoptosis 16 4.47 4.27E-04 8 2.32 7.37E-02 22 9.44 8.61E-03 22 6.85 7.06E-05 17 5.76 2.72E-03 
Cell communication 28 10.21 2.19E-04 14 5.29 1.22E-01 50 21.56 6.60E-06 41 15.64 3.63E-06 31 13.16 1.56E-03 
Proteolysis 15 8.08 1.00E+00 12 4.19 1.49E-01 19 17.06 1.00E+00 26 12.38 5.26E-02 25 10.42 8.62E-03 
Cell adhesion 9 5.23 1.00E+00 8 2.71 1.89E-01 22 11.06 6.48E-02 23 8.02 2.62E-04 18 6.75 5.86E-03 
Intracellular signalling cascade 25 7.33 1.70E-05 11 3.8 2.24E-01 34 15.48 3.15E-03 31 11.23 7.11E-05 15 9.45 1.00E+00 
Granulocyte-mediated immunity 6 0.54 2.93E-03 3 0.28 4.19E-01 6 1.14 1.63E-01 6 0.83 3.05E-02 6 0.69 1.20E-02 
Mesoderm development 12 4.64 3.92E-01 8 2.4 4.31E-01 36 9.79 6.43E-09 26 7.11 3.21E-06 19 5.98 1.80E-03 
Cell proliferation and differentiation 22 8.65 2.05E-03 10 4.49 4.57E-01 34 18.27 1.48E-02 28 13.26 6.12E-03 21 11.16 1.41E-01 
Neurogenesis 11 4.94 1.00E+00 8 2.56 8.60E-01 23 10.43 8.70E-02 16 7.57 8.94E-01 19 6.37 5.79E-03 
Cell structure and motility 22 9.66 9.63E-03 10 5.01 8.96E-01 47 20.4 4.48E-06 33 14.81 5.75E-04 28 12.46 2.03E-03 
Protein biosynthesis 1 4.97 1.00E+00 0 2.58 1.00E+00 1 10.5 4.13E-02 3 7.62 1.00E+00 1 6.41 1.00E+00 
Ectoderm development 13 5.82 9.04E-01 8 3.02 1.00E+00 25 12.3 1.16E-01 17 8.93 1.00E+00 21 7.51 4.11E-03 
Cell motility 13 2.96 1.64E-03 5 1.54 1.00E+00 20 6.26 1.11E-03 23 4.54 5.71E-08 15 3.82 1.38E-03 
Ligand-mediated signalling 18 3.54 5.25E-06 6 1.84 1.00E+00 21 7.48 6.07E-03 14 5.43 2.67E-01 13 4.57 1.62E-01 
Cell adhesion-mediated signalling 5 3.19 1.00E+00 5 1.65 1.00E+00 12 6.74 1.00E+00 16 4.89 8.80E-03 9 4.11 1.00E+00 
Oncogenesis 14 3.97 1.75E-03 6 2.06 5.51E-01 17 8.39 1.67E-01 14 6.09 1.16E-01 8 5.12 1.00E+00 
NF-kappaB cascade 6 0.6 7.10E-03 2 0.31 1.00E+00 3 1.26 1.00E+00 3 0.92 1.00E+00 4 0.77 1.00E+00 
Cytokine and chemokine mediated signalling pathway 10 2.12 1.30E-02 4 1.1 1.00E+00 11 4.48 1.00E+00 6 3.25 1.00E+00 7 2.73 1.00E+00 
Steroid metabolism 8 1.54 2.69E-02 4 0.8 1.00E+00 5 3.25 1.00E+00 6 2.36 1.00E+00 5 1.99 1.00E+00 
Sulphur metabolism 5 0.78 3.85E-02 3 0.41 2.51E-01 3 1.65 1.00E+00 4 1.2 1.00E+00 2 1.01 1.00E+00 
Table 6: Host cellular biological processes identified to be affected by transcriptional regulation during JFH-1 infection of Huh7.5 cells.  
Panther analysis was performed using all genes which met the cut-off of a 2-fold change.  Processes identified as having an enriched number of genes (with a 
p-value cut-off of 0.05, stringently calculated using the Bonferroni correction option), represented in the microarray data compared with the expected 
random number of genes based on the whole human genome, for at least one timepoint, are shown.  Given for each timepoint and biological process are the 
observed number of genes regulated during infection, the expected number of genes based on the proportion of genes involved in that process in the entire 
human genome, and finally a p-value representing the probability that the difference between observed and expected numbers is not significant. 
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A striking pattern observed in the microarray data was the downregulation of metallothionein 
genes.  Figure 20 shows that expression of all forms of MT1, and MT2A, were down during JFH-1 
infection of Huh7.5 cells.  Expression levels of MTs in infected cells were also observed to decrease 
over time. 
 
 
Figure 20: Fold change in expression of Metallothioneins during JFH-1 infection of Huh7.5 cells. 
Metallothioneins were clearly seen to be down regulated in infected Huh7.5 cells, with 
expression levels in infected cells decreasing over time.  Where a gene is represented on the 
microarray by more than one probe set, data were averaged and displayed with error bars.  The 
data set MT1 corresponds to a probe set which recognises all MT1 isoforms 
 
 
Genes observed to be regulated by more than two fold at 48 hours post-infection have been 
presented in heatmap form.   Figure 21 presents these genes grouped by biological processes 
identified in the Panther analysis of microarray data (Table 6, Figure 21).  As a visual aid, heatmap 
data is presented on a log2 scale.  Upregulated genes are shown in red and downregulated genes are 
shown in green.  Maximal colour intensity is assigned to genes with a relative expression change of 3 
fold or higher (1.5 fold on the log2 scale).  
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Figure 21: Host biological processes regulated during JFH-1 infection of Huh7.5 cells. 
Genes identified to be regulated during JFH-1 infection of Huh7.5 cells are presented in heatmap 
form with each heatmap corresponding to biological processes identified using Panther analysis.  
Heatmaps were generated using MeV software and genes are clustered within heatmaps by 
Pearson correlation.  Genes shown in red were upregulated and genes shown in green were 
downregulated, displayed on a log2 fold change scale.  Data presented is an average calculated 
from the three replicates each performed for JFHF-1 infected and mock infected Huh7.5 cells. 
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To confirm the validity of the data obtained from the microarray study, gene expression level 
changes were measured by qPCR.  A new set of replicate infections was performed in Huh7.5 cells, 
and the expression levels of a number of genes were measured by qPCR.  A small number of genes 
only were chosen, as the purpose of the experiment was just to validate the principal that the 
microarray data were true representations of the expression changes occurring during infection.   
Validation was performed on the genes presented in Figure 22 and Figure 23.  Figure 22A shows the 
correlation between PCR and microarray data for genes upregulated at 6 hours post-infection, and 
Figure 22B for genes upregulated at 48 hours post-infection.  Figure 23 shows the correlation 
between PCR and microarray data for genes in the metallothionein family at 48 hours post-infection, 
all of which were observed to be downregulated during infection. 
 
 
Figure 22: Validation by PCR of gene expression levels in Huh7.5 cells infected with JFH-1.  
Huh7.5 cells were infected with JFH-1 at an MOI of 3 or mock infected for 6 hours (A) or 48 hours 
(B).  PCR quantification of relative expression levels for a selection of genes was performed (as 
described in methods 2.6).  Mean and SEM are presented for quantitative PCR results which 
were obtained from triplicate infections in two separate experiments.  For microarray data, 
where more than one probeset corresponding to a single gene was present in the array, the data 
presented is the mean and standard error of the mean.  The majority of gene expression levels 
determined by PCR and microarray were observed to be in agreement. 
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Figure 23: Validation by PCR of metallothionein gene expression levels in Huh7.5 cells infected 
with JFH-1.  
Huh7.5 cells were infected with JFH-1 at an MOI of 3 or mock infected for 48 hours.  PCR 
quantification of relative expression levels for a selection of metallothionein genes was 
performed as described in methods.  Mean and SEM are presented for quantitative PCR results 
which were obtained from triplicate infections in two separate experiments.  For microarray 
data, where more than one probeset corresponding to a single gene was present in the array, 
the data presented is the mean and standard error of the mean.  All metallothioneins identified 
by microarray analysis to be downregulated were also identified by PCR to be downregulated.   
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3.3.3 Identification of Host Genes Regulated During HCV Infection of Huh7 Cells 
 
Huh7.5 cells are a useful model for the study of HCV infection.  However, they are a cell line that has 
been created by selection for their ability to support HCV replication.  In particular, they are known 
to lack functional RIG-I, and hence do not have that mechanism for the detection of HCV RNA.  This 
is not the case in human liver, where RIG-I is functional.  Alteration of gene expression due to 
infection in the absence of RIG-I may not reflect the situation found in infected liver cells.  Huh7 cells 
have functional RIG-I.  In order to more closely replicate the situation that may exist in liver cells, 
Huh7 cells were used in a microarray experiment to determine the effect of HCV infection on host 
cell gene expression.   
 
A timecourse experiment was designed to determine the effect of HCV infection on gene expression 
in Huh7 cells by microarray analysis.  The infection protocol was performed as described, with the 
aim of reducing the number of manipulations of the cells to an absolute minimum.  Briefly, Huh7 
cells were seeded in 25cm2 cell culture flasks.  The next day, cells were infected at an MOI of 3 or 
mock infected.  At 0, 6, 12, 18, 24, and 48 hours post-infection, growth medium was removed and 
total cell RNA was extracted by the Trizol method.  Microarray hybridisation and data analyses were 
performed as described.   
 
After analysis 2885 probe sets (comprising of 1726 named genes and 461 poorly characterised loci or 
transcripts) were found to be altered in expression by at least 2-fold for at least one timepoint in 
JFH-1 infected cells compared to mock infected cells.   
 
 6 hours 12 hours 18 hours 24 hours 48 hours 
Fold change > 2 74 270 146 617 1275 
Fold change < -2 165 117 232 383 870 
|Fold Change| > 2 239 387 378 1000 2145 
Table 7: Number of probe sets significantly regulated between JHF-1 infected and mock infected 
Huh7 cells.  
Huh7.5 cells were infected with JFH-1 at an MOI of 3 or mock infected, and RNA was extracted at 
0, 6, 12, 18, 24, and 48 hours post-infection.  All conditions were performed in triplicate.  
Affymetrix GeneChip Human Genome U133 Plus 2.0 arrays were used for hybridisation and Array 
Studio software was used for analysis.  One array was used per RNA sample.  Microarray data 
were analysed by Array Studio software, and cut-offs for significant changes in expression were 
set selected as a fold change in expression of greater than two, with a significance of p<0.05.  
The number of probe sets identified as meeting these conditions at each timepoint is given. 
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To aid interpretation of the data comprising the large number of genes identified as changing during 
infection, further bioinformatic analysis was performed.  Use of Panther software allowed 
identification of the biological pathways containing genes observed to be changing during infection.  
Table 10 describes the major biological processes identified to be affected during infection.   Several 
processes of particular interest to the study of HCV, based on current knowledge, were identified.  
These included immunity, apoptosis, proliferation, and lipid metabolism. 
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Fold Change in Expression 
Gene Gene Title Probe Set Id 6 hr 12 hr 18 hr 24 hr 48 hr 
TXNIP thioredoxin interacting protein 201010_s_at 1.38 9.3 6.03 20.51 21.96 
STC2 stanniocalcin 2 203438_at 1.55 8.65 4.68 18.35 20.5 
INHBE inhibin, beta E 210587_at -1.77 7.16 2.44 22.93 18.01 
TXNIP thioredoxin interacting protein 201008_s_at 1.3 8.39 5.26 20.15 15.32 
STC2 stanniocalcin 2 203439_s_at 1.32 9.49 5.52 21.94 14.32 
TXNIP thioredoxin interacting protein 201009_s_at 1.15 6.56 4.99 13.55 14.3 
ALDH1L2 Aldehyde dehydrogenase 1 family, member L2 231202_at 1.05 2.05 2.47 8.6 11.78 
SLC16A14 solute carrier family 16, member 14  238029_s_at 1.52 1.3 1.04 3.08 11.23 
ASNS asparagine synthetase 205047_s_at 1.08 5.82 6.76 15.53 11.22 
ARRDC4 arrestin domain containing 4 225283_at -1.14 4.1 3.22 11.77 10.77 
SAMD5 sterile alpha motif domain containing 5 228653_at 1.4 1.56 2.25 3.71 9.06 
ATF3 activating transcription factor 3 202672_s_at -1.99 5.28 1.54 6.97 8.57 
PRNP prion protein 201300_s_at 1.09 1.07 1.49 2.21 8 
SOCS2 suppressor of cytokine signaling 2 203372_s_at -1.69 1.6 -1.86 4.56 7.91 
BEX1 brain expressed, X-linked 1 218332_at 1.18 1.08 2.32 2.28 7.56 
LYPD1 LY6/PLAUR domain containing 1 212909_at -1.72 -1.43 -1.47 2.16 7.33 
PPARGC1A 
peroxisome proliferator-activated receptor 
gamma, coactivator 1 alpha 
219195_at 1.23 1.12 1.02 2.17 6.94 
SLC1A4 
solute carrier family 1 (glutamate/neutral amino 
acid transporter), member 4 
212810_s_at -1.28 2.51 2.12 5.45 6.84 
C10orf10 chromosome 10 open reading frame 10 209183_s_at 1.28 2.08 2.11 3.42 6.63 
FABP3 fatty acid binding protein 3, muscle and heart  214285_at 1.13 -1.06 1.43 1.12 6.58 
KLF10 Kruppel-like factor 10 202393_s_at -1.83 1.93 1.44 4.25 6.36 
RORA RAR-related orphan receptor A 210426_x_at 1.25 -1.04 1.38 1.68 6.28 
RBM14 RNA binding motif protein 14 204178_s_at -1.04 -1.01 -1.46 -1.26 -4.6 
FDFT1 farnesyl-diphosphate farnesyltransferase 1 210950_s_at -1.23 -1.63 -1.74 -4.16 -4.6 
ID4 
Inhibitor of DNA binding 4, dominant negative 
helix-loop-helix protein 
226933_s_at 1.16 -1.66 -1.3 -2.54 -4.61 
TESC tescalcin 218872_at -1.19 -1.39 -1.55 -2.47 -4.62 
SMAD9 SMAD family member 9 227719_at -1.05 -1.44 -1.48 -3.09 -4.77 
ID4 
inhibitor of DNA binding 4, dominant negative 
helix-loop-helix protein 
209293_x_at -1.2 -1.65 -1.28 -2.21 -4.82 
BTD biotinidase 214117_s_at 1.19 -1.11 -1.19 -1.64 -4.83 
TPCN2 two pore segment channel 2 229250_at -1.16 1.01 -1.42 -1.5 -4.87 
FSCN1 fascin homolog 1, actin-bundling protein  210933_s_at -1.43 -1.66 -1.99 -4.18 -4.88 
CDKN3 cyclin-dependent kinase inhibitor 3 209714_s_at 1.01 -1.49 -1.29 -2.26 -5.09 
ID4 
inhibitor of DNA binding 4, dominant negative 
helix-loop-helix protein 
209291_at -1.2 -1.51 -1.44 -3.11 -5.14 
CCNB1 cyclin B1 214710_s_at 1.06 -1.51 -1.23 -2.38 -5.23 
SMAD6 SMAD family member 6 209886_s_at -1.39 -1.67 -1.49 -2.17 -5.24 
CDKN3 cyclin-dependent kinase inhibitor 3 1555758_a_at 1.04 -1.46 -1.34 -2.21 -5.34 
SMAD6 SMAD family member 6 207069_s_at -1.22 -1.74 -1.45 -5.19 -5.61 
HIST1H2BC histone cluster 1, H2bc 214455_at 1.05 1.05 -1.57 -2.36 -5.62 
FAM83D family with sequence similarity 83, member D 225687_at 1.14 -2.34 -1.32 -2.6 -5.64 
GATM glycine amidinotransferase  216733_s_at -1.01 -1.33 -1.55 -3.08 -5.71 
MYCBP c-myc binding protein 203360_s_at -1.2 -1.19 -1.42 -1.62 -5.78 
GATM glycine amidinotransferase  203178_at 1.05 -1.03 -1.64 -3 -5.9 
RBM14 RNA binding motif protein 14 1555639_a_at 1.02 1.05 -1.68 1.04 -6.04 
CDKN2C 
cyclin-dependent kinase inhibitor 2C (p18, 
inhibits CDK4) 
204159_at 1.39 -1.53 -1.2 -4.12 -6.87 
B3GNT1 
UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 1 
203188_at 1.79 1.11 -1.03 -2.63 -6.95 
 
Table 8: Host genes most highly regulated at 48 hours post-infection of Huh7 cells. 
Huh7.5 cells were infected with JFH-1 at an MOI of 3 or mock infected, and RNA was extracted at 
0, 6, 12, 18, 24, and 48 hours post-infection.  All conditions were performed in triplicate.  
Affymetrix GeneChip Human Genome U133 Plus 2.0 arrays were used for hybridisation and Array 
Studio software was used for analysis.  One array was used per RNA sample.  Probe sets which 
were not ascribed to a specific named gene have not been included in this table.  
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Gene 
Symbol 
Gene Title probe set id 6 12 18 24 48 
TGFB1I1 transforming growth factor beta 1 induced transcript 1 209651_at -2.92 -3.13 -5.5 -2.63 5.73 
RAB27B RAB27B, member RAS oncogene family 228708_at 2.56 2.5 3.43 2.43 5.19 
RASSF9 
Ras association (RalGDS/AF-6) domain family (N-terminal) 
member 9 
210335_at 3.28 4.28 2.53 3.62 4.45 
GPR109B G protein-coupled receptor 109B 205220_at 2.03 6.06 2.77 3.41 3.18 
CYP1A1 cytochrome P450, family 1, subfamily A, polypeptide 1 205749_at 2.17 4.18 2.28 5.19 2.58 
SLC7A2 
solute carrier family 7 (cationic amino acid transporter, y+ 
system), member 2 
225516_at 2.3 2.75 2.62 2.88 2.52 
--- --- 1570561_at 29.92 12.44 17.39 2.65 2.28 
SLC26A3 solute carrier family 26, member 3 206143_at 2.64 2.35 4.49 3.34 2.06 
DPYSL3 dihydropyrimidinase-like 3 201431_s_at -2.46 -3.63 -5.97 -3.12 -2 
--- --- 222281_s_at -2.32 -2.7 -3.07 -2.49 -2.89 
 
Table 9: Probe Sets regulated during infection of Huh7 cells by a greater than 2-fold change at all 
timepoints.  
10 probe sets were observed to be regulated by greater than 2-fold across all timepoints during 
infection of Huh7.5 cells with JFH-1.  These probe sets are sorted by fold change at 48 hours 
post-infection.  The two probe sets without an assigned named gene are shown.   
.   
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6 Hours 12 Hours 18 Hours 24 Hours 48 Hours All Hours Combined 
Biological Process Observed Expected P-Value Observed Expected P-Value Observed Expected P-Value Observed Expected P-Value Observed Expected P-Value Observed Expected P-Value 
Nucleoside, nucleotide and 
nucleic acid metabolism 
20 19.32 1.00E+00 46 32.86 3.54E-01 22 30.76 1.00E+00 115 80.71 1.86E-03 267 167.08 2.00E-13 336 222.42 2.83E-13 
Cell proliferation and 
differentiation 
15 5.94 2.99E-02 20 10.11 9.81E-02 20 9.46 4.55E-02 44 24.82 7.20E-03 99 51.38 2.98E-08 134 68.4 1.27E-11 
mRNA transcription 17 11.06 1.00E+00 27 18.82 1.00E+00 13 17.61 1.00E+00 70 46.21 5.77E-02 166 95.66 7.81E-10 211 127.34 1.15E-10 
Developmental processes 33 12.44 5.92E-06 37 21.16 2.00E-02 48 19.8 2.69E-07 76 51.96 1.89E-02 161 107.55 8.09E-06 225 143.18 5.64E-10 
mRNA transcription regulation 14 8.43 1.00E+00 24 14.34 1.00E+00 9 13.42 1.00E+00 54 35.23 2.84E-01 132 72.92 1.48E-08 168 97.07 1.73E-09 
Amino acid metabolism 5 1.33 3.48E-01 13 2.26 2.00E-05 17 2.12 2.57E-09 21 5.55 1.12E-05 38 11.5 1.29E-08 46 15.3 4.49E-09 
Lipid, fatty acid and steroid met. 10 4.45 4.49E-01 11 7.57 1.00E+00 16 7.09 7.08E-02 40 18.59 2.33E-04 77 38.48 5.12E-07 94 51.23 9.72E-07 
Transport 10 7.55 1.00E+00 23 12.84 1.65E-01 21 12.02 3.04E-01 60 31.53 6.37E-05 103 65.27 1.66E-04 138 86.89 3.56E-06 
Oncogenesis 8 2.73 2.00E-01 17 4.64 1.79E-04 11 4.34 1.47E-01 23 11.4 4.52E-02 40 23.59 3.57E-02 64 31.4 4.99E-06 
Steroid metabolism 4 1.06 1.00E+00 5 1.8 1.00E+00 6 1.68 1.00E+00 18 4.42 1.26E-04 31 9.15 1.37E-06 35 12.18 9.16E-06 
Cell structure and motility 20 6.64 3.55E-04 20 11.29 3.16E-01 29 10.56 3.18E-05 43 27.72 1.07E-01 75 57.38 3.94E-01 120 76.38 4.12E-05 
Cell cycle 13 5.83 1.85E-01 12 9.92 1.00E+00 10 9.28 1.00E+00 26 24.36 1.00E+00 79 50.43 2.63E-03 107 67.13 8.41E-05 
Cell cycle control 11 2.42 5.23E-03 7 4.11 1.00E+00 5 3.85 1.00E+00 16 10.09 1.00E+00 38 20.89 6.29E-02 57 27.81 9.17E-05 
Other metabolism 4 3.23 1.00E+00 8 5.5 1.00E+00 6 5.14 1.00E+00 23 13.5 3.29E-01 50 27.94 2.71E-03 67 37.19 1.64E-04 
Intracellular signalling cascade 14 5.03 8.25E-02 18 8.56 3.92E-01 17 8.01 4.61E-01 38 21.03 6.24E-02 60 43.53 1.00E+00 96 57.95 2.76E-04 
Signal transduction 43 19.69 1.23E-05 56 33.48 2.14E-03 57 31.34 1.39E-04 111 82.23 1.98E-02 184 170.23 1.00E+00 284 226.61 1.27E-03 
Immunity and defence 18 7.62 2.00E-02 32 12.96 8.36E-05 28 12.13 1.17E-03 51 31.82 2.36E-02 73 65.87 1.00E+00 125 87.69 2.04E-03 
Sulphur metabolism 3 0.54 5.32E-01 3 0.91 1.00E+00 7 0.86 9.16E-04 5 2.25 1.00E+00 15 4.65 3.11E-03 18 6.19 2.48E-03 
Apoptosis 10 3.07 3.47E-02 10 5.22 1.00E+00 11 4.89 3.38E-01 16 12.82 1.00E+00 40 26.54 2.53E-01 59 35.33 4.41E-03 
Cell structure 9 3.97 1.00E+00 9 6.75 1.00E+00 15 6.32 2.83E-01 22 16.59 1.00E+00 49 34.34 1.00E+00 75 45.71 4.88E-03 
Olfaction 1 1.14 1.00E+00 0 1.95 1.00E+00 0 1.82 1.00E+00 0 4.78 1.00E+00 0 9.9 9.60E-03 1 13.17 5.10E-03 
Cell communication 14 7.01 1.00E+00 22 11.92 6.64E-01 23 11.16 1.33E-01 46 29.29 2.92E-01 77 60.62 1.00E+00 118 80.7 5.50E-03 
Mesoderm development 12 3.18 1.39E-02 13 5.42 5.10E-01 18 5.07 6.64E-04 25 13.3 3.47E-01 37 27.54 1.00E+00 63 36.66 5.67E-03 
Homeostasis 3 1.13 1.00E+00 8 1.93 2.52E-02 7 1.8 7.66E-02 15 4.73 3.62E-03 18 9.8 3.58E-01 28 13.04 6.23E-03 
Chemosensory perception 1 1.2 1.00E+00 0 2.03 1.00E+00 0 1.9 1.00E+00 0 5 9.59E-01 1 10.35 5.11E-02 2 13.77 1.59E-02 
Stress response 3 1.16 1.00E+00 7 1.97 5.75E-01 5 1.84 1.00E+00 11 4.83 1.00E+00 20 10 4.80E-01 29 13.31 1.78E-02 
Cell motility 8 2.03 1.59E-01 15 3.46 4.18E-04 15 3.24 1.85E-04 17 8.5 9.04E-01 23 17.59 1.00E+00 43 23.42 2.35E-02 
Cholesterol metabolism 1 0.39 1.00E+00 2 0.67 1.00E+00 0 0.63 1.00E+00 12 1.64 3.24E-05 14 3.4 2.57E-03 14 4.52 5.12E-02 
Ligand-mediated signalling 6 2.43 1.00E+00 14 4.14 1.78E-02 8 3.87 1.00E+00 20 10.16 7.53E-01 28 21.04 1.00E+00 47 28.01 1.15E-01 
Amino acid activation 0 0.22 1.00E+00 3 0.37 9.46E-01 1 0.35 1.00E+00 7 0.92 6.91E-03 5 1.9 1.00E+00 9 2.53 1.77E-01 
MAPKKK cascade 9 1.05 2.64E-04 7 1.78 4.56E-01 5 1.67 1.00E+00 8 4.37 1.00E+00 11 9.05 1.00E+00 24 12.04 2.93E-01 
Ion transport 5 3.56 1.00E+00 13 6.06 1.00E+00 15 5.67 9.75E-02 32 14.87 8.82E-03 38 30.79 1.00E+00 60 40.98 4.08E-01 
Blood clotting 5 0.53 3.13E-02 4 0.9 1.00E+00 6 0.85 3.44E-02 7 2.22 1.00E+00 6 4.6 1.00E+00 14 6.12 6.13E-01 
Amino acid biosynthesis 1 0.27 1.00E+00 3 0.45 1.00E+00 5 0.42 1.12E-02 6 1.11 1.45E-01 6 2.3 1.00E+00 9 3.06 6.20E-01 
Amino acid transport 2 0.27 1.00E+00 4 0.46 1.87E-01 4 0.43 1.47E-01 7 1.13 2.54E-02 8 2.35 4.21E-01 9 3.13 7.11E-01 
Cell adhesion 9 3.6 3.28E-01 8 6.11 1.00E+00 15 5.72 2.30E-02 21 15.02 1.00E+00 36 31.09 1.00E+00 53 41.38 1.00E+00 
Muscle contraction 2 1.14 1.00E+00 5 1.95 1.00E+00 8 1.82 1.75E-02 7 4.78 1.00E+00 9 9.9 1.00E+00 18 13.17 1.00E+00 
Other homeostasis activities 1 0.4 1.00E+00 1 0.68 1.00E+00 2 0.63 1.00E+00 8 1.67 4.79E-02 4 3.45 1.00E+00 10 4.59 1.00E+00 
Table 10: Host cellular biological processes affected during JFH-1 infection of Huh7 cells. 
Panther analysis was performed as described (2.5.7) using all genes which met the cut-off of a 2-fold change, and the Bonferroni correction was employed for 
stringent calculation of p-values.  Processes identified as having an enriched number of genes (with a p-value cut-off of 0.05), represented in the microarray 
data compared with the expected random number of genes based on the whole human genome, for at least one timepoint, are given.  Given for each 
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timepoint and biological process are the observed number of genes regulated during infection, the expected number of genes based on the proportion of 
genes involved in that process in the entire human genome, and finally a p-value representing the probability that the difference between observed and 
expected numbers is not significant. 
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The downregulation of metallothionein genes observed in infected Huh7.5 cells was also observed in 
Huh7 cells (Figure 24). In Huh7 cells there was more fluctuation in the regulation, including a lesser 
fold change at 48 hours post infection. 
 
 
Figure 24: Fold change in expression of Metallothioneins during JFH-1 infection of Huh7 cells. 
Metallothioneins were seen to be down regulated in infected Huh7.5 cells, and can also be seen 
to be downregulated here in infected Huh7 cells.  In Huh7 cells a trend of downregulation of 
metallothioneins is seen across all timepoints, but with a rebound towards normal levels at 48 
hours.  Where a gene is represented on the microarray by more than one probe set, data were 
averaged and displayed with error bars.  The data set MT1 corresponds to a probe set which 
recognises all MT1 isoforms 
 
Genes observed to be regulated by more than two fold at 48 hours post-infection have been 
presented in heatmap form.  Figure 25, Figure 26, Figure 27, Figure 28, Figure 29 and Figure 30 
present these genes grouped by biological processes identified in the Panther analysis of microarray 
data (Table 10, Figure 21).  As a visual aid, heatmap data is presented on a log2 scale.  Upregulated 
genes are shown in red and downregulated genes are shown in green.  Maximal colour intensity is 
assigned to genes with a relative expression change of 3 fold or higher (1.5 fold on the log2 scale).  
The biological processes displayed fall into the general categories of apoptosis, cell cycle regulation, 
protein synthesis, cytoskeleton, intracellular transport, immunity, oxidative stress, and lipid 
metabolism. 
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Figure 25: Host biological processes regulated during JFH-1 infection of Huh7 cells (apoptosis and 
cell cycle).  
Genes identified to be regulated during JFH-1 infection of Huh7 cells compared to mock infected 
Huh7 cells are presented in heatmap form with each heatmap corresponding to biological 
processes identified using Panther analysis.  Heatmaps were generated using MeV software and 
genes are clustered within heatmaps by Pearson correlation.  Genes shown in red were 
upregulated and genes shown in green were downregulated, displayed on a log2 fold change 
scale.  Genes are identified by their gene symbol, and relative expression levels are presented for 
6, 12, 18, 24 and 48 hours post-infection. 
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Figure 26: Host biological processes regulated during JFH-1 infection of Huh7 cells (protein 
synthesis). 
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Figure 27: Host biological processes regulated during JFH-1 infection of Huh7 cells (cytoskeleton 
and transport). 
 
 
Figure 28: Host biological processes regulated during JFH-1 infection of Huh7 cells (immunity). 
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Figure 29: Host biological processes regulated during JFH-1 infection of Huh7 cells (lipid 
metabolism). 
 
 
 
Figure 30: Host biological processes regulated during JFH-1 infection of Huh7 cells (oxidative 
stress and detoxification). 
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An extensive validation of the microarray expression findings was performed.  Using infection 
experiments separate from the microarray experiment, a wide range of genes were tested for 
expression changes by qPCR.  The genes chosen were observed to have significant expression 
changes with infection at the 48 hour post-infection timepoint.  Genes chosen were those involved 
in the biological processes identified to be affected during infection.  Gene expression changes are 
presented in Figure 31.  Figure 31A shows the expression levels of genes involved in oxidative stress 
and it includes detoxification genes CYP1A1 and CYP1B1.  Figure 31B shows genes involved in lipid 
metabolism functions including cholesterol synthesis (EBP, FDFT1, HMGCR, MVD, SQLE), sphingolipid 
synthesis (SGMS2, SGPL1, SGPP1, SPTLC1) and fatty acid metabolism (ACLY, ACSL3, FABP3, SREBF1).  
Figure 31C also shows genes involved in fatty acid metabolism (PPARC1A, ELOVL4, ELOVL7) including 
TXNIP.  Figure 31D shows genes involved in immunity including cytokines (CXCL2, CXCL16, CXCR4) 
and genes involved in interferon signalling (IRF9. MX1, SOCS2, SOCS3).  Figure 31E shows genes 
involved in the cytoskeleton (ABLIM3) and vesicle trafficking (RAB27B, RAB37, RAB40B).  Figure 31F 
shows expression levels of metallothioneins.  It can be seen that the vast majority of qPCR data 
agreed with the microarray data.  The correlation between data obtained from the two techniques 
confirms the validity of using microarray to study expression level changes, the fact that gene 
expression level changes do occur during HCV infection, and that these changes are reproducible 
between infections. 
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Figure 31: Validation by PCR of gene expression levels in Huh7 cells infected with JFH-1.  
Huh7 cells were infected with JFH-1 at an MOI of 3 or mock infected for 48 hours.  Data are 
presented as in previous figures.  PCR quantification results were obtained from duplicate 
infections in three separate experiments or triplicate infections in two separate experiments.  
The majority of gene expression levels determined by PCR and microarray were observed to be 
in agreement.  Genes are grouped by biological processes: oxidative stress (A), lipid metabolism 
(B and C), immunity (D), cytoskeleton and intracellular transport (E), metallothioneins (F). 
  
A 
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3.3.4 Host Cell Biological Processes Altered during HCV Infection 
 
The analysis of gene expression in HCV infected cells has identified several biological processes of 
relevance to the HCV lifecycle to have a significant number of genes regulated during infection.  
These include lipid metabolism, immune responses, intracellular transport, oxidative stress and 
apoptosis.  These processes and specific genes involved are discussed in the following sections with 
reference to their potential impact on the HCV lifecycle and the pathology of disease in humans.   
 
The use of microarray technology to perform large scale expression studies has become increasingly 
common, and is usually observed to return reliable data.  In order to validate the data obtained from 
the microarray studies described in the work presented here, quantitative PCR was performed.  
Selected genes were quantified by qRT-PCR using cellular RNA material from separate infection 
experiments.  Most quantitative PCR data agreed with microarray data in the direction of regulation 
of genes during infection.  It was observed in many cases that the fold changes in gene expression 
seen by qPCR were not exactly the same as the microarray results.  A general pattern was observed 
between qPCR and microarray data.  In the case of genes that increased in expression with infection, 
qPCR generally indicated a higher expression level with infection.  For genes that decreased in 
expression with infection, qPCR generally indicated a lower expression level with infection.  The 
pattern observed, of larger expression level changes when measured by qPCR, may indicate that this 
technique is more sensitive than microarray technology in identifying gene expression changes.  This 
phenomenon has been observed in previous work by other groups410-411. 
 
A recently performed study investigated gene expression changes in Huh7.5 cells infected with a 
J6/JFH-1 chimaera411, providing a useful comparison study for the data described here.  Whole 
genome microarrays were used to identify gene expression changes at 24, 48, 72, 96 and 120 hours 
post-infection.  This study used a MOI of 1 to infect cells, lower than was used in the work presented 
here.   This study also demonstrated that the expression of a large number of host genes was altered 
during infection, with 860 genes differentially regulated at 72 hours post infection.  This study also 
differed from the work presented here by using cells treated with UV-inactivated virus as a control 
to remove any gene expression changes induced in cells by the binding of virus during the initial 
infection event.  However, few genes were observed to be regulated by treatment of Huh7.5 cells 
with the UV-inactivated HCV.  This may either be due to the amount of virus not being sufficient to 
induce anti-viral responses, or that the viral detection mechanisms (including RIG-I and TLR3) are 
impaired in Huh7.5 cells.  This study highlights the observations of gene expression changes in 
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apoptotic, cell cycle and oxidative stress processes.  There is good correlation between these 
observations and the work presented here.  Three areas of interacting components involved in 
oxidative stress responses were described, p53 signalling, NRF2-mediated oxidative stress response, 
and TGFβ signalling.  There is correlation in gene expression between their study and the work 
presented here for the following, upregulated, genes involved in p53 signalling: TP53BP, GADD45A, 
GADD45B, MYC, PMAIP, JMY, JUN and SIRT1.  For TGFβ signalling correlation is also generally 
upregulated and seen in genes LTBP1, NEDD9, SKIL, NHBA, BMP2, KLF10, JUN and JUNB.  For NRF2 
signalling correlation is seen in genes MAFF, JUN, JUNB, MAFK (all upregulated), MAP2K6, EPHX1 and 
CAT (all downregulated).  The gene expression data from both this study and the work presented 
here support each other in the indication that there are changes in both cell cycle and oxidative 
stress factors occurring in HCV infected cells, potentially leading to apoptosis and providing a 
possible cause for liver damage observed in HCV infected patients.   
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3.3.4.1 Immune Modulation 
 
The work presented here has shown genes involved in immunity and defence to be regulated during 
HCV infection.   
 
There was an observed increase in expression of cytokines and chemokines during infection.  HCV 
infected patients can develop inflammation in the liver. The observed increase in expression of 
cytokines and chemokines in the work presented here correlates with previous studies indicating a 
role for infected hepatocytes as sources of inflammation in the liver411.  The CXCL chemokines were 
generally observed to be upregulated, in particular CXCL 1, 2, 3, 5, 6 and 8.  These chemokines bind 
CXCR1 and CXCR2 receptors which have been shown to induce hepatocyte proliferation and liver 
regeneration412, as well as being able to stimulate infiltration and respiration of neutrophils and 
monocytes413.  The chemokines were similarly upregulated in Huh7 and Huh7.5 cells (including in the 
study performed using J6/JFH-1 in Huh7 cells411), which implies that the regulation of this response is 
probably not initiated through RIG-I signalling.  Chemokines and receptors (including CXCL11 and 
CXCR3) have previously been observed to be upregulated in HCV infected humans and 
chimpanzees398.  In expression studies performed in chimpanzees329,379-380, a variety of interferon 
stimulated genes were observed to be upregulated.  This was not observed to such an extent in this 
work.  This may reflect the more complicated immune situation in vivo, compared to cell culture, 
which includes other cell types and aspects of the adaptive immune response. 
 
There was an observed increase in the expression of SOCS genes during HCV infection.  SOCS genes 
are negative regulators of cytokine responses414.  Upregulation of SOCS genes has been reported in 
previous studies411,415, and has been implicated as a possible reason for interferon resistance in some 
HCV patients416. 
 
Acute phase response genes were upregulated during infection, particularly in Huh7.5 cells.  These 
included SAA1, PLG and complement factors. Acute phase genes such as these are produced by the 
liver in response to infection and cytokine stimulation.  Complement factors were also observed to 
be regulated during HCV infection.  Factors MASP1 and MBL2 were observed to be increased in 
expression during infection.  These genes can induce fibrosis, and may provide a mechanism that 
contributes to the fibrosis observed in the liver of HCV infected patients417-418.  Complement factors 
CFH and CFI were observed to be upregulated during HCV infection (more highly in Huh7.5 than 
Huh7).  These are negative regulators of the complement system419, and as such may be in part 
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responsible for a mechanism to allow virus to escape host defences.  Flaviviruses including West Nile 
virus and Dengue virus have been observed to target complement factors with the effect of 
inhibiting complement activation and therefore evading complement control of infection420-421.  
However, siRNA silencing of CFH and CFI did not inhibit HCV replication in cell culture, implying that 
complement is not a major mechanism for the host to defend against HCV infection in cell culture. 
 
 
3.3.4.2 Lipid Metabolism 
 
Lipids have been shown to play an important role in the HCV lifecycle.  As described in the 
introduction, HCV requires an envelope made of lipid membrane, endocytotic pathways reliant on 
lipids are used for entry into the cell, replication occurs on membranous structure in the cell, 
assembly of the virus requires the presence of lipid droplets, and lipid secretion pathways are 
required for exit from infected cells. 
 
The work presented here has identified that genes involved in lipid metabolism are regulated during 
HCV infection.  Analysis of microarray data showed lipid, fatty acid and steroid metabolism genes to 
be regulated during HCV infection (Figure 21, Table 6, Figure 29, and Table 10).  The regulation of 
several of these genes was confirmed by qRT-PCR (Figure 22, Figure 31B and C).  Genes involved in 
the synthesis of sphingolipids, phospholipids and fatty acids were generally observed to be 
upregulated during HCV infection.  This is consistent with the requirement of these molecules for the 
efficient replication of HCV.  Previous studies have also shown the upregulation of expression of 
genes involved in sphingolipid and fatty acid metabolism.  This has been demonstrated in a variety of 
systems including in replicon models382, in vivo380, and by expression of core protein422.  This implies 
that transcriptional regulation of lipid metabolism is induced by HCV infection, and may be a result 
of action of the HCV proteins.  A key gene in the production of sphingolipids, SPTLC3, was observed 
to be upregulated during infection, and siRNA silencing of the gene was found to impair efficient 
HCV replication (Figure 40E).  This gene is discussed in more detail in a subsequent section (3.5.2.3). 
 
A common factor in the regulation of several of the lipid metabolism genes observed to be 
upregulated during HCV infection is the transcription factor PPARα.  Previous studies have identified 
hepatic lipid metabolism target genes of PPARα, including CPT1A, ACSL1, ADFP, MBL2 and 
CYP1A1423.  The siRNA silencing of two genes involved in PPARα signalling, TXNIP and CYP1A1, was 
shown, in the work presented here, to inhibit efficient HCV replication (Figure 40B and F).  TXNIP has 
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been shown to be a negative regulator of PPARα (and SREBP)424.  A study has shown that agonists of 
PPARα can suppress HCV replication382, suggesting that TXNIP suppression of PPARα could be 
important in ensuring efficient HCV replication.  The silencing of a glucose responsive transcription 
factor capable of inducing TXNIP, MXLIPL, was recently identified as reducing HCV replication425, 
further indicating the possible importance of TXNIP to efficient HCV replication.   CYP1A1 is involved 
in both PPARα and AHR pathways, and activation of CYP1A1 through either pathway can control lipid 
metabolism events423,426-427.  These two genes, TXNIP and CYP1A1, are discussed in more detail in 
following sections (3.5.2.4 and 3.5.2.2). 
 
Genes involved in the synthesis of cholesterol were also observed to be regulated during HCV 
infection (Figure 29).  There was a general trend for these genes to be down regulated.  Reduced 
cholesterol levels have been observed in patient serum428.  It is also possible for other RNA viruses to 
reduce the levels of cholesterol synthesis, such as the Measles virus429.  A study performed using an 
HCV replicon system found that cholesterol synthesis genes were increased in expression levels382.  
This may be a feature of the reduced interferon response in the Huh7.5 cells used in this replicon 
study, as interferon can downregulate expression of miR122, which in turn would prevent miR122 
from upregulating cholesterol synthesis genes.  Further discussion of the involvement of miR122 in 
gene expression regulation and the HCV lifecycle is given in a following section (3.3.4.2.1).   
 
Since performing these experiments it has been shown that expression of genes involved in 
cholesterol synthesis are upregulated in JFH-1 infected cells at 72 hours post-infection (personal 
communication from M. J. McGarvey).  Genes have been observed to be expressed at levels 
between 1.5- and 5-fold higher in JFH-1 infected cells than in mock infected cells.  This indicates a 
biphasic mechanism of control of gene expression during HCV infection.  It appears that HCV may 
play a role in upregulation of the lipid metabolism genes essential for the efficient replication of 
HCV.  However before this can happen, the expression of these genes is downregulated possibly due 
to immune responses and competition from miR122 as discussed in the following section on miR122.   
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3.3.4.2.1 Micro RNA 122 (miR122) 
 
As has already been established, miR122 is known to be required for efficient replication of HCV92.  
There are a number of cellular genes already known to be regulated by miR122.  Of particular 
interest to the study of HCV, miR122 has been shown to regulate cholesterol production.  Inhibition 
of miR122 by use of antisense oligonucleotide has been shown to reduce plasma cholesterol 
levels430-431.  This study demonstrated by microarray analysis that a number of genes involved in the 
production of cholesterol were down regulated during infection of Huh7 cells with JFH-1 up to 48 
hours post-infection.  This may represent competition for miR122 by the abundant HCV genomes, 
resulting in less miR122 available for genes involved in cholesterol synthesis.  This state is unlikely to 
continue as cholesterol is required for the HCV lifecycle, in particular for composition of the 
lipoprotein particles that HCV forms as it is released from the cell, which form the most infectious 
particles.  It is known that expression of miR122 itself is downregulated by an interferon-β 
response431-432, so an anti-viral response by the host cell may also lead to conditions where there is 
less miR122 available. 
 
The micro RNA miR122 is also known to regulate other cellular genes, and the microarray data was 
analysed for transcriptional changes in these genes.  The cationic amino acid transporter SLC7A1 is 
known to be regulated by miR122433-434, with SLC7A1 levels decreasing as miR122 increases.  In Huh7 
cells, SLC7A1 was upregulated 2-fold at 12 hours and over 4-fold at 24 and 48 hours, Implying that, if 
miR122 was responsible for the expression changes, miR122 levels were dropping.  This could 
potentially be due to sequestration of miR122 by HCV.  N-myc downstream regulated 3 (NDRG3) was 
not observed to be regulated by at least 2-fold during JFH-1 infection, but NDRG1, NDRG2, and 
NDRG4 were observed to be downregulated by an average of 2-fold by 24 hours post-infection.  
These genes are involved in cell cycle control, but there is debate as to their precise functions.  It is 
interesting to note that the N-myc gene is often rearranged in tumours occurring in woodchucks 
with woodchuck hepatitis virus.  Aldolase A (ALDOA) was previously shown to be downregulated in 
mouse AML12 cells on treatment with a miR122 antagomir431.  ALDOA is involved in glycolysis, but is 
usually suppressed in human adult liver.  In Huh7 cells it was found to be downregulated by 2-fold at 
48 hours post-infection.   Downregulation of ALDOA in the Huh7 microarray indicated that miR122 
was being sequestered, possibly by HCV.  Cyclin G1 (CCNG1) is known to have its 3’UTR targeted by 
miR122 and they have been shown to have an inverse relationship in some HCC, where CCNG1 is 
upregulated and miR122 is downregulated435, although miR122 is expressed in Huh7 cells.  CCNG1 
was not observed to change in the microarray study during infection of Huh7 with JFH-1, but the 
related gene CCNG2 was observed to be downregulated by 2-fold at 48 hours post-infection, 
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although as CCNG2 is more tightly regulated during the cell cycle and has an additional C-terminal 
PEST protein destabilisation motif, so the downregulation may not be related to miR122.  Overall, 
given the direction of changes in expression of several genes known to be regulated by miR122, 
which are not known to be regulated by other means in common, it is tempting to propose that HCV 
is sequestering the available miR122 for its own replication, leaving little for the cellular genes which 
require miR122 for their own regulation.  This demonstrates a method for HCV to affect the 
expression of host cellular genes, and therefore potentially to induce pathologies in the host.  
However, it is possible that if longer timeframes were studied, it may be found that miR122 levels 
increase to compensate, or that the genes identified use regulation by another method to 
compensate. 
 
The apparent reduction in miR122, as determined by the direction of expression changes of genes it 
regulates, may be explained by another hypothesis.  It is known that miR122 is downregulated by an 
interferon-β response431-432.  It is possible that the immune response induced by the infection of 
Huh7 cells by JFH-1 is causing a decrease in miR122 expression and therefore the expression changes 
observed in the microarray study.  This possibility is tentatively supported by the fact that the 
expression changes seen during infection of Huh7 cells were not seen to the same extent in Huh7.5 
cells. 
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3.3.4.3 Oxidative Stress 
 
Infection with HCV has been shown to induce production of reactive oxygen species (ROS) in 
patients, which leads to oxidative damage of the liver418.  ROS are particularly destructive and can 
attack most molecules, and when ROS inflict damage on host DNA, errors may occur leading to 
cancer.   It has also been suggested that oxidative stress damage can contribute to steatosis in HCV 
patients436.  Analysis of the gene expression data presented here has shown an overall 
downregulation in the expression of genes involved in the oxidative stress response.  This implies 
that any production of ROS due to HCV infection will not be dealt with as efficiently as usual by the 
cell, indicating a further mechanism for oxidative stress damage.  A decrease in expression of 
antioxidant genes such as catalase (CAT) have previously been shown to occur following stimulation 
by cytokines437.  As an increase in cytokine expression was observed in the work presented here, this 
may provide a mechanism for the observed expression pattern.  The metallothionein family of genes 
are involved in antioxidant responses and were strongly downregulated in expression during HCV 
infection.  This gene family is discussed in further detail below.  Other oxidative stress genes were 
observed to be upregulated (Figure 30).  This indicates that there are still some mechanisms in place 
for detection and combat of ROS.   
 
3.3.4.3.1 Metallothionein (MT) 
 
In both the microarray studies on Huh7.5 and Huh7 cells there was a decrease in metallothionein 
expression during JFH-1 infection compared to mock infected cells.  All isoforms of the MT1 family 
and also isoform MT2A were downregulated at all timepoints.  MTs were some of the most strongly 
downregulated of all genes, with expression of MT1E, F and G in JFH-1 infected Huh7.5 cells at only 
20% of the levels in mock infected Huh7.5 cells 48 hours post-infection. 
 
Metallothioneins are low molecular weight proteins, usually of less than 10kDa.   MTs are cysteine 
rich proteins with 20 – 30% cysteine content.  For example, the isoform MT1E has 20 cysteine amino 
acids out of a total 61 amino acids.  MTs have metal-binding capacity.  MTs typically bind 4 Zn2+ ions, 
and can also bind Cu and Cd.  This ability seems to be important to its identified functions of zinc 
regulation and protection against oxidative stress.  MTs can scavenge free radicals in the cell 
preventing damage, especially protecting DNA.  This anti-oxidant function of MT may be particularly 
important in the reduction of damage induced during viral infection.  If this function is removed, as 
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seems to be the case with the downregulation of MT expression observed in this study, it may 
contribute to the damage of cells and initiation of cancer that occurs in HCV infected liver.   
 
MT1 and MT2 are the forms of MT found in the liver, as well as in the kidneys and other peripheral 
epithelial tissues.  Two other forms of MT exist; MT3 which is expressed in the brain, and MT4 which 
is expressed in squamous epithelial cells.  Heavy metals, particularly zinc, copper and cadmium can 
regulate the expression of MTs, with an increased presence of metals inducing MT expression.  
PPARγ agonists have been shown to downregulate the expression of MTs438.  Infection with other 
viruses, including the measles virus439, can affect the expression of MTs. 
 
There is evidence from other studies that MT may be important in HCV infection.  Other studies have 
shown a decrease in MT expression, followed by an increase at later timepoints post-infection than 
were measured in this study411.  This could indicate a disregulation of MT expression during HCV 
infection.  MT1E has been shown to be associated with regulation of cancer cell migration440, but 
most studies indicate tumour suppressor roles for MTs.   MTs have been shown to be down 
regulated in some cancers.  This could be a contributory factor to the emergence of cancer, as the 
MT provides a protective function for DNA against stress damage.  Expression of MT1F by exogenous 
induction in the liver cell line HepG2 has been shown to slow cell growth441.  MT1G deletion has 
been shown to be associated with hepatocellular carcinoma442, and the MT1G gene has been shown 
to be hypermethylated (which usually results in transcriptional silencing) in renal cell carcinoma443.  
MT2A has been implicated as being able to regulate p53 by Zn exchange, and that increased Zn, and 
therefore MT, can help restore wild type p53 function in tumours444.  MT protein expression has also 
been shown to be three times lower in the liver of patients infected with HCV, compared to 
uninfected controls445. 
 
Metallothioneins have been identified to play a role in protection of cells from oxidative stress and 
seem to be tumour suppressive.  These features may be important in the context of HCV infection.  If 
MT levels are indeed reduced in HCV infected liver, then this may partially account for oxidative 
stress damage and eventual progression to cancer.  As MT expression has been shown to be 
regulated by Zn, it may be advantageous to have HCV patients take Zn supplements to their diet.  It 
has been previously shown that Zn can increase the therapeutic response to IFN in HCV patients446-
447.  In these studies, Zn was given as 300mg/day of zinc sulphate, corresponding to 68mg of Zn.  MT 
can be induced by IFN, but if Zn levels are depleted MT will not be induced448, indicating another 
reason to maintain Zn in HCV patients.  
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3.3.4.4 Protein Synthesis 
 
During infection of Huh7 cells with HCV JFH-1, genes involved in protein synthesis were observed to 
be upregulated.  These genes included those involved in protein synthesis, turnover, post-
translational modification, and tRNA synthesis.  This effect of HCV on gene expression has not been 
shown before.  However, other viruses have been shown to induce similar changes in the host.  HIV 
has been show to induce protein synthesis and use host protein sulphation processes for 
modification of viral proteins449-450.   
 
The host gene MGAM was observed to be upregulated during infection with HCV.  This gene is a 
glucosidase known to be required for maturation of HCV structural proteins.  It is involved in the 
processing of N-linked oligosaccharides on envelope proteins451.  The potential importance of MGAM 
for HCV replication is illustrated by the clinical trials which are underway to test the efficacy and 
safety of a MGAM inhibitor in combination therapy for treatment of HCV452. 
 
 
 
3.3.4.5 Intracellular Transport 
 
The work presented here has shown that genes involved in the regulation of vesicle trafficking 
between ER, Golgi and plasma membranes were regulated during HCV infection.  This indicates a 
potential role for these genes in viral processes including entry, exit and construction of replication 
complexes.  Host proteins which regulate intracellular transport have been shown to be important in 
the HCV lifecycle175,453-454.     
 
Genes coding for proteins involved in endocytosis (e.g. SNX12, SNX16) were observed to be 
upregulated during infection.  HCV is known to enter the cell through clathrin-mediated endocytosis, 
and regulation of expression of these genes may aid HCV entry of cells.  Genes RAN6B and RAB33B, 
involved in retrograde transport from the Golgi to the ER, were observed to be increased in 
expression levels during HCV infection.  These genes may aid in the accumulation of viral proteins 
required for formation of the replication complex455-456.  RAB33B is also involved in autophagy, and 
has been shown to be important for HCV replication and assembly457-458.  Increased expression of 
RAB27A, RAB27B and RAB37 was observed during HCV infection.  These genes are expressed in cells 
which require high levels of secretion459-460, indicating that these genes may facilitate viral exit. 
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3.3.4.6 Apoptosis and Cell Proliferation 
 
Genes involved in the control of apoptosis and cellular proliferation were observed to be regulated 
during HCV infection.  Other studies have found increases in pro-apoptotic gene expression, and 
regulation of cell cycle411,461.  It has been shown that HCV replication is dependent on the cell cycle, 
and that most efficient replication occurs in S phase411.  An increase in the proportion of cultured 
cells in S phase has been observed after infection with HCV by others411 (and in data not shown).  
The combination of data presented here and data from recent studies indicates that the liver 
damage seen in patients due to hepatocyte death may be due not only to the action of cytotoxic 
immune cells, but also due to apoptosis of cells induced by viral infection.   
 
Phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1), also known as Noxa, is a protein of 
103 amino acids.  It is a member of the Bcl-2 protein family, and contains a BH3 domain.  PMAIP1 
can be induced by a number of signals.  These include cellular stress responses such as hypoxia 
(mediated through Hif1a) and DNA damage (mediated through p53).  PMAIP1 can then induce 
apoptosis by targeting the pro-survival proteins MCL1/A1 for degradation, thus facilitating the 
activation of Bax/Bak proteins, which induce apoptosis associated with mitochondrial disfunction462.   
PMAIP1 was upregulated in JFH-1 infected Huh7 cells, but not Huh7.5 cells, at the 48 hour post 
infection timepoint.  This could indicate that PMAIP1 is part of a cellular response to HCV infection in 
Huh7 cells of which Huh7.5 cells are not capable.   
 
PMAIP1 transcription and expression can be 
activated by diverse apoptotic or mitogenic 
signals in a p53-dependent and p53-independent 
manner (Figure 32).  PMAIP1 exerts its pro-
apoptotic function mainly by neutralizing the 
pro-survival Bcl2 proteins Mcl1/A1, facilitating 
activation of Bax and/or Bak proteins 
 
 
 
 
 
Figure 32: Induction and action of PMAIP1462.  
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3.4 Inhibition of JFH-1 Replication by Anti-Viral Inhibitors 
 
The microarray analysis comparing gene expression in RNA isolated from infected and mock infected 
cells identified the genes altered in expression during JFH-1 infection.  By inhibiting the replication of 
JFH-1, the differentiation can be made between genes which are altered in expression due to a 
stimulus during the initial stages of infection, and those which either require the presence of actively 
replicating HCV or are a response to a later stage of infection.   
 
A number of anti-HCV molecules have been developed with the intention of use in patients, but 
have ultimately failed clinical trials.  BILN2061 (Figure 33A) is an HCV protease inhibitor which has 
shown good anti-viral activity but had to be withdrawn from clinical trials after inducing side-effects.  
BILN2061 is very effective at inhibiting HCV in cell culture models.  BILN2061 has an EC50 of 4nM in 
genotype 1 based replicon cells models, and 250nM in JFH-1 cell culture.  NM107 (Figure 33B) is a 2’-
C-methyl cytidine analogue HCV polymerase inhibitor which showed strong inhibition of HCV and 
other flaviviruses.  In clinical trials NM107 is the active constituent of the pro-drug NM283.  NM107 
also has EC50 of around 4µM in genotype 1 replicon cells models, and 12µM in JFH-1 cell culture.     
 
 
 
 
Figure 33: Structures of anti-viral molecules. 
A BILN2061, an HCV protease inhibitor64 (molecular weight 776.919) B NM107, an HCV 
polymerase inhibitor74 (molecular weight 257.24) 
 
Literature suggested EC50 values of around 4nM for BILN2061 and 4µM for NM107 in genotype 1 
replicon cell culture, and EC50 values between 4 and 10 times higher in JFH-1 cell culture.  To 
A B 
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establish the EC50s in the JFH-1 infected Huh7 cells and obtain a working concentration for each 
inhibitor, dose responses were generated (Figure 34).    
 
 
 
Figure 34: JFH-1 dose responses to anti-viral treatment. 
Huh7 cells were infected with JFH-1 at an MOI of 3.  At 12 hours post infection, cells were 
treated with anti-HCV inhibitors.  At 48 hours post-infection, intracellular RNA was isolated and 
JFH-1 RNA levels quantified by qRT-PCR.  Conditions were performed in triplicate, and two 
experiments were performed.  A Dose response to BILN2061 B Dose response to NM107 
 
BILN2061 was found to have anti-JFH-1 activity at low µM concentrations, and activity increased at 
concentrations tested, up to 20µM.  NM107 was not as potent as BILN2061, especially at low µM 
concentrations, but a dose of 50µM could induce a 2-log drop in intracellular JFH-1 RNA titre.  Cell 
culture studies employing a compound typically use working concentrations of 10-50x EC50, 
depending on efficacy and toxicity.   
 
Before performing the microarray analysis of Huh7 cells infected with JFH-1 and treated with anti-
viral compounds, the effect of anti-viral treatment on cell viability was assessed.  Treatment of cells 
with a cytotoxic compound could affect the expression of host cell genes in a non-HCV dependent 
manner.   
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Figure 35: Cellular toxicity of anti-viral compounds. 
Huh7 cells were infected with JFH-1 at an MOI of 3, or mock infected.  At 12 hours post infection, 
cells were treated with anti-HCV inhibitors.  At 48 hours post-infection, methyl violet staining of 
cells was performed and absorbance at 490nm was read to give an assessment of   the survival 
of cells exposed to the anti-viral compounds.  Four replicates were performed per condition. 
 
 
The toxicity of anti-viral compounds on Huh7 cells was tested by methyl violet assay.  The 
polymerase inhibitor NM107 was shown not to have a significant effect on the viability of Huh7 cells 
at any concentration tested, up to 100µM as seen in Figure 35B.  The protease inhibitor BILN2061 
was shown to be decrease cell viability in mock infected cells at concentrations of 15µM and greater 
(Figure 35A).   Mock infected cells were nearly all killed by treatment with 100µM BILN2061.  Cells 
infected with JFH-1 were to a large extent protected from the cytotoxic effect seen in the mock 
infected cells.  This indicated that BILN2061 probably has some anti-protease activity on essential 
host cell proteases.  A small effect on cell viability was seen at BILN2061 concentrations of 20µM and 
greater in cells infected with JFH-1.   
 
The dose response data described in Figure 34 indicated that treatment with NM107 at a 
concentration of 50µM gave the greatest knockdown of intracellular JFH-1 RNA achievable.  The 
mean intracellular JFH-1 RNA concentration in cells treated with 100µM NM107 was slightly lower 
than that in cells treated with 50µM, but this difference was not significant (determined by t-test in 
GraphPad Prism).  An NM107 dose of 50µM was found not to be cytotoxic (Figure 35B), so this was 
selected as the dose at which to perform microarray analysis. 
The dose response data described in Figure 34A indicated that treatment with BILN2061 at a 
concentration of 20µM gave the greatest knockdown of intracellular JFH-1 RNA achievable.  A 
BILN2061 dose of 20µM was found to be slightly cytotoxic (Figure 35A) in mock infected cells.  A 
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dose of 10µM was seen not to be toxic, and gave a strong knockdown of intracellular JFH-1 RNA, so 
this was selected as the dose at which to perform microarray analysis. 
 
Gene expression changes between anti-viral treated samples and infected samples were calculated 
using Array Studio as before.  No genes were observed to change in expression significantly (|FC|≥2, 
p≤0.05) on analysis of the comparison of NM107-treated infected samples with mock-treated 
infected samples.  Eight probe sets were observed to change in expression significantly (|FC|≥2, 
p≤0.05) on analysis of the comparison of BILN2061-treated infected samples with mock-treated 
infected samples, as can be seen in Table 11. 
 
 
Gene 
Symbol 
Probe Set ID 
Fold Change 
Infected, BILN2061-treated vs 
Infected, mock-treated 
CYP1B1 
202435_s_at 2.68 
202436_s_at 2.62 
202437_s_at 3.16 
MT1E 212859_x_at 2.07 
MT1F 213629_x_at 2.04 
MT1M 217546_at 2.5 
Table 11: Effect of BILN2061 treatment on gene expression in JFH-1 infected Huh7 cells.  
Host cell gene expression changes between JFH-1 infected Huh7 cells treated with BILN2061, and 
JFH-1 infected Huh7 cells.  Expression changes were observed in CYP1B1 and three 
metallothionein family members 
 
 
Three probe sets observed to indicate a change in expression levels corresponded to one gene, 
CYP1B1 (cytochrome P450 1B1).  In the analysis of infected Huh7 cells compared to mock infected 
Huh7 cells, CYP1B1 was one of the most highly up-regulated genes during infection.  Three probe 
sets identified belonged to members of the metallothionein gene family.  Metallothioneins were 
identified in both Huh7 cells and Huh7.5 cells as a gene family highly down-regulated during JFH-1 
infection.  The inhibition of HCV replication by BILN2061 may have also removed the stimulus that 
was inhibiting expression of metallothionein genes.  Comparison of infected and mock infected Huh7 
cells indicated that metallothioneins were expressed at lower levels in infected cells (Figure 24, 
Figure 30).  The BILN2061-treated infected Huh7 cells expressed metallothioneins at double the level 
seen in mock treated infected Huh7 cells.  This may indicate a return to normal expression levels for 
the metallothioneins.   
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3.5 Host Genes with a Role in HCV Replication 
 
The microarray analysis of Huh7 and Huh7.5 cells infected with JFH-1 identified host genes that were 
regulated during HCV infection.  It was hypothesised that some of the genes seen to be regulated 
during HCV infection may be changing in expression level because it confers an advantage on HCV 
replication efficiency. 
 
3.5.1 Identification of Host Genes with a Role in HCV Replication 
 
In order to identify genes which have an effect on HCV replication, a selection of genes were 
targeted for knockdown by RNA interference.  Genes were selected based on the magnitude of fold 
change seen in their expression during HCV infection, and genes were selected based on the 
existence of evidence pointing to potential functional roles in the cell which may enhance efficient 
HCV replication.   
 
In this part of the study a modified chimaeric HCV was used in addition to the wild type JFH-1.  
Jc1p7FLuc2A (hereon referred to as Jc1) is based on the chimaera of genotype 2a isolates J6 and JFH-
1.  As shown in the introduction (Figure 8) and here in Figure 36, the chimaeric genome Jc1 is formed 
from the structural region of J6 and the non-structural regions of JFH-1.  This construct also 
incorporates a luciferase reporter gene, and a Foot and Mouth Disease virus (FMDV) 2A gene for 
autocleavage of the luciferase from the polyprotein.  The advantage of using this reporter virus is 
that a large number of experiments can be performed using a simple luciferase reporter assay, 
rather than performing the multiple steps required for measurement of viral RNA by quantitative 
PCR.   
 
 
Figure 36: HCV constructs used to identify host genes with a role in HCV replication.  
A Representation of the JFH-1 genome.  B Representation of the Jc1 genome.  The genetic 
elements C, E1, E2, p7 and NS2 (up to C3 position as shown in Figure 8) are from the J6 isolate.  A 
firefly luciferase gene (FLuc) is positioned after p7, and an FMDV 2A gene immediately after FLuc 
to allow for autocleavage of FLuc from the expressed polyprotein.  All other genetic elements are 
from isolate JFH-1. 
A 
B 
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Gene 
Probe 
Set 
Huh7 
JFH-1 vs Mock Fold Change in Expression 
Huh7.5 
JFH-1 vs Mock Fold Change in Expression 
Functions 
  
6 hr 12 hr 18 hr 24 hr 48 hr 6 hr 12 hr 18 hr 24 hr 48 hr 
 
ABLIM3 
205730
_s_at 
1.43 1.58 2.1 1.63 -1.37 -1.64 -1.32 1.14 1.68 2.84 
cytoskeleton 
organisation 
CFH 
213800
_at 
1.48 1.47 1.65 1.46 1.51 -1.28 2.68 5.02 2.55 2.14 
complement 
215388
_s_at 
1.44 1.37 1.19 1.17 1.03 1.62 2.36 2.49 1.2 1.33 
CFI 
203854
_at 
1.27 1.19 1.49 1.16 1.53 1.86 2.24 2.79 2.11 2.02 
complement 
155556
4_a_at 
1.28 1.21 1.49 1.33 1.34 1.98 2.51 2.25 2.01 1.77 
CYP1A1 
205749
_at 
2.17 4.18 2.28 5.19 2.58 1.44 1.5 1.82 1.45 2.5 
cytochrome 
p450 
MAT1A 
205813
_s_at 
1.26 1.05 1.12 1.05 -1.03 4.69 1.96 4.35 1.71 1.57 
makes methyl 
donor (SAMe) 
MT1F 
213629
_x_at 
-1.7 -2.19 -1.24 -2.45 -1.46 -1.43 -2.53 -3.03 -3.93 -5.35 
oxidative stress, 
metal regulation 217165
_x_at 
-1.69 -2.28 -1.18 -2.34 -1.39 -1.58 -2.54 -3.28 -4.14 -5.19 
MT1G 
204745
_x_at 
-1.49 -1.54 -1.09 -1.87 -1.25 -1.34 -2.15 -2.9 -3.6 -4.62 
oxidative stress, 
metal regulation 210472
_at 
-1.14 -1.14 -1.02 -1.03 -1.03 1.38 1.17 -1.14 -1.04 -1.19 
MT2A 
212185
_x_at 
-1.49 -2.06 -1.04 -2.24 -1.25 -1.28 -1.77 -1.87 -2.47 -2.85 
oxidative stress, 
metal regulation 
RAB40B 
204547
_at 
1.31 -1.05 -1.1 -2.07 -1.31 3.3 1.78 1.13 1.07 1.81 
vesicle transport 
217597
_x_at 
-1.13 -1.02 1.22 -1.11 -1.2 1.59 1.1 1.28 -1.32 1.28 
RAB27B 
207017
_at 
1.47 1.22 1.32 1.25 1.25 1.24 1.2 1.07 -1.11 1.21 
vesicle transport 
207018
_s_at 
1.45 -1.01 1.48 1.43 1.46 -1.06 1.34 1.27 -1.02 -1.33 
228708
_at 
2.56 2.5 3.43 2.43 5.19 3.13 3.62 2.52 2.08 1.59 
RAB37 
228113
_at 
1.53 1.26 1.63 2.07 2.5 1.71 1.04 1.35 1.24 1.74 
vesicle transport 
244124
_at 
1.06 -1.32 1.02 -1.08 -1.14 1.31 -1.05 1.55 1.23 1.08 
SLC27A2 
205768
_s_at 
1.21 -1.02 1.35 -1.09 -1.41 3.47 2.53 2.84 1.59 1.29 
lipid metabolism 
205769
_at 
1.17 1.29 1.18 1.04 -1.29 3.8 2.33 2.74 1.67 1.39 
SOCS3 
206359
_at 
-1.05 -1.07 1.41 1.11 1.41 1.09 1.19 1.09 1.04 1.2 
cytokine 
signalling 
206360
_s_at 
1.07 -1.1 -1.04 1.08 -1.04 1.3 -1.11 1.32 1.06 -1.26 
214105
_at 
1.07 -1.07 1.18 -1.07 -1.11 1.18 -1.06 1.12 1.11 1.19 
227697
_at 
1.3 1.36 2.2 1.86 2.92 1.03 1.4 1.33 1.15 1.9 
SPTLC3 
220456
_at 
1.28 1.01 -1.17 1.04 -1.3 2.44 1.51 1.29 1.2 -1.17 
sphingolipid 
synthesis 227752
_at 
2.14 1.57 1.12 -2.04 -3.05 3.26 1.79 1.96 1.42 -1.04 
TXNIP 
201008
_s_at 
1.3 8.39 5.26 20.15 15.32 1.24 1.92 1.66 1.22 3.18 oxidative stress, 
apoptosis, cell 
proliferation, 
sugar 
metabolism 
201009
_s_at 
1.15 6.56 4.99 13.55 14.3 1.2 1.39 1.38 1.55 2.14 
201010
_s_at 
1.38 9.3 6.03 20.51 21.96 2.05 1.52 2.6 1.41 3.03 
Table 12: Expression level changes, during JFH-1 infection of Huh7 and Huh7.5 cells, of genes 
selected for RNA interference studies. 
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This table presents fold change data from both Huh7 and Huh7.5 microarray studies for every 
probe set of the genes selected.  Also presented are biological functions and potential biological 
functions of selected genes as identified from literature and databases 
 
Optimal concentration of siRNA for transfection was previously determined.  In order to show that 
siRNAs were being efficiently delivered to the majority of cells, a control was performed using a 
fluorescently labelled oligonucleotide designed for this purpose.  Figure 37 shows the efficient 
delivery of fluorescent oligonucleotide to Huh7.5 cells.  Red staining indicates the presence of 
fluorescent oligonucleotide, and this can be seen in the majority of cells.  The diffuse red staining 
seen throughout the cytoplasm and also localised to the nucleus indicates that siRNA has been 
delivered to the cells.  The reason for the presence of discrete points of bright staining is unknown, 
but may correspond to endosomes or p-bodies (or some other nucleic acid degradation structure).  
This result indicates that transfection by the described protocol is efficient and suitable for further 
studies. 
 
 
Figure 37: Efficiency of siRNA delivery. 
Huh7.5 cells were transfected with 25nM Block-iT AlexaFluor Red oligo.  Cells were 
photographed at 40x magnification.  Images were obtained in the red (A) and phase (B) 
channels, and a merged image was created (C).  It can be seen that Block-iT AlexaFluor Red oligo 
is present in the greater than of 90% of cells. 
 
  
A B C 
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Having established the efficient delivery of siRNA, the potency of the siRNAs was tested.  For each of 
the 15 cellular targets, two siRNAs were synthesised.  For the initial testing, the two siRNAs were 
pooled.  A control pool of siRNAs directed against DDX3X, known to knockdown both the target host 
gene and HCV, was used as a positive control in these experiments.  The efficiency of the pooled 
siRNAs to knockdown their host gene targets was measured by qRT-PCR.  As can be seen in Figure 38 
the efficiency of knockdown varied for each target.  Knockdowns achieved ranged from 85% for 
CYP1A1 to 60% for CFH.  The siRNA pool directed against DDX3X had already been determined to 
give target knockdown of greater than 80%. 
 
 
Figure 38: Knockdown efficiency of siRNAs targeted to the 15 host genes selected for study by 
RNA interference. 
Huh7.5 cells were transfected with 25nM of two pooled siRNAs per target for 48 hours, and 
target transcript levels were measured by RT-qPCR.  Data were normalised to average host gene 
levels in cells separately transfected with two different non-targeting siRNAs. 
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The pooled siRNAs for each host gene target were then tested for any anti-HCV effect.  The HCV Jc1 
virus carrying a firefly luciferase reporter gene was used for this purpose.   The target cells were 
transfected with siRNA to knockdown the host gene transcript levels, before being infected with 
virus.  Luciferase activity was measured as a determination of HCV replication efficiency.   
 
 
 
Figure 39: Effect of host gene knockdown on HCV replication using pooled siRNAs. 
Huh7.5 cells were transfected with 25nM of two pooled siRNAs per target 48 hours before 
infection with Jc1.  48 hours post infection, luciferase activity was measured.  Data were 
normalised to average host gene levels in cells separately transfected with two different non-
targeting siRNAs.  The pool siDDX3X was used as a positive control, as knockdown of this host 
cell gene was known to inhibit HCV replication.   An additional pool of all the metallothionein 
siRNAs combined was also tested (column labelled siMTs). 
 
 
A range of responses was seen to the use of these siRNAs.  Knockdown of some host targets had an 
effect on HCV replication, and knockdown of other host targets having no effect on HCV replication.  
The siRNAs seen to have the most inhibitory effects on HCV replication were selected for further 
testing.  These were the siRNAs against the genes ABLIM3, CYP1A1, SPTLC3, and TXNIP. 
 
To obtain more precise data on the effect on HCV replication of the individual siRNAs, the pools 
were no longer used.  Instead, the individual siRNAs were used in transfections.  This meant that 
there were two separate siRNAs for each host gene which could be tested for their inhibition of HCV 
replication.  
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Figure 40: Effect of host gene knockdown on HCV replication using deconvoluted siRNAs. 
Huh7.5 cells were transfected with 25nM siRNA 48 hours before infection with Jc1.  48 hours 
post infection, luciferase activity was measured.   Four replicates were performed in each 
experiment, and three experiments performed.  Data were normalised to the average luciferase 
level in cells separately transfected with two different non-targeting siRNAs.  The pool siDDX3X 
was used as a positive control, as knockdown of this host cell gene was known to inhibit HCV 
replication.  T-tests were performed to calculate whether there was a statistically significant 
difference in luciferase levels between cells treated with siRNAs targeting host genes and the 
non-targeting siRNAs.  F-testing indicated a difference in variance when comparing siDDX3X, 
siTXNIP 1, siMAT1A 1 and siMT1F 2 with siNon-Targeting data so a Welch’s correction was 
applied to these t-tests.  A significant difference (p ≤ 0.05) in Jc1 levels was found for all siRNAs 
except siMAT1A 1 and siMT1G 1. 
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The effect of knockdown of host cell genes by individual siRNAs on Jc1 replication can be seen in 
Figure 40.  The positive control siDDX3X inhibits HCV replication (as measured by luciferase activity) 
by 90%.  The most effective inhibition of HCV on knockdown of a host gene was seen when targeting 
TXNIP.  Both siTXNIP 1 and 2 inhibited HCV replication by greater than 80% (Figure 40F).  Knockdown 
of CYP1A1 inhibited HCV replication by 75% (Figure 40B).  Knockdown of genes ABLIM3 and SPTLC3 
(Figure 40A and E) also inhibited HCV replication, but to a lesser extent, by around 50% each.   
 
The effect of knockdown of metallothionein genes on HCV replication was also tested.  The 
microarray analysis indicated that metallothionein expression is decreased during HCV infection.  
Knockdown of MT genes prior to infection was therefore predicted not to inhibit HCV replication.  As 
can be seen in Figure 40D, a range of changes in HCV replication was seen in response to inhibition 
of MT genes.  Knockdown of MT1G did not affect HCV replication.  Use of siMT1F 1 inhibited HCV 
replication, but siMT1F2 increased HCV replication.  MT2A is the most abundant form of 
metallothionein in the liver, use of siMT2A 1 did not inhibit HCV replication, but siMT2A 2 did inhibit 
HCV replication by 70%.   
 
In order to show that the inhibitory effects observed on HCV replication were not due to stress 
effects on the cells induced by knockdown of the host genes, cell viability assays were performed.  A 
standard technique for assessing the viability of cells by measuring their ATP content was 
performed.  Figure 41 shows that the act of transfection with siRNA results in a very small increase in 
the viability of cells, as indicated by comparison of cells transfected by non-targeting siRNAs with 
untransfected cells.  The siRNA siTXNIP 2 had a small effect on the viability of cells, decreasing the 
observed light levels by about 10%.  Overall, the transfections of siRNAs targeting host cell genes 
were shown not to have a major effect on cell viability.  This supports the hypothesis that the effects 
on HCV replication observed were due to knockdown of the host cell genes targeted by RNA 
interference. 
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Figure 41: Cellular toxicity of siRNAs. 
 Huh7.5 cells in a 96-well plate were transfected with 25nM siRNA for 48 hours, and the viability 
of transfected cells was measured by Cell Titer-Glo assay.  Each transfection was performed as 
four replicates, with the mean data and standard error plotted.  Wells containing no cells gave 
an average fluorescence of 40 relative light units.  As a positive control for cytotoxicity, cells 
were treated with 100µM H2O2, giving an average fluorescence of 2000 relative light units. 
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To establish whether the gene expression changes observed in the microarray studies were limited 
to the infectious HCV model, the transcript levels of genes of interest were quantified in replicon 
cells relative to the parental line.   All experiments were performed in Huh7.5 cells.  Two replicon cell 
lines were used, both based on Huh7.5 cells, one line harbouring a genotype 1b replicon (cell line 
Rep4.5) and one line harbouring a genotype 2 replicon (cell line 15.53).  The expression levels of 
genes of interest in replicon lines compared to Huh7.5 cells are reported in Figure 42.  The most 
striking differences in expression were seen for genes MAT1A and TXNIP.  Both of these genes were 
observed to be expressed at significantly lower levels in replicon cells compared to Huh7.5 cells.  It 
was also observed that expression in 2a replicon cells was lower than that in 1b replicon cells.  This 
may indicate a relationship between gene expression genotype, or it may be a function of the level 
of HCV replication.  HCV replicon RNA titres are higher in genotype 2a replicon cells than in genotype 
1b replicon cells.  The low levels of TXNIP in replicon cells are the opposite of the highly induced 
levels seen in JFH-1 infected cells.   
 
 
Figure 42: Relative expression of genes observed to change in microarray studies in Huh7.5 cells 
harbouring subgenomic replicons compared to Huh7.5 cells. 
Cells harbouring a genotype 1b replicon (Rep4.5), a genotype 2a replicon (15.53) and Huh7.5 
cells were seeded in duplicate.  48 hours later, total cell RNA was extracted and qRT-PCR 
performed.  Gene expression was normalised using GAPDH.  Mean expression levels with 
standard error are shown for each gene, with genotype 1b replicon data in white and genotype 
2a replicon data in grey bars.  Another housekeeping gene, 18S, is displayed as a control to 
demonstrate a gene known not to be affected by the presence of replicon.  Three separate 
experiments were performed. 
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3.5.2 Genes Identified as Required for HCV Replication 
 
The microarray analysis of Huh7 and Huh7.5 cells infected with JFH-1 identified host genes that were 
regulated during HCV infection.  This information may be of importance for the understanding of the 
influence that HCV has on patient physiology.  However, it does not tell us why the genes are 
regulated and, importantly, whether these genes are regulated because they have an effect on HCV 
replication (or whether they are, for example, a secondary effect or part of the host’s reaction to 
infection).   
 
Several genes were identified as being upregulated during JFH-1 infection, and having potential 
functional roles in the HCV lifecycle (Table 12).  These genes were silenced by siRNA to investigate 
whether they were required for HCV replication (Figure 39).  Four genes were identified as being 
required for efficient HCV replication, based on an inhibition of HCV replication when these genes 
were silenced (Figure 40).  These genes were ABLIM3, CYP1A1, SPTLC3 and TXNIP. 
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3.5.2.1 Actin binding LIM protein family, member 3 (ABLIM3) 
 
The levels of ABLIM3 were observed to be deregulated during infection with HCV.  At most 
timepoints ABLIM3 was slightly upregulated, however at 48 hours post-infection in Huh7 cells and at 
6 hours post infection in Huh7.5 cells, expression was downregulated in infected cells.  Knockdown 
of ABLIM3 by RNA interference inhibited HCV replication by up to 60%. 
 
Actin binding LIM protein family, member 3 (ABLIM3) is not yet well studied.  It is the third member 
in a family of three ABLIM proteins, each of which contain four LIM domains and a villin head piece 
domain463.  LIM domains are double zinc fingers, and have been found in proteins involved in cell 
development and cancer determination.  Proteins containing LIM domains can interact with each 
other.  The villin head piece domain enables the protein to bind actin464-465.  ABLIM and its drosophila 
homologue UNC-115 have been shown to be involved in axon guidance 466-467. 
 
A recent study identified ABLIM3 as a component of the adherens junction in several epithelial cell 
types, including hepatocytes468.  This study revealed colocalisation of ABLIM3 with the adherens 
junction marker protein β–catenin, but not with the tight junction marker ZO-1 (zona occludens 1).  
Tight junctions have been shown to be involved in cell to cell transmission of HCV469, and certain 
tight junction proteins (including occludin and claudin-1) are important molecules for entry of HCV 
to the cell.  Adherens junctions are the first junctions to form between cells, including before tight 
junctions. The reduction in levels of ABLIM3 due to knockdown by siRNA may disrupt or impair 
adherens junction formation and therefore subsequent tight junction formation.  This could inhibit 
the ability of HCV to be transmitted from cell to cell within culture.  Clathrin-coated pits are found in 
close proximity to adherens junctions, and adherens junctions are known to be associated with 
microtubules470.  Both of these structures are involved in the entry and internalisation of HCV, so 
their disruption could impede HCV replication.  The recent evidence that ABLIM3 is a component of 
the adherens junction, its ability to interact with actin, its ability to interact with other proteins 
through its LIM domains, and the siRNA data indicating that its reduction impairs the efficient 
replication of HCV all suggest that ABLIM3 may be worth further investigation.   
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3.5.2.2 Cytochrome P450, family 1, subfamily A, polypeptide 1 (CYP1A1) 
 
In this study, CYP1A1 and CYP1B1 were observed to be upregulated during HCV infection.  CYP1A1 
was upregulated in both Huh7 and Huh7.5 cells with slight initial upregulations increasing to 2.5-fold 
(Huh7.5) and 5-fold (Huh7) changes in expression compared to mock infected cells at 48 hours post 
infection.  A small increase in expression of CYP1B1 was observed in Huh7 cells, but not in Huh7.5 
cells.  As CYP1A1 was amongst the more highly regulated genes and given its potential involvement 
in lipid metabolism, CYP1A1 was chosen as a target for RNA interference to determine whether 
knockdown would impair HCV replication.   Knockdown of CYP1A1 prior to infection was found to 
inhibit HCV replication by up to 80%.   
 
Cytochrome P450 (CYP) proteins are haeme-containing monoxygenase enzymes which play a role in 
the metabolism of xenobiotic environmental chemicals including drugs, as well as endogenous 
molecules such as lipids, steroids, cholesterol and bile acids.  Lipophilic xenobiotics are oxygenated 
by CYP enzymes as a first step in transforming the xenobiotics into hydrophilic, and therefore 
excretable, molecules.  CYP1A1 localises to the ER in the cell, and CYP proteins are most common in 
the liver.  CYP1 can metabolise molecules including polycyclic aromatic hydrocarbons (PAH)471, 
aflatoxin B1472-474 and arylamines475-476.  CYP1A1 expression can also be induced by polycyclic 
aromatic hydrocarbons, which it can then convert into carcinogenic intermediates477-478.  CYP1A1 has 
been associated with risk of lung cancer.  CYP1A1 and CYP1B1 can also metabolise endogenous 
estradiol into 2-hydroxyestradiol and 4-hydroxyestradiol (which is mutagenic) respectively475.   
CYP1A1 is also known to be able to convert ethylene into ethylene oxide479-480. 
 
The biological action of CYP on xenobiotics means that the efficacy of many drugs can be affected by 
its action.  It is now common for drugs to be tested for metabolism by CYP during development.  
Tamoxifen, a treatment for breast cancer is catalysed into its active form tamoxifen to 4-
hydroxytamoxifen by CYP481.  CYP have been shown to be decreased in expression in hepatoma 
cells482.  Treatment of hepatoma cell lines with the anti-cancer drug emodin rapidly induced 
expression of CYP1A1 and CYP1B1, and cell cycle arrest483.   
 
CYP1A1 induction is mediated through the aryl hydrocarbon receptor (AhR).  AhR-mediated 
induction of CYP1A1 expression has been shown to be impaired in cells harbouring a subgenomic 
HCV replicon.  Constitutive expression of CYP1A1 was shown to be higher in these replicon cells than 
their parental cells484.  It has been reported that CYP1A1 activity can lead to oxidative stress485-486, 
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and it is possible that increased expression of CYP1A1 during HCV infection could be contributing to 
the oxidative stress that has been previously observed in HCV infected cells.  It has also been shown 
that there is a link between smoking and development of liver lesions in HCV patients487-488, and this 
could be linked to the ability of CYP1A1 to convert PAH into carcinogenic compounds, or oxidative 
stress effects.   
 
 
Figure 43: The cytochrome P450 catalytic cycle. 
This diagram shows the steps involved when a substrate binds to the cytochrome P450 enzyme.  
(1) The normal state of a P450 with the iron in its ferric [Fe3+] state.  (2) The substrate binds to 
the enzyme.  (3) The enzyme is reduced to the ferrous [Fe
2+
] state by the addition of an electron 
from NADPH cytochrome P450 reductase. The bound substrate facilitates this process.  (4,5) 
Molecular oxygen binds and forms an Fe2+OOH complex with the addition of a proton and a 
second donation of an electron from either NADPH cytochrome P450 reductase or cytochrome 
b5. A second proton cleaves the Fe2+OOH complex to form water.  (6) An unstable [FeO]3+ 
complex donates its oxygen to the substrate (7). The oxidised substrate is released and the 
enzyme returns to its initial state (1). 
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3.5.2.3 Serine palmitoyltransferase long chain base subunit 3 (SPTLC3) 
 
The levels of SPTLC3 were observed to be deregulated during infection with HCV.  At early 
timepoints SPTLC3 was upregulated by 2-fold in infected Huh7 and 3-fold in infected Huh7.5, but 
levels reduced over time and were downregulated in infected cells at 48 hours post infection.  
Knockdown of SPTLC3 by RNA interference inhibited HCV replication by around 50%. 
 
SPT catalyses the condensation of serine and palmitoyl coA to produce 3-ketodihydrosphingosine.  
This is the first, and rate limiting, step in the production of sphingolipids.  Sphingolipids are 
important constituents of cellular membranes, and are important in the formation of lipid rafts489-492.  
SPT is upregulated in response to some stresses, and sphingolipids have also been shown to be 
involved in apoptosis, indicating that SPT could be upregulated in order to induce apoptosis493-495.  
 
It has been proposed that the stoichiometry of the SPTLC1/2/3 complex, and therefore its activity, 
depends on the SPTLC2 and 3 expression levels496.  It has also been shown that SPTLC3 forms C(16)-
sphingoid bases and that a significant proportion of sphingolipids (about 15%, found in HDL and LDL)  
have C(16) backbones497.  This may explain why only SPTLC3 levels were observed to change during 
HCV infection, and would indicate that a change in only SPTLC3 levels will still be important in 
determining the activity of the final enzyme complex.   
 
In agreement with the finding here, that RNA interference of SPTLC3 inhibits HCV replication, other 
studies have shown the ability of a chemical SPT inhibitor to suppress HCV498-499.  These studies 
indicate that NS5B binds sphingomyelin and that the inhibitor disrupts this binding, resulting in the 
movement of NS5B to from detergent resistant membranes to detergent soluble fractions.  
Combination therapy of humanised chimaeric 
mice infected with HCV with the SPT inhibitor and 
PEG-IFN resulted in a 3-log drop in serum HCV 
RNA. 
 
 
 
 
 
Figure 44: Biosynthetic pathway of 
sphingolipids in mammalian cells500. 
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3.5.2.4 Thioredoxin-interacting protein (TXNIP) 
 
The most significant finding of these studies has been the importance of TXNIP to HCV replication.  
TXNIP was identified, through microarray analyses validated by qRT-PCR, to be highly upregulated 
during HCV infection.  In both Huh7 and Huh7.5 cell lines, TXNIP was found to be one of the most 
highly upregulated host genes (Table 4 and Table 8).  The three probe sets identifying TXNIP 
expression present in the microarrays showed similar expression levels at all timepoints.  Validation 
performed by qRT-PCR of RNA from Huh7 cells at 48 hours post-infection also showed very strong 
upregulation of TXNIP expression (Figure 31C).  Expression of TXNIP was seen to have increased 
significantly by 12 hours post-infection, and transcript levels increased at each timepoint.  
Knockdown of TXNIP by RNA interference inhibited HCV replication by up to 90% 
 
There is evidence to suggest that TXNIP, also known as VDUP1 and TBP-2, has roles in multiple 
cellular processes.  As its name suggests, TXNIP binds and inhibits the activity of thioredoxin thus 
providing a regulatory role for cellular redox state and oxidative stress501-504.  TXNIP can affect cell 
proliferation and cell cycle by acting as a tumour suppressor505-511, and can promote apoptosis503,512.  
Natural killer cell development is affected in mice lacking TXNIP513.  Most research so far on TXNIP 
has focused on its role in glucose and lipid metabolism.  Many of the functions of TXNIP are a result 
of its interaction with thioredoxin (TRX).  TRX is a 12kDa thiol reductase which is conserved across 
kingdoms and has several functions in the cell.  The two cysteine residues in the WCGPC active site 
provide sulphydryl groups for the reducing activity of TRX.  Once oxidised, TRX can be reduced to a 
dithiol again by NADPH and TRX reductase514-515.  TRX exists in several locations.  In the cytoplasm it 
protects against oxidative stress516-517 and regulates signal transduction518-519.  It has been shown to 
exist in the mitochondrial intermembrane space507.  In the nucleus it regulates transcription factors 
including NF-κB and AP-1520-521.  It can also be secreted to act like a cytokine522-524. 
 
TXNIP transcriptional expression is not fully understood, but it is known that the promoter region 
contains two ChoREs (carbohydrate response elements), two CCAATs and one FOXO (forkhead box 
O)525.  There are also a vitamin D response element and a glucocorticoid response element present 
in the promoter.  TXNIP is known to be stimulated by vitamin D526, glucocorticoid527-528, PPAR 
agonist423-424,529, TGF-β509, an inhibitor of histone deacetylase (HDAC) called suberoylanilide 
hydroxamic acid511,530, molecules containing adenosine531 and heat shock factors532.  TXNIP is known 
to be inhibited by insulin533, and stimulated by glucose531,534-536.   
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There is increasing evidence that TXNIP regulates glucose uptake in humans.  It has been shown that 
glucose can induce the expression of TXNIP in several cell types.  It has also been found that forced 
expression of TXNIP will reduce glucose uptake and inhibition of TXNIP will increase glucose uptake, 
and that the presence of insulin will reduce TXNIP expression533.  The same study found levels of 
TXNIP to be elevated in diabetics and pre-diabetics.  Patients with HCV can develop insulin 
resistance537-539 and therefore type 2 diabetes.   The observed increase in TXNIP expression during 
HCV infection described in this thesis may indicate a mechanism for this pathology.  Insulin 
resistance can be a predictor for non-response to anti-viral therapy540-544.  It has been proposed that 
glucose and glutamine can affect the state of the transcription factor ModoA, for which there is a 
binding site (ChoRE) in the TXNIP promoter.  Glutamine has been shown to repress TXNIP through 
this mechanism545.  Elevated levels of TXNIP would result in reduced glucose in the cell.  As glucose is 
essential for cell growth this may also have the effect of inhibiting proliferation.  TXNIP has been 
shown to be a regulator of hepatic glucose production, and study of TXNIP-/- mice found them to be 
hypoglycaemic and hypoinsulinemic546.   Regulation of glucose metabolism by TXNIP has been shown 
to be possible independently of TRX, and the TXNIP-related protein ARRDC4 can also inhibit glucose 
uptake, indicating that the arrestin domain is important for this function547.   
 
TXNIP plays a role in regulation of oxidative stress through its ability to bind and inhibit TRX501-504.  
TRX can reduce reactive oxygen species (ROS) and protects against damage by H2O2.    It follows that 
increases in TXNIP will inhibit TRX and therefore inhibit the cellular response to ROS.  Conditions 
promoting TXNIP expression such as hyperglycaemia have been shown to promote oxidative stress 
through this mechanism535.  It has been shown that in response to ROS, TXNIP dissociates from TRX.  
As well as freeing TRX to perform anti-oxidant functions, this makes TXNIP available.  TXNIP can 
associate with NLRP3 leading to activation of the inflammasome548-549.  The inflammasome activates 
caspase 1, which in turn generates mature IL-1β.  This may be a mechanism for the inflammation 
observed in diabetics (who have raised levels of TXNIP).   The drug glibenclamide, which is used in 
the treatment of diabetes, can inhibit the induction of TXNIP by glucose and also NLRP3 
inflammasome activation548,550.   
Oxidative stress is observed in cells infected with HCV.  Upregulation of TXNIP in infected cells would 
inhibit the ability of the cell to respond to oxidative stress, and could increase the damage suffered 
by infected cells.   
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Several lines of investigation point to the role of TXNIP as a tumour suppressor, and there is some 
evidence for a role in apoptosis.  An important target for TRX reduction is ribonucleoside reductase, 
which is required for DNA synthesis551, and inhibition of TRX by TXNIP could slow DNA synthesis.  
TXNIP-/- mice have been shown to develop HCC in 40% of cases with slightly increased prevalence in 
males505.  Fibroblasts deficient in TXNIP had reduced levels of p27kip1, a cyclin dependent kinase 
inhibitor, seemingly due to the interaction of TXNIP and JAB1 promoting the destabilisation of p27kip1 
and blocking p27kip1 translocation to the nucleus.  As a result, these cells were observed to 
proliferate more rapidly, supporting the evidence for the role of TXNIP as a tumour suppressor506.  
Overexpression of TXNIP has been shown to induce apoptosis (in pancreatic β cells) by measurement 
of expression of Bax, Bcl-2 and caspases 3 and 9534, and TXNIP upregulation was shown in neuronal 
apoptosis552.   TRX has been shown to have anti-apoptotic effects through ASK1 binding, and TXNIP, 
as an inhibitor of TRX, can induce apoptosis through this mechanism.  The haematopoietic stem cell 
(HSC) population is quickly lost in TXNIP-/- mice, and expression of TXNIP is decreased in HSC 
activation, indicating that TXNIP can maintain HSC quiescence553.  TXNIP expression is lost in adult T-
cell leukaemias that are induced by human T-cell leukaemia virus type 1, indicating the role of TXNIP 
in tumour suppression508.  Ceramide, which is generated as part of sphingolipid metabolism in 
response to apoptotic stimuli, is a promoter of TXNIP expression.  Knockdown of TXNIP by siRNA has 
been shown to inhibit ceramide induced ASK1, p38 and JNK phosphorylation, and cell apoptosis512.  
Degradation of TXNIP can occur in an ubiquitin-dependent manner, regulated by the E3 ubiquitin 
ligase Itch, leading to an anti-apoptotic effect554.  TXNIP expression is upregulated by TGF-β1 and 
1,25-dihydroxyvitamin D3, and can arrest the cell cycle at G0/G1 phase
509.   
The tumour suppressive role of TXNIP would aid the response to liver damage by HCV infection.  
Apoptosis induced by increased levels of TXNIP could help to account for the damage suffered to the 
liver during HCV infection.   
 
TXNIP has been shown to play a role in cell differentiation.  In the TXNIP-/- mice, a deficiency of NK 
cells was observed and it was suggested that TXNIP is required for CD121 expression and NK cell 
maturation513.    
 
TXNIP plays a role in lipid metabolism.  Both TXNIP-/- and HcB-19 mice (which have a nonsense 
mutation in TXNIP) have hyperlipidaemia, with elevated levels of triglyceride and cholesterol in 
plasma555-557.  TXNIP expression is also downregulated in PPARα-null mice, and it is possible that the 
lipid and glucose metabolism changes seen in these mice are in some part to do with the altered 
TXNIP expression423.  The lack of TXNIP in TXNIP-/- mice was shown to inhibit the development of 
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steatohepatitis (during a methionine and choline deficient diet) by lowering oxidative stress, 
inhibiting release of cytokines and inhibiting cellular infiltration and fibrosis558.  As TXNIP levels were 
greatly increased during HCV infection in the work presented here, this could contribute to HCV 
related steatosis. 
 
TXNIP has been reported to be stimulated by glucocorticoid, and this stimulation resulted in 
apoptosis527.  A case in which an HCV patient was treated with a glucocorticoid (prednisolone, for 
polymyositis), resulted in a large increase in serum HCV RNA titre559.  It would be interesting to 
determine whether a similar reaction occurs in vitro, and whether glucocorticoid stimulation of 
TXNIP occurred, and was responsible for the increase in HCV. 
 
All of these points make an attractive proposition for further research into TXNIP inhibition as a 
therapeutic for HCV patients.   
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3.6 Cellular Metabolites in JFH-1 Infected Cells 
 
The microarray analyses have identified gene expression changes in JFH-1 infected cells.  The genes 
identified may have functions resulting in changes in levels of metabolites in the host cells.  In 
particular, as many of the genes identified are involved in lipid and carbohydrate metabolism, a 
study was undertaken to investigate any corresponding changes in metabolites during JFH-1 
infection. 
 
 
3.6.1 Spectroscopic Profiling of Cellular Metabolites  
 
Protocols have been developed to quantify the levels of metabolites in cells by proton magic-angle 
spinning (MAS) magnetic resonance spectroscopy (MRS)403.  The technique employed primarily 
identifies lipid molecules, as well as some amino acids, and sugar molecules such as glucose and 
glycogen.  The MRS technique used has been performed on liver biopsy material.  The experiment 
described here was the first time that live, infected cultured cells had been used in MRS.  Figure 45 
shows an example MRS profile with the major metabolite peaks identified.  
 
Figure 46 shows the four profiles obtained for mock infected (Figure 46A-D) and JFH-1 infected 
(Figure 46E-H) Huh7.5 cells.  The average area of each metabolite peak was then calculated for mock 
infected and infected cells (Figure 47).  The most distinct change in a metabolite level observed is 
the decrease in height of the phosphocholine (PC) and glycerophosphocholine (GPC) peak with 
infection.  The phosphatidylcholine (PtdC) peak was seen to increase in height with infection.  The 
height of each peak of interest was measured to give a quantitative estimate of the amount of each 
metabolite in each sample.   
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Figure 45: An example proton MAS MRS profile with the major metabolite peaks identified. 
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Figure 46: Magnetic resonance spectra of mock infected and JFH-1 infected Huh7.5 cells. 
Huh7.5 cells were mock infected (A-D) or infected with JFH-1 virus at an MOI of 3 (E-F).  48 hours 
post-infection MAS MRS was performed.  Spectra were obtained for four replicates each of 
infected and mock infected cells, performed in two experiments 
A B 
C D 
E F 
G H 
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Figure 47: Relative areas of magnetic resonance spectra peaks for mock infected and JFH-1 
infected Huh7.5 cells. 
The areas under each peak were calculated using ImageJ (NIH) and GraphPad Prism.  Average 
data and standard error are presented for the four replicates of each condition.  T-tests were 
performed in GraphPad Prism to identify significant differences in metabolite levels between 
Mock Infected (white bars) and JFH-1 Infected (grey bars) samples (differences where p≤0.05).  
Statistically significant differences were identified in the phosphocholine and 
glycerophosphocholine (PC and GPC) levels and in the phosphatidylcholine (PtdC) levels between 
infected and mock infected Huh7.5 cells. 
 
 
 
  
A B 
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3.6.2 Choline Metabolites 
 
The analysis by MAS MRS of metabolite levels in Huh7.5 cells infected with JFH-1 indicated that 
there were significant changes in choline compound levels during infection.  During infection with 
JFH-1, glycerophosphocholine (GPC) and phosphocholine (PC) levels decreased, and 
phosphatidylcholine (PtdC) levels increased compared to mock infected cells (Figure 46 and Figure 
47).   
 
This change may have significance in the context of HCV replication.  PtdC is a major component of 
cell membranes, and is required for normal secretion of VLDL and HDL.  The HCV lifecycle requires 
cell membranes at several stages (as described in the introduction).  During replication of RNA, 
replication complexes are formed in a membranous web made from the ER.  Lipid droplets are 
required for construction of viral particles, and the mature virion requires its own lipid envelope.  It 
is therefore advantageous to the virus to induce conditions where there is increased production of 
the required lipids.   
 
The change in choline metabolite levels also has significance for HCV patients, as whether this helps 
the virus or not, a change does happen during infection, and therefore alters the pathology of the 
liver.  Another group has performed MRS on liver biopsy material from HCV infected patients and 
correlated lipid quantities and fibrosis severity560.    In their study, total choline levels were observed 
to decrease with increasing fibrosis, and total choline levels decreased with increasing hepatic lipid 
levels.  It has previously been observed that there is decreased PC in non-alcoholic fatty liver 
disease561.  Decreased PtdC can lead to accumulation of intracellular triglycerides562, and as this 
would inhibit normal secretion of VLDL563, it would not benefit the virus, but could explain fatty liver.   
The observations presented here, of increased PtdC, would seem to benefit the viral lifecycle.  
However, it does not quite match up with observations by others, performed on liver biopsy, that 
show decreased total choline (including PtdC).  It may be that the situation inside the cell changes 
over time.  The acute model of infection presented here may represent the situation where the virus 
is inducing optimal conditions for replication.  The conditions seen in cirrhotic liver biopsy of chronic 
HCV may indicate the later stages, when HCV does not need to spread, and liver pathology has 
altered many normal metabolic processes over the long period of time infection has occurred.  It is 
also known that mice fed on a diet deficient in choline and methionine develop steatosis564, so if 
there is a reduction in choline in the liver of HCV patients due to biochemical abnormalities, a similar 
process could be at work. 
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4. Summary 
 
JFH-179 was the first HCV isolate to be identified to replicate in vitro, and derivatives of this genome 
are still by far the most efficient at replication and production of HCV.  Chimaeric JFH-1 genomes 
including the structural (but not the non-structural) coding regions of other HCV isolates and 
genotypes have been shown to replicate354, suggesting that viral determinants for the ability of JFH-1 
to replicate in cell culture are in the non-structural coding region.  The NS3 protein is essential to the 
HCV lifecycle, providing multiple functions including helicase and protease activities, and as such was 
chosen as the target for study.  Chimaeric JFH-1 genomes were created, containing full length NS3, 
NS3 protease or NS3 helicase coding regions from genotype 1a and 1b isolates (section 3.1.2).  The 
replicative ability of these chimaeras was assessed by transfection into Huh7.5 cells and 
measurement of intracellular HCV RNA over time.  None of the genomes created were observed to 
have the ability to persist by replicating in cell culture (section 3.1.3).  The chimaeric JFH-1 genomes 
created have shown that NS3 and both its individual protease and helicase domains are essential 
genotype specific determinants for replication.  The method employed has not specified, to further 
than domain level, the sequence determinants within NS3 that enable JFH-1 to replicate.  This could 
be pursued by creating sub-domain level chimaeras to pinpoint the specific regions and amino acids 
involved.  This would provide more information to identify the interactions involved, such as those 
between NS3 and other HCV proteins, substrates, or cellular proteins.  The interaction between NS3 
and NS4A enhances protease activity, and inclusion of genotype matched NS4A sequence into the 
existing chimaeras may restore replicative ability in some or all of the chimaeras.  This has recently 
been demonstrated by creating chimaeras using a J6/JFH-1 backbone and inserting NS3 and NS4A 
sequence from several genotypes407.  Acquisition of replicative ability for chimaeric JFH-1 would 
provide a useful tool for the study of the effects of NS3 from different genotypes on the host cell, 
including on host gene expression.  It could also provide a tool for the study of the effect, on 
different genotypes, of potential NS3 inhibitors to be used as antiviral drugs.   
 
 
The host cell environment is of great importance in determining the ability of HCV to replicate.  HCV 
naturally replicates in hepatocytes, and in vitro work has found that the most efficient cell line for 
hosting HCV replication is Huh7, and its HCV replicon-cured derivatives79,318,375.  HCV can induce 
changes in host gene expression during infection, as indicated by studies in human395-398 and 
chimpanzee liver329,379-380, replicon cell lines381-388, and protein expression systems389-394 .  Use of the 
JFH-1 culture system for investigation of changes in host gene expression has several advantages 
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over other models including the presence of all HCV proteins, the occurrence of entry, assembly, 
release, and RNA replication, and the ease of material acquisition and experimental control 
compared to in vivo models. 
 
Whole genome microarray analyses were performed to identify gene expression changes in Huh7.5 
cells (section 3.2.2) and Huh7 cells (section 3.3.3) that had been infected with JFH-1.  Gene 
expression changes were observed in cells infected with JFH-1 at an MOI of 3 for 6, 12, 18, 24, and 
48 hours compared to mock infected cells.  For Huh7.5 cells, between 593 and 1418 probe sets were 
observed to change by more than two-fold at each timepoint, with a total of 2473 genes and 
transcripts observed to change during at least one timepoint. For Huh7 cells, between 239 and 2145 
probe sets were observed to change by more than two-fold at each timepoint, with a total of 2187 
genes and transcripts observed to change during at least one timepoint.  In addition, the gene 
expression was measured in Huh7 cells infected with HCV and treated with polymerase or protease 
inhibitors (section 3.4), but very few genes were observed to change compared to infected cells 
(further validation of this microarray data by quantitative PCR analysis of separate infection 
experiments is required to determine if this is a replicable result).  The expression changes of 
selections of genes were also assessed by quantitative PCR (of infection experiments separate from 
those used in microarray analysis) for both Huh7.5 (section 3.2.2) and Huh7 cells (section 3.3.3).  The 
quantitative PCR data was in general agreement with the microarray data, providing validation for 
the microarray data both through use of another technique and by repeat infection experiments.  
Analysis of the microarray data found that many host genes regulated during JFH-1 infection are 
involved in biological processes of importance to HCV replication and disease.   
 
These processes included lipid metabolism, immune modulation, oxidative stress, apoptosis and 
intracellular transport.  Genes involved in lipid metabolism, including cholesterol and sphingolipid 
synthesis, were observed to be regulated during infection.  This is of importance as lipid structures 
including membranes and lipid droplets are vital to the HCV replication.  Profiling of cellular 
metabolites 48 hours post HCV infection by magnetic resonance spectroscopy identified changes in 
the level of choline metabolites (section 3.6.1).  The observed increase in phosphatidylcholine was of 
particular interest as this is an important component of the cellular membranes and lipid structures 
required by HCV.  The pathological changes to the livers of infected patients usually take long 
periods of time to manifest, so observations of large scale changes in lipid metabolites may not 
necessarily be made in this model.  Measurement of lipid metabolites at timepoints longer than 48 
hours (days or weeks) after infection may yield more discernable differences, as transcriptional 
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changes have their effect.  Changes in expression of genes involved in immune modulation were 
observed, including in cytokines, SOCS and acute phase response proteins, but the same large range 
of interferon stimulated genes observed to be regulated in vivo329,379-380 was not observed.  This may 
be an indication of the lack of complexity in the cell culture model, where interactions and signalling 
between other cell types (such as immune cells) are not present, and cannot have the effect that 
they would in vivo.  Genes involved in the cellular response to oxidative stress were observed to be 
regulated during infection.  These included the metallothionein family of genes, which were 
observed to be downregulated during infection.  Regulation of genes involved in apoptosis and cell 
proliferation was observed, indicating that both cell cycle regulation and apoptotic cell death may be 
induced by viral infection.  A similar study looking at gene expression has since been performed in 
Huh7.5 cells infected with a J6/JFH-1 chimaera411.  This study focused on p53 signalling, NRF2-
mediated oxidative stress response, and TGFβ signalling, and the correlations between this study 
and the work presented here support each other in indicating that there are changes in cell cycle 
and oxidative stress factors, potentially leading to apoptosis and providing a possible cause for liver 
damage.  Genes involved in vesicle trafficking between ER, Golgi and plasma membranes regulated 
during HCV infection, indicates potential roles for these genes in viral processes such as entry, exit 
and construction of replication complexes.  It has been demonstrated that HCV infection does 
induce gene expression changes in the host cell, and that many of these are involved in processes of 
importance to the HCV lifecycle.   
 
 
It was hypothesised that genes regulated during HCV infection may be required for efficient HCV 
replication.  To test this, a selection of genes observed to be highly regulated in microarray studies 
(with potential roles in the HCV lifecycle suggested by their known functions) were inhibited by RNA 
interference prior to infection.  Other groups have since identified host genes important for HCV 
replication by RNA interference methods, including PI4K and Rab7565-566, indicating the value of this 
approach.  Of 15 genes tested, knockdown of 4 genes resulted in impaired HCV replication, as 
measured by quantitative PCR 48 hours post infection (section 3.5.1).  This indicates that although 
not all genes regulated during HCV infection may be required for HCV replication, nevertheless the 
observation of the regulation of gene expression can serve as a guide to identify genes of 
importance to HCV replication.  The knockdown by siRNA of genes ABLIM3, CYP1A1, SPTLC3 and 
TXNIP resulted in significant impairment of HCV replication (section 3.5.1).  These are novel findings, 
and only SPTLC3 had previously been shown to reduce HCV replication when chemically inhibited498.  
The knockdown by siRNA of gene TXNIP (thioredoxin interacting protein) resulted in the greatest 
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reduction in HCV replication.  This may be of importance to the study of HCV as TXNIP plays roles in 
oxidative stress, lipid metabolism and glucose metabolism, all of which have potential roles in HCV 
replication and disease.  Genes required for the efficient replication of HCV have therefore been 
identified through RNA interference of genes observed by microarray and quantitative PCR analyses 
to be highly regulated during HCV infection.   
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Further Work 
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5.1 Viral Determinants of HCV Replication 
 
HCV JFH-1 chimaeric genomes containing the NS3 coding regions from genotypes 1a and 1b were 
constructed and shown to be replication deficient in Huh7.5 cells. This indicates the presence of 
genotype specific viral determinants in efficient HCV replication.   As the NS3 proteins generated 
retained all the functional elements required for activity, it is likely that the chimaeras have reduced 
activity rather than no activity.  This activity was not enough to establish a persistent infection of 
cultured cells.  The reduced activity of chimaeric NS3 may still be quantifiable by other methods. 
These include measurement of protease activity by processing of in vitro translated polyprotein, and 
measurement of helicase activity by nucleotide duplex unwinding assays.  In order to identify the 
specific regions of the NS3 gene which are responsible for the efficiency of genotype specific activity, 
subdomain level HCV JFH-1 chimaeric genomes should be constructed, and tested for their 
replication ability.  Regions identified as starting points for this study are those which show 
significant diversity in amino acid sequence across the different HCV genotypes.  Any chimaeric 
viruses with the ability to replicate could be passaged in cell culture multiple times in an attempt to 
identify any compensatory mutations which occur in other regions of the HCV genome, indicating 
interactions between either HCV proteins or the RNA itself.  In order to aid NS3 protease function, 
genotype matched NS4a sequence could be introduced into the chimaeras already made.  The 
cofactor activity of NS4A may rescue the replication incompetent NS3 protease chimaeras, and 
possibly the full length NS3 chimaeras.   Any non-replicative chimaeric viruses, including those 
already created, should have their translation efficiency and their subsequent polyprotein processing 
investigated by in vitro translation. 
 
 
5.2 Metabolic Changes during HCV Replication 
 
The analysis of Huh7.5 host cell metabolites at 48 hours post-infection, using magnetic resonance 
spectroscopy (MRS), showed a change in choline metabolite levels compared to mock infected cells. 
Additional MRS experiments should be performed on cells hosting a sub-genomic replicon to 
determine whether HCV non-structural proteins alone can induce this change in the host cell 
metabolite profile.  It is also possible to gain further details of the relative amounts of metabolites in 
infected cells compared to mock infected cells by performing methanol/chloroform extraction of the 
cells.  This allows analysis of the lipid soluble metabolites (e.g. choline) and water soluble 
metabolites (e.g. phosphatidylcholine) separately.  Microarray analysis of host gene expression also 
identified genes involved in lipid metabolism to be regulated during HCV infection, including genes 
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involved in cholesterol and sphingolipid metabolism.  These metabolites should be investigated by 
MRS, and this work could be supported by HPLC (high pressure liquid chromatography) analysis.  It 
would also be beneficial to analyse the metabolite levels in cells infected with HCV for time periods 
greater than 48 hours.  MRS analysis of cells infected for several days may allow for the time 
required for the changes in gene expression to have an effect on the metabolite levels in cells.  As 
pathologies such as steatosis in patients take years to develop, longer infection periods may help to 
identify slowly progressing changes in metabolite levels.   
 
 
5.3 Host Gene Expression Changes during HCV Replication 
 
The work presented here has identified several areas of interaction between HCV and the host cell 
which would benefit from further investigation.   
 
Whole genome microarray analysis of gene expression has identified many genes to be regulated 
during HCV infection.  There is further analysis to be performed on genes which were observed to be 
highly regulated during HCV infection.  These genes may not have fit easily into the previously 
described categories of biological process, or there may be little currently known about their 
function.  However, the magnitude of regulation of some of these genes indicates further 
investigation may be of interest to the study of the interaction between HCV and the host cell.  For 
example inhibin beta E and stanniocalcin C were observed to be upregulated by around 20 times in 
Huh7 cells infected with JFH-1 at 24 and 48 hours post-infection.  The microarray results will initially 
need to be validated by quantitative PCR as before.  Any potential relationships with HCV can then 
be explored such as protein interaction, roles in cellular processes required for HCV replication, or 
roles in cellular anti-viral mechanisms.   
 
Analysis of the genes regulated during HCV infection identified groups of genes involved in cellular 
processes of importance to HCV replication.  Further analysis of the genes involved in pathways 
highlighted by these analyses could determine the mechanisms of regulation.  For example in the 
cholesterol synthesis pathway genes were observed to be downregulated upto 48 hours post-
infection, and have recently been shown to be upregulated at 72 hours post-infection.  The 
investigation of the mechanisms of this regulation would be of interest, including the investigation of 
the involvement of miR122 sequestration by HCV or downregulation by interferon response, and the 
subsequent upregulation of gene expression by HCV.  Further exploration of the pathways involved 
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could include siRNA knockdown of genes that were not necessarily regulated by HCV but are 
involved in the processes identified as generally regulated during HCV infection.   
 
Four host genes (TXNIP, ABLIM3, CYP1A1 and SPTLC3) have been identified through these studies 
which are required to varying extents for HCV replication.  So far, the absence of these genes has 
been determined to be detrimental to the ability of HCV to replicate.  Overexpression studies should 
be performed in order to establish whether there is also an advantage to HCV replication conferred 
by the presence of additional quantities of these proteins.  These overexpression studies could be 
performed by transfection of Huh7.5 cells with mammalian expression vectors (e.g. plasmid pCR3.1, 
Invitrogen).  As stable transfection will require antibiotic selection for cells containing the vector, 
controls should include cells containing empty vector, and cells containing vector with a control 
protein (e.g. lacZ).  Cells overexpressing proteins of interest can then be infected with HCV and 
replication efficiencies measured as before.   
 
Follow up studies should be performed in order to identify how these host genes are relevant to the 
HCV lifecycle. The role of CYP1A1 in the metabolism of cellular molecules such as lipids, steroids and 
cholesterol could be investigated in the context of the requirement of lipids for HCV replication.  
SPTLC3 is already a target of research for the development of inhibitory drugs for combination 
therapy of HCV.   
 
Knockdown of ABLIM3 by siRNA showed a moderate impairment of HCV replication.  ABLIM3 has the 
capacity to bind actin, which implies a role for it in transport of HCV or HCV elements around the 
cell.  The likely interaction between ABLIM3 and other proteins is through the LIM domains.  The 
recent study showing ABLIM3 to be a component of the adherens junction suggests that it may be 
important for cell-cell interaction.  Investigation of the capacity for cell-cell transmission of HCV in 
the cells with knocked down ABLIM3 would be of interest.  The role of ABLIM3 in regulation of 
intracellular transport through its interaction with actin could also be of interest to the study of HCV.   
 
 TXNIP is of interest as it was very highly upregulated during infection, its knockdown strongly 
inhibited HCV replication, and it has multiple functions in the cell.  TXNIP has functions in lipid 
metabolism, glucose metabolism and oxidative stress responses, all of which can be linked to HCV 
replication.  These biological functions should be separated to determine which plays the major role 
in allowing the replication of HCV.  It is known that glucose induces expression of TXNIP.  Huh7.5 
cells could therefore be induced to express TXNIP through addition of glucose to the culture 
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medium, before infection with HCV.  It is known that different cell lines respond in different ways to 
stimuli, so in the event that glucose does not stimulate TXNIP in Huh7.5 cells, another sugar could be 
used, such as D-allose, which has been shown to induce TXNIP in Huh7 cells567.  TXNIP is involved in 
lipid metabolism and the HCV lifecycle is dependent on cellular lipids for functions such as formation 
of replication complexes and formation of the viral envelope.  The effect of TXNIP inhibition by RNA 
interference and TXNIP overexpression on cellular lipid content should be investigated.  Total lipid 
content analyses can be performed by staining cells with lipid dyes such as Oil Red O and 
microscopic observation, and direct biochemical assays.  Quantification of specific lipid metabolites 
could also be performed by MRS as before.  TXNIP plays a role in determining the redox state of the 
cell and regulating oxidative stress by inhibition of TRX.  It would be interesting to investigate 
whether the role of TXNIP in HCV replication is a function of its interaction with TRX.  This could be 
performed by treating cells with both TXNIP siRNA and a chemical TRX inhibitor to determine 
whether HCV replication is rescued by the chemical TRX inhibitor.  Alternatively, inhibition of the 
enzyme thioredoxin reductase would also ultimately have the effect of inhibiting TRX, by disabling its 
ability to return to its active state (methylarsenicals and arsinothiols have been shown to inhibit 
thioredoxin reductase568).  It is also possible that TXNIP is assisting HCV by inhibiting the ability of 
TRX to reduce essential disulphide bonds present in HCV proteins.  For example, the envelope 
proteins of HCV contain nine conserved disulphide bonds which are required for correct folding of 
the proteins569.    
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Appendix 
A1 Primer Sequences 
 
These tables list all primers used in this thesis.  Primers were purchased from Invitrogen or Sigma.  
The sequences of all primers are written in the standard 5’-3’ order.  All primers were designed using 
Primer3 (http://frodo.wi.mit.edu/primer3/) or Primer-Blast software 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). 
 
A1.1 Primers used in the construction of chimaeric JFH-1 
 
Target of 
Primer Pair 
Forward Primer Reverse Primer 
Name Sequence Name Sequence 
JFH-1 NS3 
(AflII-NsiI) 
AflII 
NS3ampF 
TTGGGCCTGCTTACCTCTTA 
NsiI 
NS3ampR 
ACCTCAAGGTCAGCTTGCAT 
S.D.M. to 
insert BlpI 
QC NS32a 
BlpI F 
CATCACTGCTTATGCTCAGCAAACACGAGG 
QC NS32a 
BlpI R 
CCTCGTGTTTGCTGAGCATAAGCAGTGATG 
HCV 1a NS3 
BlpI NS31a 
F 
GCTCAGCAGACGAGAGGCCTCCTAGG 
NsiI NS31a 
R 
ATGCATGTCATGATGTATTTGG 
HCV 1a NS3 
Protease 
BlpI NS31a 
F 
GCTCAGCAGACGAGAGGCCTCCTAGG 
ClaI NS31a 
Pro R 
ATCGATTTTAGCCACTCCACGGG 
HCV 1a NS3 
Helicase 
ClaI NS31a 
Hel F 
ATCGATGACTTTATCCCTGTGGAG 
NsiI NS31a 
R 
ATGCATGTCATGATGTATTTGG 
HCV 1b NS3 
BlpI NS31b 
F 
GCTCAGCAGACGCGAGGCCTACTTGG 
NsiI NS31b 
R 
ATGCATTCGAACTCCCGGTAAAGG 
HCV 1b NS3 
Protease 
BlpI NS31b 
F 
GCTCAGCAGACGCGAGGCCTACTTGG 
ClaI NS31b 
Pro R 
ATCGATTTTCGCAACCCCTCGGG 
HCV 1b NS3 
Helicase 
ClaI NS31b 
Hel F 
ATCGATGACTTTGTACCCGTCGAG 
NsiI NS31b 
R 
ATGCATTCGAACTCCCGGTAAAGG 
 
 
A1.2Primer used for reverse transcription of JFH-1 RNA 
 
Name Sequence 
HCV2a RT 9482 GGAACAGTTAGCTATGGAGTGTACC 
 
 
A1.3 Primers used in the sequencing of JFH-1  
 
Forward Primer Reverse Primer 
Name Sequence Name Sequence 
JFH 64 F CTGTGAGGAACTACTGTCTT JFH 829 R GGTAGGTTCCCTGTTGCATA 
JFH 637 F TGGGCAGGATGGCTCCTGTC JFH 1303 R GGCGACCAGTTCATCATCAT 
JFH 1158 F GATGTCCGCCACCTTCTGCT JFH 2348 R CCATTCCGTGGTAGAGTGCA 
JFH 2305 F AACTTCACTCGTGGGGATCG JFH 3491 R TGTCCTGTCACGCCCCGTCA 
JFH 3489 F CCTGGGCGCCATAGTGGTGA JFH 4648 R GCGTCGGTGGCGACGACCAC 
JFH 4566 F AAAGTGTGACGAGCTCGCGG JFH 5951 R CTTCTCGCCAGACATGATCT 
JFH 5902 F CTGGGTAAGGTGCTGGTGGA JFH 6983 R GGTGGTGCAGGTGGCCCGCA 
JFH 6967 F GCGAGCTCCTCAGTGAGCCA JFH 8015 R CCACACGGACTTGATGTGGT 
JFH 7972 F TCTGCAAGATCCAAGTATGG JFH 8872 R GCCATGAATTGATAGGGGAG 
JFH 8700 F CTTCACGGAGGCCATGACCA JFH 9262 R AATGGAGTGAGTTTGAGCTT 
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A1.4 Primers used in JFH-1 quantitative PCR 
 
Forward Primer Reverse Primer 
Name Sequence Name Sequence 
HCV2a RTqPCR F TCTGCGGAACCGGTGAGTA HCV2a RTqPCR R TCAGGCAGTACCACAAGGC 
 
 
A1.5 Primers used in qRT-PCR and qPCR of host genes 
 
Gene Forward Primer Reverse Primer 
Normalising Controls 
  
GAPDH TCTCTGCTCCTCCTGTTCGAC CGGATTTGGTCGTATTGGG 
RPLPO CGACCTGGAAGTCCAACTAC ATCTGCTGCATCTGCTTG 
   
Oxidative Stress Forward Primer Reverse Primer 
AHR CTGCCTTTCCCACAAGATGT AGTTATCCTGGCCTCCGTTT 
AOX1 TTGCTTTGTTGCCTCCTTCT ATGGATAGCGAAAAACACGG 
CAT CGTGCTGAATGAGGAACAGA AGTCAGGGTGGACCTCAGTG 
CYP1A1 AACTAGCCAAACCAGGACCC TAGGGTCAGATTGCTCAGCC 
CYP1B1 CCCCAGTCTCAATCTCAACG CTCCCACTCGAGTCTCTTGG 
DNAJC8 GGAAAGTCGAGATGGTCGTG GGTTCTGTGCCTGTGACCTT 
GPX2 CCTTCACCCTTGTCCAAAAA AAATGATGAGCTTGGGATCG 
GPX3 ATCCTGTCCTACATGAGGCG TGGAGACACGGATTTCTTCC 
GPX8 CAGGAGGAGATTTGAAAGCG GGTAGCAGCACATCAGCAAA 
GSTM3 TCCTGGAGTTCACGGATACC TCTTGTTCTTCCCATCCAGG 
GSTM4 CGCCTATGATGTCCTTGACC ATGCCACAGGAAACCTCAAA 
HSPB8 GCTTCAAGCCAGAGGAGTTG TGCAGGAAGCTGGATTTTCT 
MT1E GCAAGTGCAAAGAGTGCAAA AGAGCTGTTCCCACATCAGG 
MT1F GCAAGTGCAAAGAGTGCAAA AAAGGTTGTCCTGGCATCAG 
MT1M TGAGATCTCCAGCCTTACCG AGGAGCAGCAGCTCTTCTTG 
MT2A GCCTCCTCCAAGTCCCAG TGCATTTGCACTCTTTGCAT 
NQO1 TATGACAAAGGACCCTTCCG AATGACATTCATGTCCCCGT 
SOD2 GGAACGGGGACACTTACAAA GGTAGTAAGCGTGCTCCCAC 
   
Interferon Signalling Forward Primer Reverse Primer 
IRF1 ACCCTGGCTAGAGATGCAGA AGGCATCCTTGTTGATGTCC 
IRF9 ATGGATGTTGCTGAGCCCTA ATGGCATCCTCTTCCTCCTT 
MX1 CCACATCCCTTTGATCATCC TTCAGGAGCCAGCTGTAGGT 
SOCS2 AGGGACTCGTTTTGGGATTC GGGTCATGAGAGAAGGGTCA 
SOCS3 TGGTCAGCTGGTCTCCTTTT AGGGAGCATTTAAGGCGAAT 
   
Apoptosis and 
proliferation 
Forward Primer Reverse Primer 
CCNB1 ATAAAGCTTGTGGCCCCTTT TCAATTGGATCCCCAGGTAA 
CDC25C ATGCATCATCAGGACCACAA GCCAGTGGCTGGAATGTTAT 
GADD445B ACAGTGGGGGTGTACGAGTC GGATGAGCGTGAAGTGGATT 
GADD45A GGCCCGGAGATAGATGACTT TTTTCCTTCCTGCATGGTTC 
   
Inflammatory 
Chemokines 
Forward Primer Reverse Primer 
CXCL1 GGAGGAGGAAGCTCACTGG GCGATGCTCAAACACATTAGG 
CXCL16 TTCCTGGAGCGTGTGTGG GGGCTGGTAGGAAGTAAATGC 
CXCL2 ACCAGAAGGAAGGAGGAAGC TGATGCTCAAACACATTAGGC 
CXCL3 GGGCTTTCCAGTCTCAACC GGAAGCTGTGCGAGAAGC 
CXCL5 ACCCAGGGAAGACAAGAAGG GCTTAAGCGGCAAACATAGG 
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Cholesterol Metabolism Forward Primer Reverse Primer 
EBP AGACAGCCGATACATCCTGG CTGTAGAATGAAGCGGAGGG 
FDFT1 CTCAAGAGGTTTGGAGCAGG TGATGACATCTGGGATGTGG 
HMGCR ATAATCCTGGGGAAAATGCC TTGACAAGATGTCCTGCTGC 
MVD GATGAAGAGCTGGTTCTGCC GTGAAGTCCTTGCTGATGACG 
SQLE AATCTTTAGGTTGGGGCTGC TTCAGAGGCTTCTTTTTCCG 
   
Sphingolipid 
Metabolism 
Forward Primer Reverse Primer 
SGMS2 CAATTCCTTGCTGCTTCTCC AGCTGATGCCTTTGTTTTGC 
SGPL1 AAGATGGAGAAGCATGTGCC TTGAAAAACACCATCTCCCC 
SGPP1 CTTCTGGATCTGGAACCTGG AGACCTCCAACTTGACCACG 
SPTLC1 ACTGATTGAAGAGTGGCAACC ACAGTTTTGTGGCTTGGAGG 
   
Fatty acid Metabolism Forward Primer Reverse Primer 
ACADSB CACCATTGCAAAGCATATCG GTGGAAGTTTATTCCCACGC 
ACAT2 AGATGATCTGTGGGTCAGGC ATATTTTCCATGCCTCCTGC 
ACLY CCACACTGCAAACTTCCTCC GTGGTGCTCTTTCCTTGTGG 
ACSL3 TGTTGTGCCAAATCAAAAGG TTGCTGAAATAGCAGCTTCG 
ELOVL4 CTGGTCCATCGCAGATAAGC AGGTTCTCGGTCCTTCATCC 
ELOVL7 CTATGGACTTTCTGCATTGGG AACTGGCTTATGTGGATGGC 
FABP3 AGTTCAGTCAGTGATGGGGC GAACCTGAATTCTGGAAAGGG 
PPARGC1A TCAAGCCACTACAGACACCG GCCTCTCGTGCTGATATTCC 
SREBF1 GGAGAGCCTGTACAGCTTGG TGGGTCACACAGTTCAGTGC 
TXNIP ATAAAAGCCCTTTGAACCCC GCTCAGTGCTCTGACACAGG 
   
Vesicle Trafficking/ 
Cytoskeleton 
Forward Primer Reverse Primer 
ABLIM3 GACCCTTCCCTCTTTCAAGG GCTCTGGTGGGAACATTAGC3 
RAB21 AGTAGCATTTGCCTTTTGGG AAATTCAACATGAGCCACCC 
RAB27A TGGTTGATTGAAGGGTCAGG CTCATCGCAAATAACTCGGC 
RAB27B AATCTGACACCTGCTCTCCC AGAAATGTTGTCTTCCCCACC 
RAB33B GAAACGTCTGCTAAAAACCCC TAATTCCATTATCAGGGGGC 
RAB37 GAGCAGCGAAAGAGTGATCC CGGTATTTCAGTTCCTTGGC 
RAB40B CATCTCAGATCCCGGTTCC CAAGAGCTTCATGCACATCC 
RAB6B CTACAGGCAGGAAAACCAGG CATTTGTTCACACACAGGGC 
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A2 siRNA Sequences 
 
All siRNAs were purchased from Ambion, except for the HCV, Non-Targeting 1 and Non-Targeting 2 
siRNAs which were purchased from Sigma.  All sequences are written in the standard 5’-3’ order, 
with deoxyribonucleic acids indicated in brackets.  DDX3X 1-4 were always used as a single combined 
pool of siRNAs.   
 
 
siRNA Sense Strand Antisense Strand 
HCV CCCGGGAGGUCUCGUAGAC[dT][dT] GUCUACGAGACCUCCCGGG[dT][dT] 
Non-Targeting 1 GAUCAUACGUGCGAUCAGA[dT][dT] UCUGAUCGCACGUAUGAUC[dT][dT] 
Non-Targeting 2 CACUGGAUGUGGAUGACUA[dT][dT] UAUAUUCGCGCUAUCGCGC[dT][dT] 
CFH 1 GGACCAAUGAUAUUCCUAU[dT][dT] AUAGGAAUAUCAUUGGUCC[dA][dT] 
CFH 2 GGUUGCUCUUAAUCCAUUA[dT][dT] UAAUGGAUUAAGAGCAACC[dC][dA] 
CFI 1 CGACCUUAAACGUAUAGUA[dT][dT] UACUAUACGUUUAAGGUCG[dG][dG] 
CFI 2 GAACUAUGGGUUACCAGGA[dT][dT] UCCUGGUAACCCAUAGUUC[dT][dT] 
CYP1A1 1 CCCUCAUCAGUAAUGGUCA[dT][dT] UGACCAUUACUGAUGAGGG[dT][dG] 
CYP1A1 2 GUGUAUCGGUGAGACCAUU[dT][dT] AAUGGUCUCACCGAUACAC[dT][dT] 
DDX3X 1 GGUAUUAGCACCAACGAGA[dT][dT] UCUCGUUGGUGCUAAUACC[dT][dT] 
DDX3X 2 GCAAAUACUUGGUGUUAGA[dT][dT] UCUAACACCAAGUAUUUGC[dT][dT] 
DDX3X 3 ACAUUGAGCUUACUCGUUA[dT][dT] UAACGAGUAAGCUCAAUGU[dT][dT] 
DDX3X 4 CUAUAUUCCUCCUCAUUUA[dT][dT] UAAAUGAGGAGGAAUAUAG[dT][dT] 
MAT1A 1 AGGGUUUGAUGUUCGGCUA[dT][dT] UAGCCGAACAUCAAACCCU[dG][dA] 
MAT1A 2 GAUUAUUGUGGACACCUAU[dT][dT] AUAGGUGUCCACAAUAAUC[dT][dT] 
MT1F 1 AGACAUGUACAAACCUGGA[dT][dT] UCCAGGUUUGUACAUGUCU[dC][dT] 
MT1F 2 CCUUGACCCAUUUGCUACA[dT][dT] UGUAGCAAAUGGGUCAAGG[dT][dG] 
MT1G 1 GAGUGACCCGUAAAAUCUA[dT][dT] UAGAUUUUACGGGUCACUC[dT][dA] 
MT1G 2 CAAAUAGAGUGACCCGUAA[dT][dT] UUACGGGUCACUCUAUUUG[dT][dA] 
MT2A 1 ACCCUGACCGUGACCGUUU[dT][dT] AAACGGUCACGGUCAGGGU[dT][dG] 
MT2A 2 AGAACGCGACUUCCACAAA[dT][dT] UUUGUGGAAGUCGCGUUCU[dT][dT] 
RAB27B 1 GACUUAAUCAUGAAGCGAA[dT][dT] UUCGCUUCAUGAUUAAGUC[dC][dA] 
RAB27B 2 GGAAUAGACUUUCGGGAAA[dT][dT] UUUCCCGAAAGUCUAUUCC[dT][dA] 
RAB37 1 CCAGAUCCGAGACUAUGUA[dT][dT] UACAUAGUCUCGGAUCUGG[dA][dA] 
RAB37 2 CCAGCUUCCAGAUCCGAGA[dT][dT] UCUCGGAUCUGGAAGCUGG[dG][dC] 
RAB40B 1 CGCUGGUCUUUUGACGGCA[dT][dT] UGCCGUCAAAAGACCAGCG[dG][dT] 
RAB40B 2 UCACAGAGUCGUUCACGGA[dT][dT] UCCGUGAACGACUCUGUGA[dT][dG] 
SLC27A2 1 GUAUAUCGGUGAACUGCUU[dT][dT] AAGCAGUUCACCGAUAUAC[dT][dG] 
SLC27A2 2 GCACAUUGCUGAUUACCUA[dT][dT] UAGGUAAUCAGCAAUGUGC[dT][dG] 
SOCS3 1 UGAUUUGGUUUAAACCUGA[dT][dT] UCAGGUUUAAACCAAAUCA[dA][dA] 
SOCS3 2 AGAAGAGCCUAUUACAUCU[dT][dT] AGAUGUAAUAGGCUCUUCU[dG][dG] 
SPTLC3 1 CAAAUCAUCAGAUCACUAA[dT][dT] UUAGUGAUCUGAUGAUUUG[dC][dT] 
SPTLC3 2 GGAUGGGAUUCGCAACUAA[dT][dT] UUAGUUGCGAAUCCCAUCC[dC][dA] 
TXNIP 1 CAUCCUUCAAAGGAAAAUA[dT][dT] UAUUUUCCUUUGAAGGAUG[dT][dT] 
TXNIP 2 GAAUAUUCCUUACUGAUCU[dT][dT] AGAUCAGUAAGGAAUAUUC[dA][dA] 
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A3 SDS-PAGE and Western Blotting Solutions 
 
Resolving Gel (10ml at 10% acrylamide) 
Protogel (30% w/v acrylamide:bisacrylamide 37.5:1, National Diagnostics) 3.3ml 
4x Protogel Resolving Buffer (National Diagnostics)    2.5ml 
10% Ammonium Persulphate       100µl 
N,N,N',N'-Tetramethylethylenediamine (TEMED)    10µl 
Water          4.2ml 
Stacking gel (10ml at 4% acrylamide) 
Protogel (30% w/v acrylamide:bisacrylamide 37.5:1, National Diagnostics) 1.3ml 
4x Protogel Stacking Buffer (National Diagnostics)     2.5ml 
10% Ammonium Persulphate       100µl 
N,N,N',N'-Tetramethylethylenediamine (TEMED)    10µl 
Water          6.2ml 
Sample Loading Buffer 
125mM Tris-HCl pH6.8 
10% SDS 
10% β-mercaptoethanol 
10% Glycerol  
0.1% Bromophenol blue 
Western Transfer Buffer 
10x Tris-Glycine SDS-PAGE Running Buffer (National Diagnostics)  100ml 
Methanol         200ml 
Water          700ml 
Coomassie Blue Stain 
0.1% Brilliant Blue R 
25% Isopropanol 
10% Acetic Acid 
Coomassie Blue Destain 
40% Methanol 
10% Acteic Acid 
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A4 Immunofluorescence microscopy reagents 
 
Mowiol mounting medium 
2.4g Mowiol 4-88 (Sigma) was added to 6g glycerol and 6ml water and stirred for 2 hours.  12ml 
0.2M Tris-HCl pH8.5 was added and the mixture stirred at 50°C until the Mowiol dissolved.  The 
solution was clarified by centrifugation at 3000g for 20 minutes.  0.72g 1, 4-Diazabicyclo [2.2.2] 
octane (DABCO, Sigma) and 0.1% 4, 6-diamidino-2-phenylindole, dilactate (DAPI, Invitrogen) were 
added to the clarified Mowiol, and it was aliquoted for storage at -20°C.   
 
 
 
A5 DNA Ladders 
 
DNA ladders were purchased from Promega.   
 
 
Figure 48: DNA Ladders. 
These DNA ladders were used as reference markers for agarose gel electrophoresis.  A 1kb DNA 
ladder.  B 100bp DNA ladder.  
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A6 Characterisation of JFH-1 Cell Culture 
 
It is now possible to study the full life cycle of HCV in vitro thanks to the discovery of the genotype 2a 
isolate called JFH-179.  This isolate formed the major model for these studies, so the system had to 
be set up and characterised.  Initial preparation of in vitro transcribed RNA from plasmid DNA was 
performed by a method based on that described by Wakita et al79,570.  Plasmid pJFH-1 provided the 
wild type sequence to produce infectious virus.  Two controls were used during the characterisation 
of the system.  JFH-1 GND (hereafter referred to as GND) contains an asparagine amino acid codon 
in place of the first aspartic acid codon in the GDD motif of NS5B.  This mutation inhibits the viral 
polymerase activity, resulting in a viral genome which is unable to replicate.  JFH-1 delE1E2 
(hereafter referred to as delE1E2) has had the E1 and E2 regions of the genome deleted.  This means 
that, although the viral genome can replicate, it cannot produce infectious virus particles.   
 
The initial step in production of RNA transcripts is to digest plasmid DNA with restriction enzymes 
XbaI and Mung Bean Nuclease.  Linearisation of DNA was confirmed by agarose gel electrophoresis 
(Figure 49A).  RNA was produced by in vitro transcription and the presence of single transcripts of 
the desired size was confirmed by agarose gel electrophoresis (Figure 49B).   
 
 
 
Figure 49: Preparation of RNA transcripts of JFH-1 and its derivatives. 
A Agarose gel electrophoresis of JFH-1 constructs in supercoiled plasmid form and linearised 
form after digestion with XbaI and mung bean nuclease restriction enzymes.  Each lane contains 
approximately 100ng DNA.   Lanes 1 and 8: 1kb DNA ladder, Lane 2: Undigested pJFH-1, Lane 3: 
Digested pJFH-1, Lane 4: Undigested pJFH-1 GND, Lane 5: Digested pJFH-1 GND, Lane 6: 
Undigested pJFH-1 delE1E2, Lane 7: Digested pJFH-1 delE1E2.  B Non-denaturing agarose gel 
electrophoresis of purified RNA transcripts.  Each lane contains approximately 1µg RNA.   Lane 1: 
1kb DNA ladder, Lane 2: JFH-1, Lane 3: JFH-1 GND, Lane 4: JFH-1 delE1E2. 
 
After the production of RNA, optimisation of the protocol for transfection of Huh7.5 cells was 
performed.  Huh7.5 cells were chosen for production of JFH-1 as they have been shown to be 
permissible to JFH-1 replication after transfection with RNA.  Several scales of transfection were 
A B 
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attempted.  The 6-well format was chosen as the most practical scale.  As shown in Table 13, 
transfection of 5 x 105 Huh7.5 cells with 5µg RNA and 10µg transfection reagent resulted in 20% of 
cells staining positive for HCV core protein four days post-transfection. 
 
 
RNA (µg) Lipofectamine 2000 (µl) Lipofectamine:RNA ratio Number of Cells Scale Cells transfected (%) 
2 4 2 5x105 6-well 5 
5 5 1 5x105 6-well 15 
5 10 2 5x105 6-well 20 
10 20 2 5x105 6-well 5 
 
Table 13: Transfection optimisation of Huh7.5 cells with JFH-1.  
In all cases, 5 x 105 Huh7.5 cells were seeded on coverslips in 6-well plates, and transfection was 
performed with Lipofectamine 2000 for 8 hours in 1ml of OptiMEM.  At four days post-
transfection, transfected cells were stained for HCV Core protein, and visualised by 
immunofluorescence microscopy.  The number of HCV positive cells was estimated by counting 
the percentage of cells stained for HCV core in two microscope fields of view at 40x 
magnification. 
 
 
After transfection of Huh7.5 cells with JFH-1 RNA, immunofluorescence staining for HCV core protein 
was performed.  The staining pattern of cells expressing HCV core protein (Huh7.5 cells transfected 
with JFH-1, Figure 50A) is clear and distinct from cells which do not contain core protein and 
therefore do not stain red by this protocol (Huh7.5 cells, Figure 50B).    A high magnification image of 
a single cell, exhibiting the expected pattern of staining, is shown in Figure 51. 
 
 
.   
 
Figure 50: Immunofluorescent staining for HCV core protein.  
A Huh7.5 cells transfected with JFH-1.  Core protein can be observed as the red staining in the 
cytoplasm of the cells.  Nuclei are stained blue with DAPI.  B Mock transfected Huh7.5 cells do 
not stain red as there is no HCV core present. 
 
A B 
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Figure 51: Image of a JFH-1 infected Huh7.5 cell stained for HCV core protein.  
Huh7.5 cells transfected with JFH-1 RNA were stained for core protein (red) and imaged at 63x 
magnification by confocal microscopy. The nucleus, observed in the top right of the picture, 
is not stained as the virus localises to the cytoplasm.  The general staining of the 
cytoplasm is typical of the localisation of the virus to the endoplasmic reticulum and 
Golgi apparatus.  The nuclear envelope is also seen to be stained positive for HCV core.  
The round bodies, of various sizes up to 1µm, seen in the cytoplasm are likely to be lipid 
droplets coated in HCV core protein 
 
 
Huh7.5 cells transfected with JFH-1 RNA were cultured in 75cm2 flasks until all cells were infected 
with JFH-1, as observed by immunofluorescent staining.  Cultures at this stage were characterised by 
measurement of RNA and infectious virus levels.  Intracellular JFH-1 RNA was typically in the order of 
108 copies per µg total cell RNA, extracellular RNA was typically in the order of 107 copies per ml 
culture medium, and infectious virus was typically in the order of 103 focus forming units per ml 
culture medium. 
 
Once concentrated by centrifugal filtration, titres of infectious JFH-1 generated by the cell passage 
method were in the order of 105 infectious viruses per ml.  In order to perform infection experiments 
where the majority of cells in culture were infected during the first round of infection, higher titre 
stocks needed to be generated.  To obtain higher titres of infectious virus, the cell culture medium 
containing infectious virus was harvested from transfected Huh7.5 cells and used to infect naive 
Huh7.5 cells.  Using this process, it was possible to obtain titres in the order of 106, as is shown in 
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Figure 52.  Since performing this experiment, others have demonstrated use of media passage 
techniques to produce virus for infection studies411. 
 
 
 
 
Figure 52: Production of infectious JFH-1 virus titres by cell culture.  
A culture of Huh7.5 cells with all cells infected with JFH-1 was selected as the seed culture for 
this experiment.  Culture media containing JFH-1 collected from each method were concentrated 
by the centrifugal method previously described (2.3.7), before titration of JFH-1.   A Infected cells 
were continuously passaged as normal Huh7.5. This method shows the infectious titres initially 
at 7.5 x 10
4
, before dropping to 1x10
4
 (and even lower at passage 4) before recovering at 
passage 7 to the high 104 range.   B Cell culture medium containing infectious JFH-1 was 
passaged onto naive cells. 10% of the medium from the previous passage was transferred onto 
the new passage.  This method showed an increase in infectious titre at each passage from 2.5 
x104 at passage 1, to the low 106 range at passage 5, which was then maintained to passage 8.  
Titres are initially low as a low percentage of cells were infected, but as media titres increased, 
so did the number of cells that could be initially infected with the virus from the medium.  A 
constant volume of medium was passaged in these experiments, not a constant MOI of JFH-1, 
hence initial low levels of infection. 
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In order to establish the percentage of cells in culture that could be infected, Huh7.5 cells and Huh7 
cells were infected with JFH-1 at a range of MOI.  Figure 53 shows that for both Huh7.5 cells and 
Huh7 cells infection with an MOI of 3 resulted in the maximum possible intracellular JFH-1 RNA titre 
at 48 hours post-infection.  Immunofluorescent staining for core protein revealed that greater than 
95% of Huh7.5 cells and Huh7 cells were expressing HCV core at 48 hours post-infection with an MOI 
of 3. 
   
Figure 53: Intracellular JFH-1 RNA levels after infection with a range of MOI. 
Huh7.5 cells (A) and Huh7 cells (B) were infected with JFH-1 at a range of MOI.  5x105 cells in 4ml 
DMEM were seeded into T25 flasks.  The next day, 1ml of JFH-1 was added to the flasks.  4 hours 
later the medium was removed, cells were washed with 5ml PBS and 5ml DMEM was added to 
the flasks.  48 hours post-infection intracellular RNA was harvested by the Trizol method, and 
JFH-1 RNA quantified by RT-qPCR.    
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A7 Microarray Data Quality Control 
 
Quality control (QC) was vital to obtain accurate results from the microarray experiments.  The 
qualities of RNAs extracted from cells were tested by Expression Analysis using Agilent Bioanalyzer 
technology.  All RNAs were determined to be of sufficient quality to be used for the microarray 
hybridisation protocol.  Controls were also performed on the data obtained from the microarray 
hybridisation.  Two forms of quality control were performed on data obtained using Array Studio 
software.   
 
Principal component analysis (PCA) is used to reduce the high dimensionality of the relationships 
between the 55,000 probe sets down to (in this case) two dimensions, which can be easily and 
usefully represented visually.  From this visual representation, arrays can be identified as outliers 
and excluded from the subsequent analyses of gene expression data.  
  
Correlation based quality control in Array Studio calculated the MADScore for each array.  In this 
case, arrays with a MADScore of less than -5 were considered outliers.  Array Studio calculates 
MADScores based on these principles: 
MADScore = (Correlation Difference Sample – Median Correlation Differences)/ (MAD * 1.46138189) 
Median Absolute Deviation= median (|Yi-Median Correlation Differences|). 
 
PCA and correlation based QC results are shown for the microarray experiment using Huh7.5 cells 
(Figure 54) and the experiment using Huh7 cells (Figure 55).  In the experiment using Huh7.5 cells, 
one array was identified as an outlier by both QC methods.  This was a sample in the group that was 
infected with JFH-1 virus for 6 hours.  This array was excluded from the subsequent analyses of gene 
expression data.  In the experiment using Huh7 cells, one array was identified as an outlier by PCA 
(Figure 55A), and two arrays were identified as outliers by correlation QC (Figure 55B).  These were a 
sample in the group that was infected with JFH-1 virus for 6 hours, and a sample in the group which 
had RNA extracted at 0 hours.  Both arrays were excluded from the subsequent analyses of gene 
expression data.  Scatter plots providing another visual representation of the unsuitable variation 
observed in the probe sets of these two outlier arrays are given in Figure 55C and Figure 55D. 
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Figure 54: Quality control of arrays used in Huh7.5 microarray experiment, performed using 
Array Studio.  
A Principal component analysis of arrays.  Each array is colour coded by time, and shape coded 
by treatment.  In this two dimensional representation, most arrays were observed to cluster 
together indicating good correlation.  One outlier was identified, labelled with the array code 
55209, which represented a sample infected with JFH-1 for 6 hours.  B Correlation based QC of 
arrays.  Arrays are grouped by time and treatment.  One outlier, array 55209 was identified as 
having a MADScore of less than -5.  This was also identified as an outlier by PCA, and 
consequently excluded from subsequent analyses. 
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Figure 55: Quality control of arrays used in Huh7 microarray experiment, performed using Array 
Studio.  
A Principal component analysis of arrays.  Each array is colour coded by time, and shape coded 
by treatment.  In this two dimensional representation, most arrays were observed to cluster 
together indicating good correlation.  One outlier was identified, labelled with the array code 
84565, which represented a sample infected with JFH-1 for 6 hours.  B Correlation based QC of 
arrays.  Arrays are grouped by time and treatment.  Two outliers, arrays 84565 and 84568 were 
identified as having a MADScore of less than -5.  These were both consequently excluded from 
subsequent analyses.  C Scatter matrix plots of arrays.  The scatter matrices of pairwise 
comparisons of arrays are given to show the unacceptable variation in the outlier array 84565.  
The expected patterns can be seen in plots iii and vi, where arrays 84566 and 84567 are 
compared.  The increased scatter observed in the comparisons involving array 84565 (i, ii, iv and 
v)show the unsuitability of this array for use in gene expression analysis. D Scatter matrix plots of 
arrays.  The scatter matrices of pairwise comparisons of arrays are given to show the 
unacceptable variation in the outlier array 84568.  The expected patterns can be seen in plots iii 
and vi, where arrays 84569 and 84570 are compared.  The increased scatter observed in the 
comparisons involving array 84565 (i, ii, iv and v) show the unsuitability of this array for use in 
gene expression analysis. 
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A8 Metallothionein proteins levels 
 
Gene expression analysis indicated that metallothioneins were downregulated during infection with 
JFH-1.  To determine whether this downregulation of transcripts lead to a downregulation of 
protein, western blotting was performed.  Huh7.5 cells were infected with JFH-1 at an MOI of three, 
or mock infected.  Triplicates of each condition were performed.  Three days post-infection, protein 
was harvested, 100µg put through SDS-PAGE, and western blotting performed.  Figure 56 indicates 
that metallothionein protein levels in JFH-1 infected Huh7.5 cells may be lower than in mock 
infected cells.  Repeat experiments are required before a conclusion can be drawn.   
 
 
Figure 56: Metallothionein protein levels in JFH-1 infected and Mock infected Huh7.5 cells. 
